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Coronary artery bypass surgery (CABG) effectively relieves angi-
na, but is associated with significant morbidity.1-3 The potential
benefits gained by avoiding cardiopulmonary bypass (CPB) have
led to a renewed interest in bypass surgery on the beating 
heart.4-6 The Octopus Stabilizer is one of the recently developed
devices that can immobilize and present all sides of the beating
heart, thus facilitating coronary bypass surgery without the use of
CPB (off-pump CABG).7
Predominantly observational studies have claimed advantages of
off-pump CABG, including less morbidity,8 faster recovery,9
shorter hospitalization8,10,11 and a reduction of costs.10,12 While
sternotomy is virtually always required when CPB is used, off-
pump CABG may be performed via smaller incisions.13,14 The
most important potential advantage of off-pump CABG, how-
ever, is improved cerebral outcome. A substantial number of
studies indicate that conventional coronary bypass surgery using
CPB (on-pump CABG) is associated with postoperative cognitive
decline, which has been attributed to the use of CPB.3,15-20 These
studies are systematically reviewed in chapter 2 of this thesis. It is
assumed that cardiac outcome after off-pump CABG is similar to
conventional procedures.4,9 Off-pump CABG, however, is tech-
nically more demanding and no proof is yet available that off-
pump surgery can match the long-term cardiac benefits of the
on-pump operation.21 It is conceivable that grafting vessels in the
depth of the thoracic cavity on a slightly moving target might
compromise the quality of the distal anastomoses and result in
more late cardiac complications.22
The Octopus Study was designed to compare off-pump CABG to
intracoronary stent implantation, and to conventional CABG with
use of CPB. The Octopus Study therefore consists of two ran-
domized trials: one directly comparing off-pump CABG and
intracoronary stent implantation (OctoStent Trial) and one direct-
ly comparing off-pump CABG and on-pump CABG (OctoPump
Trial).23 In this thesis, the rationale, design, and principal results
of the OctoPump Trial are presented. The term Octopus Study
therefore refers here to the OctoPump Trial, i.e. the randomized
comparison of off-pump and on-pump CABG.
The primary objective of the study was to compare cognitive out-
come between patients randomized to off-pump or on-pump
3
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CABG. As it was assumed, but not established that off-pump and
on-pump CABG are equally effective in terms of myocardial
revascularization, an important secondary objective of the trial
was to compare cardiac outcome. An extensive description of the
objectives and methods of the Octopus Study is given in chapter 3.
The principal results of the study, i.e. the effect of CPB on cogni-
tive outcome, are described in chapter 4. In addition, the effects of
CPB on quality of life are presented. We constructed multivariate
models in order to identify predictors of cognitive decline after
CABG. These multivariate analyses are presented in chapter 5.
The clinical outcomes are the focus of the following two chap-
ters. In chapter 6, the in-hospital and early postoperative course of
the patients are described. This includes the completeness of
revascularization, transfusion rate, and perioperative complica-
tions. Chapter 7 presents cardiac outcome at one year after sur-
gery, including the occurrence of cardiovascular events,
recurrence of angina, exercise testing, and coronary angiography.
In this chapter, we also present a cost-effectiveness analysis.
Finally, chapter 8 discusses explanations for some unexpected
results of the study, together with its methodological limitations.
Suggestions for future research are provided.
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Abstract
Objective Substantial, albeit scattered, evidence suggests that coronary
artery bypass grafting may impair cognitive function. As methods
and definitions differ greatly across studies, the reported incidence
of cognitive decline after coronary bypass surgery varies widely as
well. The aim of the present study was to systematically review
those studies on cognitive decline that are relatively comparable
and meet with certain quality criteria.
Methods Four electronic databases and the references of several abstract
books and earlier reviews were used to identify relevant literature.
Stringent criteria, based in part on the 1994 consensus meeting on
assessment of neurobehavioral outcomes after cardiac surgery,
were used to assess the studies that were found. In total, 256 dif-
ferent titles were found, of which 23 met with the formulated
selection criteria.
Results Twelve cohort studies and eleven intervention studies were evaluat-
ed. A pooled analysis of six highly comparable studies yielded a
proportion of 22.5% (95% confidence interval, 18.7%-26.4%) of
patients with a cognitive deficit (a decrease of at least 1 standard
deviation in at least two of nine or ten tests) 2 months after the
operation.
Conclusions Neurocognitive dysfunction is a frequently occurring complication
of coronary artery bypass grafting. The etiologic contribution of
cardiopulmonary bypass to this complication will remain unclear
until a randomized trial that directly compares off-pump and on-
pump bypass surgery is carried out.
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Introduction
Coronary artery bypass grafting (CABG) with the use of car-
diopulmonary bypass (CPB) is associated with significant cerebral
morbidity.1 The two main clinical manifestations of brain injury
after CABG are stroke and cognitive decline.1 The incidence of
postoperative stroke is consistently reported to be around 3%1,2
and as high as 9% in patients older than 75 years.3,4 However, the
reported incidence of cognitive decline varies widely.5 This vari-
ability is partly caused by methodologic problems: a multitude of
definitions of cognitive decline are used, and a large number of
neuropsychologic tests exist to assess the various cognitive
domains.6 Moreover, the interval between operation and adminis-
tration of the neuropsychologic tests may range from a few days
to several years. Some literature reviews on cognitive deficits
after CPB have been published,7-10 but the methodologic variabil-
ity of the studies hampers comparison of the results.
At a consensus meeting in 1994, several guidelines for the assess-
ment of neuropsychologic deficits after CPB were established.11 It
was recommended that the neurologic and neuropsychologic state
be assessed before the operation to provide accurate baseline
information. A second important recommendation was that the
analysis should be based on the individual change in performance
from baseline to a particular time after the operation. In general,
practice effects cause the overall group performance to improve
after the operation. Accordingly, when the overall postoperative
mean is compared with the preoperative mean, the decline of
some individuals is overshadowed by the improvement of others.
Also, it was agreed that a late assessment (ideally after 3 months)
should be included in the study design, because the patients’ per-
formances are unstable in the immediate postoperative period.
Although these consensus guidelines were developed for the
design of new research protocols, we found some of them also
suitable to interpret studies carried out in the past. This systemat-
ic review is restricted to studies on cognitive decline 1 to 12
months after CABG, which were considered methodologically
homogeneous according to well-defined and strict criteria. Both
the primary selection of studies and the assessment and compari-
son of the studies that were included were largely based on rec-
9
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ommendations of the 1994 consensus.11 As a result of the techni-
cal improvements of CPB and the alterations in anesthetic man-
agement, studies published before 1980 were considered less
relevant and therefore were excluded.
Methods
Literature search
For the literature search, four electronic databases (MEDLINE,
PsychLit, PubMed, and Current Contents) and references of four
earlier published (abstract) books and three reviews were used.
The precise search strategy is described in Table 1. To assess the
quality of the search strategy, we sampled ten studies that we
already had on file and considered relevant. The search strategy
was able to identify these articles. The total number of different
titles found was 256 (Table 1).
Selection of the literature
The studies were independently judged by a clinician and a psy-
chologist using the following selection criteria:
Inclusion criteria:
• Primary research on cognitive decline after CABG, including a
preoperative neuropsychologic assessment to provide baseline
information
• Postoperative neuropsychologic assessment between 1 and 12
months after the operation
• Data analysis based on the individual change in performance
from baseline to a time after the operation
Exclusion criteria:
• Studies published before 1980
• Studies including open chamber or valvular procedures
• Studies with unclear timing of test administration
• Articles describing the same or an overlapping patient sample
as other articles already included in the review
These selection criteria were applied on the 256 titles found.
Thirty-four articles could be excluded on the basis of the title
only and 111 articles were excluded on the basis of the abstract.
For the remaining 111 titles, the complete article was studied.
10
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The majority of these publications were written in English. Many
articles were excluded because data of patients undergoing CABG
were mixed with data of patients having valve replacement,
because data analysis was based on comparison of mean group
performance before and after the operation, or because only an
early postoperative neuropsychologic assessment (ie, less than 1
month) was performed. Seven studies were excluded14-20 because
the same patient series had (partly) been used in other studies
already included in the review and their inclusion would have
overemphasized the results of these series. Finally, one article
published in Japanese was rejected because a translation could not
be obtained. Only 23 articles matched all the selection crite-
ria.5,21-42
Literature processing
The 23 articles meeting the selection criteria were processed
independently by a psychologist and a clinician using a three-page
standard form. This form was filled out to systematically assess
the research question, study design, neuropsychologic tests used,
statistics, main conclusions, and other items. The forms were the
basis for Tables 2 and 3 in the “Results” section.
The neuropsychologic sections were independently judged by
two trained neuropsychologists, blinded for author and journal
11
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Table 1: Literature search: sources and results
Source No. of titles found
• MEDLINE electronic database 1980-1999: Medical Subject Heading (MeSH) standard 
terms: (heart surgery or coronary artery bypass or extracorporeal circulation or cardio-
pulmonary bypass) and (cognition disorders or cognitive symptoms or neuropsychology or
neuropsychological tests) 161
• Psychlit electronic database 1980-1999: standard terms: (heart surgery) and (neuro-
psychological assessment or cognitive assessment or cognition or concentration or attention) 10
• Book: ‘cardiac surgery and the brain’ by Smith and Taylor12: relevant references of relevant 
chapters 67
• Abstract books of the conferences on cardiac surgery and the brain (‘Outcomes - The Key 
West Meeting’ ‘97, ‘98, ’99): relevant references of relevant chapters 69
• The references of three recent reviews on cardiac surgery and cognitive decline9,10,13 91
• Current Contents and PubMed 1999: January - September 18
Total number of different titles 256
In the numbers of titles found, articles published before 1980 and books are not included
names. Again, several recommendations of the Statement of
Consensus 11 were taken into account. Neuropsychologic test
batteries were rated with respect to (1) the cognitive domain of
the tests, (2) the sensitivity of the tests, (3) the availability of par-
allel forms of the tests, and (4) the overall balance of the cogni-
tive domains assessed in the battery. So that the comparability of
the studies could be further improved, (5) a recommended core
battery was taken as the basis for our assessment of quality of the
test batteries used. This core battery minimally includes the Rey
Auditory Verbal Learning Task, the Trail Making Tests A and B,
and the Grooved Pegboard. These tests are widely used, easy to
conduct, well-normalized, and sensitive to cerebral damage.
Analysis
Studies were classified as (1) cohort studies, aiming to determine
the incidence of cognitive decline at a certain moment after the
operation and/or to identify determinants of cognitive decline, or
12
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Table 2: Cohort studies
Year of No. of Mean NP-test Lost to  
First author publication patients age, y timing, mo follow-up, %
Ellis21 1980 30 55 1 0
Shaw22 1987 259 54 6 17
Treasure23 1989 76 55 2 12
Harrison24 1989 78 55 2 40
Mahanna5 1996 232 61 1,5 / 6 60 / 61
Toner25 1996 61 60 2 0
Tardiff26 1997 65 62 1,5 12
McKhann27 1997 172 63 1 / 12 26
Braekken28 1998 14 64 2 0
Vanninen29 1998 38 64 3 3
Browne30 1999 120 ? 3 0
Rasmussen31 1999 35 70 3 17
NP-test timing indicates time between CABG and postoperative neuropsychologic test administration; Definition of cognitive
deficit: 1 (>=1 SD in >=1 test); 2 (>=1 SD in >=2 tests); 3 (>=1 SD in >=3 tests); 4 (>=0.5 SD in a domain); 
5 (>=20% in >=2 tests); 6 (>=20% in >=20%); 7 (other); Comparability: ++: tests of ‘core battery’ are used (Rey
auditory verbal learning task, Trailmaking Tests A and B, Grooved Pegboard); +: comparable tests were used; -: tests were
not comparable with core battery.
* Five different definitions were used. The percentages given are for 1 SD decline in one or more tests.
† Analyzed per domain.
‡ Three different definitions were used on two tests. Proportions of patients with deficit varied from 7% to 33 %.
(2) intervention (controlled) studies, investigating the cerebral
protective effect of intraoperative interventions.
To determine whether a pooled analysis could be carried out, we
assessed the comparability of the studies entered into the review
in terms of precise timing of neuropsychologic testing, compara-
bility of tests, and definition of decline.
Results
Cohort studies
The twelve cohort studies meeting the selection criteria are pre-
sented in Table 2. Some of these studies exclusively aimed to
determine the incidence of neuropsychologic decline, whereas
others were designed to identify determinants of cognitive
decline. The studies in Table 2 are ordered by year of publica-
tion. The mean age of the patients studied increased over time,
13
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Table 2: (continued)
No. of Definition Compar- Proportion patients 
tests used cognitive deficit ability with cognitive deficit, %
3 7 - 17
10 2 - 22
10 2 ++ 37
10 2 ++ 36
5 7* - 14* / 4*
10 2 ++ 38
7 6 - 47
8 4 + †
10 2 + 14
8 3 - 22
2 7‡ - ‡
5 7 - 14
14
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Table 3: Intervention studies
Year No. Mean NP-test Lost to No. of Definition
First of of age, iming, follow-up, tests cognitive
author public patients y tmo % used deficit
Fish32 1987 2 x 50 58 2 26 10 7
Arrow 
smith33 1998 87 + 84 59 2 7 9 2
Sellman34 1993 3 x 20 59 1 / 6 10 13 2
Pugsley35 1994 53 + 52 55 2 5 10 2
Murkin36 1995 4 x 79 61 2 24 5 7
Patel37 1996 2 x 35 57 1,5 0 10 2
Gold38 1995 2 x 124 66 6 9 11 7
Mora39 1996 54 + 55 63 1,5 23 5 1
Regragui40 1996 31+36+29 59 1,5 27 7 7
Heyer41 1997 46 + 53 64 1,5 74 5 7
Hammon42 1997 192 + 203 61 1,5 ? 11 5
NP-test timing indicates time between CABG and postoperative neuropsychologic test administration; Definition of cognitive
deficit: 1 (>=1 SD in >=1 test); 2 (>=1 SD in >=2 tests); 3 (>=1 SD in >=3 tests); 4 (>=0.5 SD in a domain); 5
(>=20% in >=2 tests); 6 (>=20% in >=20%); 7 (other); Comparability: ++: tests of ‘core battery’ are used (Rey auditory
verbal learning task, Trailmaking Tests A and B, Grooved Pegboard); +: comparable tests were used; -: tests were not
comparable with core battery.
15
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Table 3: (continued)
Compa-
rability Intervention studied Results
- prostacyclin during CPB 0% cognitive decline in intervention group and control group
+ remacemide vs placebo remacemide group: 9% decline; placebo group 12% decline 
(p=0.6)
- membrane vs bubble bubble ox - no filter: 24% / 12% decline; bubble ox - with filter:
oxygenator and use of 12% / 6% decline; membrane ox - no filter: 15% / 5% decline.
arterial line filter All differences NS
++ use of arterial filter filter-group: 8.2% decline; 
control-group: 26.7% 
decline (p<0.03)
- alpha-stat vs pH-stat alpha-stat group: 30% cognitive dysfunction; pH-stat group:
blood gas management 36% cognitive dysfunction (NS); 
and pulsatile vs  pulsatility has no effect on outcome
non-pulsatile CPB
++ alpha-stat vs pH-stat blood alpha-stat group: 45.7% np deficit;
gas management pH-stat group: 68.6% np deficit (NS)
- bloodpressure during CPB: low pressure group: 12% deteriorated;
50-60 mmHg vs high pressure group: 11% deteriorated (NS)
80-100 mmHg
- perfusion temperature 15% deterioration in both treatment groups
<28 ˚C vs >35 ˚C
- perfusion temperature significantly more deterioration in 37 ˚C group, 
28 ˚C vs 32 ˚C vs 37 ˚C compared to 32 ˚C group (p=0.015)
+ perfusion temperature 15% decline in 28 ˚C group; 39% decline in 34 ˚C group;
28 ˚C vs 34 ˚C difference NS
++ combination of epi-aortic intervention group: 18% decline; standard treatment group:
scanning, more use of 29% decline (p=0.01)
single cross clamp and (nonrandomized study)
more ventricular venting
versus standard treatment
but no clear time trend could be observed in the incidences of
cognitive deficits, which varied from 4% to 47%.
None of the studies designed as a correlation study21,25,26,28,31 was
able to identify determinants of cognitive decline in the primary
analysis. However, in a multivariate analysis, Tardiff and associ-
ates26 found a significant association between short-term memory
dysfunction after CABG and a variant form of the apolipoprotein
E gene, especially in patients with lower educational levels. This
gene encodes the APOE protein, which is responsible for repair
of neuronal injury and probably involved in the development of
Alzheimer disease.
Intervention studies
The eleven intervention studies included are shown in Table 3.
Ten of them were randomized trials. In two studies, the initial
data analysis demonstrated that the intervention studied led to a
statistically significantly (p<0.05) decreased risk of cognitive
decline. Hammon and colleagues42 compared the results in
16
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Table 4: The four cohort studies and two intervention studies that were comparable
Year of No. of Mean NP-test No. of 
First author publication patients age, y timing, mo tests used
Treasure23 1989 76 55 2 10
Harrison24 1989 78 55 2 10
Pugsley35* 1994 105 55 2 10
Toner25 1996 61 60 2 10
Arrowsmith33* 1998 171 59 2 9
Braekken28 1998 14 64 2 10
Total 505
Weighted average
The four cohort studies and two intervention studies that were comparable in definition of cognitive decline (a decline in
performance at least 1 standard deviation in at least two tests), use of the core-battery (Rey Auditory Verbal Learning Task,
the Trailmaking Tests A and B, and the Grooved Pegboard) or comparable neuropsychological tests, and timing of test-
administration (2 months after operation). These six studies include 505 patients, of whom 448 completed two months
follow-up. To calculate a weighted average, the proportion of patients with cognitive decline per study was multiplied with
the number of patients per study who completed follow-up. The sum of the multiplications was then divided by the total
number of patients who completed follow-up. On average, the proportion of patients with cognitive decline was 22.5% (p <
0.0001; 95% confidence interval 18.7 % - 26.4 %).
* Intervention studies, in which the weighted mean of the proportions of patients with a deficit in the two treatment groups
was used.
patients operated on in
1991 and 1992 with
results in patients operat-
ed on in the next 2 years.
In the second time peri-
od, the surgical team had
adopted the use of
epiaortic scanning and
had increased the use of
the single crossclamp
technique and left ven-
tricular venting. This
combined strategy
reduced the incidence of
cognitive decline by 11%
(p=0.01). The other
study with a significant
result in the initial analy-
sis showed a beneficial
effect of the use of an
arterial line filter.35
Many intervention studies had insufficient statistical power to
detect clinically meaningful differences. In some of these studies,
post hoc use of another definition of cognitive decline led to sig-
nificant results. One example is the remacemide trial by
Arrowsmith and coworkers.33 Individual cognitive decline was
less frequent in the treated group, but the study lacked power to
reach statistical significance. Redefining cognitive decline as
“overall postoperative change” made the favorable effect of
remacemide statistically significant.
Pulsatile blood flow during CPB did not improve neurocognitive
outcome in 316 patients,36 but in the same series, alpha-stat blood
gas management reduced the incidence of cognitive deficits. This
reduction was significant in patients with a bypass time of more
than 90 minutes. The protective effect of alpha-stat blood gas
management was also found by Patel and associates.37 The
observed difference became statistically significant when a more
stringent definition of neuropsychologic deficit (decline on three
tests instead of two tests) was used.
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Table 4: (continued)
No. of patients who Proportion of patients 
completed follow-up with cognitive deficit, %
67 37
47 36
100 17.45*
61 38
159 10.45*
14 14
448
22.5
The three studies on the influence of perfusion temperature39-41
failed to demonstrate a clear advantage of hypothermia compared
with normothermia, but the sample sizes of the studies were rela-
tively small, and in the study of Heyer and colleagues41 only 26%
of the study patients were available for follow-up.
Neuropsychology
The selected studies included neuropsychologic tests as the meas-
ure of cognitive decline. Of the 23 selected studies, six included
the core battery as recommended by the Statement of
Consensus.11 In addition, four studies used tests similar to the
recommended core battery (see Tables 2 and 3). Accordingly, ten
studies were at least partially comparable and met with widely
accepted quality criteria.
Four study groups5,22,30,37 used several definitions of cognitive
decline in their samples. The definition used most frequently (in
nine studies) was a postoperative deterioration of at least 1 stan-
dard deviation (of the population’s performance at baseline) com-
pared with preoperative testing in at least two tests. In one study
the same definition was used with a minimum of three tests
showing deterioration, whereas one other study took deteriora-
tion in one test as criterion. Comparability in terms of definition
of cognitive decline was thus limited to nine studies.
Pooled analysis
Four cohort studies23-25,28 and two intervention studies33,35 were
comparable not only in definition of decline and use of the core
battery or comparable tests, but also in timing of test administra-
tion. These six studies in total included 505 patients, of whom
448 completed 2 months of follow-up (Table 4). We combined
the results of these studies in a weighted average (the sum of the
proportions of patients with cognitive decline per study times
number of patients per study, divided by the total number of
patients). For the two intervention studies, the weighted mean of
the two treatment groups was used. On average, 22.5% of the
CABG patients had a decline of at least 1 standard deviation in at
least two of a total of nine or ten tests 2 months after their opera-
tion (p<0.0001; 95% confidence interval, 18.7%-26.4%).
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Discussion
This study systematically reviewed reports on cognitive decline
after CABG. The literature search was extensive. In an attempt to
select studies that could be compared, we formulated stringent
selection criteria. A limitation of using these selection criteria is
that some informative aspects of research were rejected. The rela-
tively small number of the studies that could be included in the
review underlines the lack of comparability of studies carried out
until now.
The reported incidences of cognitive deficits varied widely. At
least in part, this can be explained by the differences in timing of
test administration and definitions of cognitive deficit. A high loss
to follow-up in 3 studies5,24,41 may also have influenced the inci-
dences found, as loss to follow-up is seldom random.6 Most of
the included studies were comparable in terms of neuropsycho-
logic tests used, which is probably encouraged by the Statement
of Consensus that was held in 1994.11
Within the six studies used for the pooled analysis, there was still
a considerable variation in the reported incidence of cognitive
decline (10%-38% 2 months after the operation). It is not possible
to conclude from these studies that the incidence of cognitive
deficits has decreased in the past 10 years. Improved outcome as a
result of better anesthesiologic and perfusion management may be
offset by the increasing age of the patients, which in itself is asso-
ciated with an increased risk for cerebral complications.36,42 With
the six selected studies, we calculated an average incidence of
cognitive deficits of 22.5% 2 months after CABG. This figure
must be interpreted with caution because, even within these six
studies, methodologic differences were present. For example, the
cutoff value of 1 standard deviation, used to define a deficit, var-
ied per study, because the baseline performances of the six patient
series are inevitably not the same. A formal meta-analysis, which
is typically performed with a series of methodologically compara-
ble randomized trials, includes the use of more advanced weigh-
ing factors, testing of homogeneity of the effect estimates of the
different studies, and a sensitivity analysis. However, the method-
ology of meta-analysis of uncontrolled observational studies is
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subject to debate,43 and its use in this review would have unjustly
suggested a high level of objectiveness and precision.
The clinical meaning of a decline of 1 standard deviation in two
tests is relative, because the figure calculated, 22.5%, does not
indicate the percentage of patients who are significantly disabled
after CABG. Several authors emphasize that, in most patients, the
deficit does not matter to the patient in functional terms.
Apparently, many activities of daily life do not require the level
of performance called for during neuropsychologic testing.
However, a small proportion of patients with intellectual dysfunc-
tion or memory deficits become sufficiently disabled to prevent
return to employment.1,22
The discrepancy between decline in test performance and func-
tional decline is also expressed by the methodologic difficulties of
defining a cognitive deficit. Mahanna and colleagues5 demonstrat-
ed the enormous influence of the definition of cognitive deficit
that is chosen by applying five different definitions on the same
patient sample. Depending on the definition used, the incidence
of cognitive deficit ranged from 1.1% to 34% at 6 weeks and
from 3.4% to 19.4% at 6 months postoperatively.
Most authors defined deficit as a certain deterioration in one or
more tests, which may seem accurate. However, some tests com-
prise more than one test variable, and from most studies it was
not clear whether test deficit meant deterioration in one or all of
the variables of one test. This obviously creates a multitude of
possible outcomes and is therefore a factor complicating the
interpretation of the incidence data. A deterioration of 1 standard
deviation in postoperative functioning compared with preopera-
tive functioning was the most frequently used cutoff value. This
is arbitrary and does not necessarily reveal real cognitive change,
since it does not take into account the reliability of the change
scores. Practice effects were almost always mentioned but not
included in analyses, which may have resulted in an underestima-
tion of incidence figures. There is emerging recognition of the
importance of defining real change in test-retest scores as
opposed to artifactual change resulting from low test reliability
and susceptibility to practice effects. Recent research is increas-
ingly focused on the use of reliable change indices. These indices
define the range in which an individual score is likely to fluctuate
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because of the imprecision of the measure, providing statistically
based cut-off scores for cognitive change on each measure.44,45
For example, a 90% reliable change interval is calculated on the
basis of the correlation and the standard error of the difference
between baseline and follow-up scores of control subjects. When
the difference between an individual patient’s postoperative and
preoperative scores falls outside this interval, he or she is consid-
ered to have a statistically significant change in performance on
this particular neuropsychologic measure.44
The single-case analysis technique, recommended in the consen-
sus statements,11,46 uses the patient as his or her own control and
defines a cognitive deficit as a 20% decrease in at least 20% of the
tests. This method also has some drawbacks. In the first place,
reducing the continuous test scores to a dichotomous outcome
measure (presence of a 20% decrease or not) is a “costly” way of
data handling that reduces statistical power and may have made
several randomized studies fail to reach statistically significant
results. The 20% decrease rule is as arbitrary as the 1 standard
deviation decrease rule. The problem may be overcome by
refraining from “dichotomizing” data and just calculating how
much the patient’s performance deviates from the expected (base-
line or control group) performance. Second, due to floor effects
it may be difficult to demonstrate a deficit in patients with a low
preoperative test performance. In the third place, as demonstrated
by Browne and colleagues,30 “regression toward the mean” may
strongly influence single-case definitions of cognitive deteriora-
tion. High baseline performers may be wrongly classified as
impaired and low baseline performers may not show a deficit
although deterioration had actually occurred. This problem can
be overcome by using group mean analysis, which is free from
the influence of regression to the mean (in contrast to analysis by
single-case definitions). As discussed before, comparison of mean
group performance before and after surgery does have disadvan-
tages, especially if large practice effects are present. However, if a
suitable control group is available (randomized trial), comparison
of group means allows for the control of both practice effects and
regression to the mean.
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Conclusions
A pooled analysis of six highly comparable studies yielded a pro-
portion of 22.5% of patients with a cognitive deficit 2 months
after CABG. Although this percentage is partly determined by the
definition of cognitive deficit that was used, it demonstrates that
cognitive dysfunction is a frequently occurring complication of
CABG. The etiologic contribution of CPB to this complication
will remain unclear until a randomized trial that directly com-
pares off-pump CABG with on-pump CABG is carried out. To
improve comparability of future studies, we advocate that
researchers use the guidelines of the 1994 consensus meeting.
However, the recommended single-case analysis technique has
some drawbacks and may be replaced by other analysis tech-
niques, especially when a control group is included in the study
design.
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Abstract
The Octopus Study consists of two multicenter randomized clinical trials in which
coronary artery bypass grafting on the beating heart (off-pump CABG) using the
Utrecht Octopus Method is compared to intracoronary stent implantation and con-
ventional CABG. The primary endpoint in the comparison of off-pump CABG versus
stent implantation (OctoStent Trial) is medical effectiveness (i.e., absence of rein-
tervention and major adverse cardiac and cerebrovascular events at 1 year after
treatment). The primary endpoint in the comparison of off-pump CABG versus con-
ventional CABG (OctoPump Trial) is cerebral safety (i.e., absence of cognitive
deficits and cerebrovascular events at 3 months after treatment). Secondary end-
points in both trials include presence and severity of angina, quality of life, exercise
capacity, and cost-effectiveness. A total of 560 patients will be enrolled. A random
sample of 210 patients will undergo repeat angiography at 1 year to assess angio-
graphic restenosis rate and graft patency. Including 1-year follow-up, the study will
last for 3 years.
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Introduction
Ischemic heart disease is the leading cause of morbidity and mor-
tality in the industrialized world.1 Treatment is basically aimed at
palliation and consists of either pharmacologic intervention or
revascularization. The latter may be performed by percutaneous
transluminal coronary angioplasty (PTCA) or coronary artery
bypass surgery (CABG). PTCA is increasingly being combined
with intracoronary stent implantation, which expands the pool of
candidates for nonsurgical treatment to patients with more
advanced disease.2 Concurrently, the conventional bypass opera-
tion during which cardiopulmonary bypass is used (on-pump
CABG) is being challenged by bypass surgery on the beating
heart (off-pump CABG).3-7 The latter obviates the need for car-
diopulmonary bypass (CPB) and aortic cross-clamping, which are
held responsible for major complications following CABG, in
particular neurological and cognitive dysfunction.8,9
Recently, in the Heart Lung Institute of Utrecht University
Hospital, the Octopus Tissue Stabilizer® for local cardiac wall
stabilization has been developed.10 This device offers immobiliza-
tion and presentation of all sides of the heart and therefore allows
three-vessel revascularization without the use of CPB.7 The feasi-
bility of off-pump CABG using the Octopus method has been
demonstrated in animal studies10-14 and clinical practice.7 The
early clinical outcome and graft patency rates in the first 100
patients stimulated us to initiate randomized trials to compare this
new technique with other revascularization strategies.7
Objectives
The aim of the Octopus Study is twofold: first, to compare med-
ical effectiveness between off-pump CABG and PTCA with intra-
coronary stent implantation in patients referred for PTCA in
whom off-pump CABG is feasible (OctoStent Trial); second, to
assess the cerebral safety of off-pump CABG compared to the
cerebral safety of conventional CABG in patients referred for
CABG in whom off-pump CABG is feasible (OctoPump Trial).
In addition, in both trials the cost-effectiveness of off-pump
CABG will be estimated relative to the reference treatment.
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Rationale
PTCA and CABG play an important role in the treatment and
management of ischemic heart disease. Both treatment modalities
have their intrinsic advantages and disadvantages. A limitation of
PTCA is the risk for restenosis. Approximately 20 - 40% of the
patients who underwent a first successful PTCA will undergo
another revascularization procedure within the first year after the
procedure.15,16 Intracoronary stent placement leads to a reduction
of restenosis rate and repeat interventions, especially with
improved implantation techniques.17 Other advantages of stent
implantation are a highly predictable and complete restoration of
the coronary anatomy immediately after implantation and a
reduced risk of (sub)acute vessel closure, which improves the
safety of the procedure.18,19
CABG provides more complete revascularization and requires
fewer repeat interventions in comparison with PTCA. However,
the procedure is more invasive and is associated with cardiac as
well as noncardiac morbidity.20,21 Major neurologic complications
after conventional cardiac surgery have recently been reported to
occur in 3.1% of the patients.8 In addition, neuropsychological
dysfunction is increasingly being recognized as a complication of
on-pump CABG. Currently, cognitive deficits can be documented
accurately22,23 and may occur in up to 38% of the patients.8,9,24,25
The increasing awareness of the cerebral complications following
CABG, especially in the elderly9, has led to a renewed interest in
bypass surgery on the beating heart. The Utrecht Octopus
method is a recent technique developed to avoid CPB and the
complications associated with its use.7,10-14 A feasibility study in
the first 100 patients operated on with the Octopus Method
showed angiographic results comparable with historical controls.
There was no mortality at 30 days, and the myocardial infarction
(MI) rate was 4%. The patients had a fast recovery and quickly
resumed normal socioeconomic activities.7
The role of off-pump CABG, however, is subject to debate.
Opponents emphasize the excellent results of conventional
CABG and express their concerns about the safety, early anasto-
motic failure, and eventual incomplete revascularization related
to off-pump CABG.26 Moreover, although widely accepted, the
suspected deleterious role of cardiopulmonary bypass in the gene-
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sis of adverse cerebral outcome has never been proved, simply
because an appropriate control group has never been available. A
limited number of randomized clinical trials have directly com-
pared PTCA to CABG.15, 20, 27-29 There are no randomized clini-
cal trials comparing off-pump CABG to stent implantation or
conventional CABG. Therefore, we initiated the Octopus Study
to assess the postulated benefits of off-pump CABG.
Methods
The Octopus Study comprises two multicenter randomized clini-
cal trials, of which the design, timing of investigations, and defi-
nitions of main outcome events are presented in Figure 1, Table
1, and Table 2, respectively.
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Figure 1: Flow-chart Octopus Study
Only patients eligible for offpump CABG can enter the study. CABG = coronary artery
bypass grafting; PTCA = percutaneous transluminal coronary angioplasty; CPB =
cardiopulmonary bypass.
Primary endpoints
The OctoStent Trial
It is expected that the need for repeat revascularization after off-
pump CABG and conventional CABG is similar. PTCA with
stent implantation is less invasive than CABG, but is associated
with a higher need for repeat interventions.16 Although repeat
interventions can be seen as part of the angioplasty procedure,
they have major clinical impact and are considered as failure of
treatment in this study, which aims to compare the medical effec-
tiveness of two revascularization procedures. Therefore, the pri-
mary endpoint in comparing off-pump CABG with PTCA with
stent implantation incorporates revascularization as part of the
combined primary endpoint, which is the proportion of patients
free of cardiovascular death, nonfatal myocardial infarction, non-
fatal cerebrovascular accident (CVA), or revascularization by
means of CABG or PTCA, whichever occurs first, at 1 year
(± 1 month) after the index treatment.
32
Chapter 3
Table 1: Timing of investigations
S P D 1m 3m 6m 12m
Angiography X† X‡
History/events X X X X X X
Anginal assessment X X X X X X
Medications X X X X X
Physical examination X X X X
Electrocardiography X X X X
Neuropsychological tests* X X X X
Blood analysis
Cardiac enzymes X X
Routine laboratory X X X
Total, HDL, HDL, cholesterol X X
Resource utilization X X X X X X
Quality of life X X X X
Working status X X X X
ECG stress test X
Abbreviations: S = preprocedural screening; P = procedure; D = discharge; 1m = 1 month after intervention; 3 m = 3
months after intervention; 6 m = 6 months after intervention; 12 m = 12 months after intervention.
* Only for patients in the comparison of off-pump CABG and conventional CABG (OctoPump Trial).
† Only for patients undergoing PTCA with stent implantation.
‡ Coronary angiography will be performed in a sample of 210 patients.
The OctoPump Trial
As mentioned above, off-pump CABG and conventional CABG
are assumed to be equally effective in terms of myocardial revas-
cularization (i.e., have similar medical effectiveness). However,
the use of cardiopulmonary bypass in conventional CABG is asso-
ciated with considerable cerebral morbidity, in particular neu-
ropsychological deficits.8,9 Therefore, the primary endpoint in the
comparison of off-pump CABG to conventional CABG is cere-
bral safety. This is defined as the proportion of patients free of
the combined event of fatal and nonfatal CVA and cognitive dys-
function, whichever occurs first, to be determined at 3 months (±
3 weeks) after the index treatment. The occurrence of cognitive
dysfunction is determined using a neuropsychological test proce-
dure (Appendix 1).
Secondary endpoints
The secondary endpoints in both trials include all cause mortality,
presence and severity of angina, quality of life using SF-3630,31
and EuroQol32,33 questionnaires, and cost/effectiveness at 1
(± 1 week), 6 (± 1 month), and 12 months (± 1 month) after the
index treatment. Exercise capacity is assessed at 1 year. Finally,
angiographic restenosis rate and graft patency are evaluated in a
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Table 2: Definitions of main outcome events.
Cardiovascular death All deaths are considered cardiovascular unless an unequivocal non-
cardiovascular cause can be established. Cardiovascular death
includes fatal myocardial infarction, sudden death, terminal heart
failure, fatal cerebral infarction and hemorrhage and procedure-
related fatal bleeding (e.g. tamponade, access site bleeding).
Cerebral infarction and hemorrhage Patients with relevant clinical features (focal injury persisting for
more than 24 hours, preferably confirmed by computed tomography
scan) combined with an increase in handicap of at least one grade on
the Rankin Scale.
Cognitive dysfunction A decrease of 20% or more between the baseline and post-treatment
assessment of an individual's score in three or more tests of a battery
of eleven neuropsychological tests (Appendix 1).
Myocardial infarction Elevation of specific cardiac enzymes or the development of specific
abnormalities in the ECG specified in Appendix 2.
Repeat revascularization The initial PTCA procedure is considered completed at the time when
the guiding catheter is removed from the arterial sheath. The initial
CABG is considered comple-ted when the patient is transferred from
the operating table into his/her bed.
random subgroup of 210 patients undergoing repeat angiography
at 1 year (70 patients having undergone PTCA; 70 patients having
undergone off-pump CABG, equally split between the two sub-
studies; 70 patients having undergone conventional CABG).
In the OctoPump Trial no difference is expected in cardiac out-
come; nevertheless, cardiac death, myocardial infarction, and
repeat revascularization procedures will be assessed at 1, 6, and
12 months. Cognitive function will also be assessed 4 days after
operation. It is expected that most patients will show a decline in
this early postoperative stage. However, the fast recovery and
short hospital stay of the first 100 patients operated on in our
hospital with the use of the Octopus Method suggest that the
benefits of off-pump CABG may be especially reflected in a
reduction of neuropsychological deficits in the first week after
operation.
Patients
Patients with coronary lesions technically suitable for angioplasty
and off-pump CABG are selected for the OctoStent Trial.
Patients with coronary lesions suitable for off-pump CABG and
on-pump CABG are selected for the OctoPump Trial. This selec-
tion predominantly depends on the precise location of the
stenoses, the anticipated capacity of the heart to endure tempo-
rary occlusion of the involved coronary arteries, and hemody-
namic consequences of local immobilization of the ventricular
wall. In particular, bypass grafting of posterior coronary arteries
may result in a significant drop in left ventricular stroke volume
upon presentation of these vessels.12,13 The selection criteria for
the Octopus Study are presented in Table 3.
Randomization procedure
Patients eligible for the OctoStent or OctoPump Trial are invited
to the outpatient clinic to receive additional information.
Candidates for either trial admitted to a referring hospital are vis-
ited by one of the trial monitors. After obtaining informed con-
sent, patients are randomized by a telephone call from the trial
monitor of the participating hospital to the randomization center
of the Julius Center for General Practice and Patient Oriented
Research, Utrecht, The Netherlands. To ensure a reasonable bal-
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ance, assignment is performed according to computer-generated
lists of random permuted blocks that are unknown by the investi-
gators. After randomization patients are scheduled for the allotted
treatment.
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Table 3: Inclusion and exclusion criteria of the Octopus Study
INCLUSION CRITERIA
1. Patients with stable or unstable angina pectoris (Braunwald Class I-II, b) and/or documented ischemia
due to single or multivessel disease and a normal or moderately impaired global left ventricular
function.
2. Patients who are considered candidate for PTCA (OctoStent Trial) or CABG (OctoPump Trial).
3. Patients who are eligible for off-pump CABG: Patients with single and multivessel disease in which one
or more significant stenosis(es) in at least one major epicardial coronary artery (left anterior descending
srtery, left circumflex artery, right coronary artery or the combination of one of the former and a side
branch providing different myocardial territories) are to be treated. With respect to the left circumflex
artery, only patients in whom one graft needs to be inserted to provide sufficient revascularization are
candidates. In addition, only patients without a hemodynamic significant left main stem stenosis can be
included.
4. Written informed consent.
EXCLUSION CRITERIA
General exclusion criteria
1. Age under 18.
2. History of CABG.
3. History of PTCA < 6 months before.
4. Need for concomitant major surgery (e.g. valve replacement, resection ventricular aneurysm, congenital
heart disease, vascular surgery of the carotid artery, or thoracic-abdominal aorta).
5. Concomitant medical disorders making clinical follow-up of at least 1 year unlikely or impossible (e.g.
neoplastic disease, hepatic failure).
6. Q-wave myocardial infarction in the last 6 weeks.
7. Overt congestive heart failure.
8. Hemorrhagic diathesis or hypercoagulability.
9. Thoracic deformations technically precluding off-pump CABG.
10. Unable to give informed consent.
Criteria specifically related to PTCA/stent implantation (only for OctoStent Trial)
1. Totally occluded coronary arteries supplying documented viable myocardium. Patients with a totally
occluded coronary artery may be included provided this artery does not need to be revascularized
because it supplies an akinetic segment of the left ventricle as documented on the diagnostic
ventriculogram in combination with pathologic Q-wave on the ECG.
2. Balloon angioplasty without stent implantation is permitted as a complementary treatment provided
that at least one other target lesion is amenable to stenting.
3. Intolerance or contraindication to acetylsalicylic acid or ticlopidine.
4. Leucopenia (< 3.5 x 109/liter).
5. Neutropenia (< 1000 neutrophils/mm3).
6. Thrombocytopenia (< 100.000 platelets per mm3).
7. Documented peptic ulcer or gastro-intestinal bleeding in the last 6 months.
8. In-stent restenosis.
Number of patients required
All sample size calculations are based on a two-sided alpha error
of 0.05 and 90% power.
The OctoStent Trial
Meta-analysis of randomized trials comparing coronary angioplas-
ty with bypass surgery have disclosed no difference between
PTCA and CABG in the survival free from myocardial infarction
(92% at 1 year and 90% at 3 years after PTCA and CABG).
However, event-free survival (free from myocardial infarction,
repeat bypass surgery, or PTCA) was approximately 60% and 90%
at 1 year after PTCA and CABG, respectively.16 Additional stent
implantation is expected to improve vessel patency and 1-year
event-free survival as compared to simple balloon angioplasty.2,19
Off-pump CABG is expected to result in similar medical effec-
tiveness as conventional CABG. Accordingly, an event-free sur-
vival at 1 year of 75% after stent implantation and of 90% after
off-pump CABG is assumed. To detect the resulting absolute dif-
ference of 15% in event rate, just over 125 patients are required
in each group.
The OctoPump Trial
No difference in medical effectiveness in terms of mortality,
myocardial infarction, and repeat revascularization at 1 year is
expected between off-pump CABG and standard CABG.
However, a significant difference in morbidity is expected in
favor of off-pump CABG owing to a reduction in major neuro-
logic and neuropsychological complications. Assuming an inci-
dence of cerebral complications, including neuropsychological
deficits, of 21% after on-pump CABG8,9 and a two-thirds reduc-
tion of complications resulting from off-pump CABG, a total of
125 patients is again required in each group.
Taking into account a loss to follow-up of 10%, 140 patients will
be randomized to each group. Therefore, the total study popula-
tion will be 4 x 140 = 560 patients.
Inclusion rate and generalizibility
Eligibility for study participation is evaluated by filling out a stan-
dard checklist encompassing the inclusion and exclusion criteria
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of the study for all patients referred for coronary revascularization
(PTCA or CABG). These checklists, or “screening logs,” have
shown that off-pump CABG may currently be an alternative for
conventional CABG in approximately 15% of cases and for PTCA
with stent implantation in approximately 30% of cases. To allow
inclusion of 560 patients within 2 years (six per week) and to
improve the generalizibility of the results, two other cardiac cen-
ters in the Netherlands are participating in the trial and are
expected to enroll 125 patients each.
Analytical plan
The aim of the main analysis is to compare the incidence of the
primary outcome events in either trial. Kaplan Meier curves will
be used for graphic comparison. The occurrence of outcome
events will be compared by means of Cox’s proportional hazards
model yielding a hazard ratio. For the Octostent Trial, in addition
to the combined endpoint of cardiovascular death, nonfatal
myocardial infarction, CVA, or revascularization by means of
CABG or PTCA, each component of this primary outcome will
be assessed. The precision of the hazard ratio estimates will be
described by means of 95% confidence intervals. The primary
data analysis will be based on the intention-to-treat principle.
For all treatment modalities the costs of diagnostic procedures,
treatment procedures, complications, and short- and long-term
differences in effects will be estimated. Marginal costs in mone-
tary terms will be calculated by multiplying unit costs and mar-
ginal medical consumption as recorded for each patient.
Subsequently, marginal cost-effectiveness ratios will be estimated
from the perspective of health-care insurance (tariffs) and from a
societal perspective (actual costs). A theoretical decision model
(i.e., an arithmetical model taking into account all relevant out-
comes of interest such as efficacy, complications, quality of life,
and costs) will be used to estimate long-term cost-effectiveness.
Study organization
The departments involved each delegate one or two staff mem-
bers not directly in charge of the treatment of the patients to the
Steering Committee. This is the main policy- and decision-mak-
ing committee of the study and has final responsibility for the
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administrative, clinical, and scientific conduct of the study. A car-
diopulmonary surgeon, a cardiologist, a cardioanesthesiologist,
and a neurologist form the Critical Event Committee and confirm
and classify the major adverse cardiac and cerebrovascular events,
blinded to the treatment if possible (in the OctoStent Trial, blind-
ing is sometimes impossible). To verify whether important differ-
ences in the incidence of major adverse cardiac events and
cerebrovascular events exist between the treatment groups, the
Data Monitoring Committee performed an interim analysis after
the first 190 patients had entered each arm of the study. The
three members of this committee are experienced in patient-ori-
ented research, are independent of the study, and may also offer
unsolicited recommendations. A stopping rule was not specified
prior to the start of the study.
The Data Coordinating Center is located at the Julius Center for
General Practice and Patient Oriented Research, University
Hospital Utrecht, and is responsible for data acquisition, data
entry, data processing, and data and statistical analysis of the
study. Defined vital parameters will be double-entered. The data
will be queried at the coordinating center. An independent
Angiographic Core Laboratory is responsible for confirming all
angiographic components of the revascularization procedure and
for quantitative analysis of the angiograms before and immediate-
ly after intracoronary stent implantation or other angioplasty
technique. In addition, it will perform the analysis of the 12-
month repeat angiography performed in the predefined group of
patients who were assigned to establish the 12-month angio-
graphic restenosis rate and graft patency. All electrocardiograms
(ECGs) and stress tests will be centrally collected and analyzed by
the ECG Core Laboratory located in the Department of
Cardiology, University Hospital Utrecht. The execution of the
study, including data acquisition, data analysis, and reporting, is
the responsibility of the four Principal Investigators and two Trial
Coordinators.
Ethical aspects
This study is conducted in accordance with the principles of the
Declaration of Helsinki and with the laws and regulations of the
Netherlands. The study protocol has been approved by the local
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Ethics Committee of each participating hospital. Written
informed consent is obtained by the attending physician. It is
explained to the patient that if he or she is randomized to off-
pump CABG, eventually conventional CABG may have to be
performed due to technical difficulties.
Implementation issues
As in most patient-oriented research, the logistic implications of
the study are considerable and change the daily routines on the
wards and require flexibility of doctors, nurses, and secretaries.
The implementation of the study therefore was accompanied by a
large number of presentations for the hospital personnel. A con-
stant supply of letters, news bulletins, and presentations about the
goals and progress of the study appears to be necessary to keep
everyone motivated.
The waiting list for bypass surgery is longer than it is for angio-
plasty. The latter is more easy to plan, especially when a patient is
admitted to a referring hospital. The difference in waiting time to
the intervention can be a reason for patients to refuse participa-
tion in the study, and much effort was made to harmonize it.
Referring cardiologists and cardiopulmonary surgeons have vary-
ing degrees of belief with regard to the effectiveness of the treat-
ment modalities; it was difficult for them to accept a new
treatment and allow their patients to participate in the trial. Not
all cardiopulmonary surgeons of the participating hospitals were
trained to use the Octopus immobilization device for the new
treatment and therefore did not participate in the study.
To keep our independence we chose not to approach an industri-
al sponsor, so only costs are refunded. Other running trials can
create a conflict of interest for patients and physicians, and it was
recommended to take these into account with regard to the
inclusion rate.
Initially the study was hampered by these problems. Due to com-
bined ongoing efforts of the Steering Committee, especially its
chairman, the trial monitors, and principle investigators, patient
enrollment was on schedule.
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Epilogue
The Octopus Study is designed to include patients who need
coronary revascularization and for whom several treatment strate-
gies are feasible. Currently, it represents the only randomized
study comparing off-pump CABG to conventional CABG and
PTCA with stent implantation. The results of the study may facil-
itate selection of the most appropriate therapy for individual
patients and foster the appropriate use of available resources.
Randomization of patients started in April 1998 and was complet-
ed in June 2000. The baseline characteristics of the first 360 ran-
domized patients are presented in Table 4. Including 1-year
follow-up, the study will last for 3 years. The results will be
reported in 2001.
Pa r t i c i p a t i n g  h o s p i t a l s Utrecht University Hospital, Utrecht, The
Netherlands; Isala Klinieken, Zwolle, The Netherlands; Antonius Ziekenhuis,
Nieuwegein, The Netherlands.
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Table 4: Baseline characteristics of the first 360 randomized patients
OctoStent Trial OctoPump Trial
Randomized to Randomized to Randomized to Randomized to
PTCA with off-pump off-pump conventional 
stenting CABG CABG CABG
(n=89) (n=91) (n=89) (n=91)
Mean age (years) 60 59 61 61
Males 73% 74% 67% 71%
One–vessel disease 63% 78% 29% 22%
Two–vessel disease 34% 20% 51% 50%
Three–vessel disease 2% 2% 20% 27%
History of myocardial infarction 27% 21% 24% 29%
History of PTCA 3% 2% 17% 22%
Peripheral vascular disease 7% 3% 8% 13%
Diabetes 6% 16% 11% 14%
History of smoking 71% 81% 70% 77%
Hypertension 35% 32% 41% 40%
Hypercholesterolemia 58% 56% 66% 67%
Familial history of CAD 67% 65% 55% 60%
COPD 12% 12% 9% 13%
PTCA = percutaneous transluminal angioplasty; CABG = coronary artery bypass grafting; CAD = coronary artery disease;
COPD = chronic obstructive pulmonary disease.
S t e e r i n g  c o m m i t t e e P.P.Th. de Jaegere, E.O. Robles de Medina, J.J.
Bredée, D.E. Grobbee, C. Borst, J.T.A. Knape, R.S. Kahn, J.C. Diephuis, F.A.M.
Spijkers, H.W.M. Plokker.
F u n d i n g The Octopus Study is funded by the Netherlands National Health
Insurance Council.
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Appendix 1: Neuropsychological tests
The neuropsychological tests consist of the following:
1. Motor Choice Reaction Test (MCRT). A computer test in which reaction time is
studied as a function of the complexity of the task requirements. Dependent
variables are movement time and initiation time.
2. Grooved Pegboard. A test for manual dexterity, it is a highly sensitive test for
studying improvement in motor functions following stroke. Time to completion is
scored.
3. Trail Making Test Part A and B. A test procedure in which shifting between
concepts is operationalized. Time to completion of both tests is scored.
4. Symbol Digit Modalities Test. The subject has to fill in blanks that correspond to a
key in which a symbol corresponds to a digit. The test measures speed of simple
information processing. The number of filled blanks in a fixed time is scored.
5. Stroop Color Word Test. This test consists of subtasks that measure, first, the speed
at which color names are read; second, the speed at which colors are named;
third, the speed at which the color of the printing ink is named when there is
interference from the printed color name. An interference score is calculated by
subtracting the time scores for subtasks 3 and 2. The test measures selective
attention.
6. Continuous Performance Task. A computerized test for sustained attention. The
test requires the subject to react to a visual target. The median of reaction time is
recorded.
7. Rey Auditory Verbal Learning Test. The learning list consists of 15 meaningful
monosyllabic words that are presented in five trials. Each trial ends with a free
recall of the words. After a period of 20 minutes following the fifth trial, the subject
is requested to recall as many words as possible (delayed recall), immediately
followed by a recognition trial. Main variables consist of (a) the total number of
correct words in the five trials, (b) the total number of correct words on delayed
recall, and (c) the total number of correct words on delayed recognition.
8. Self-Ordering Tasks. The procedure consists of three tasks: digit span, missing item
scan, and randomization task. The tasks measure immediate memory and verbal
working memory.
9. Visual/spatial Working Memory Test (DOT test). The procedure consists of 20 trials.
Trials 1 through 8 have no delay; the other trials have a timed interval of 10, 20,
and 30 seconds. The subject has to fill in as accurately as possible a visuospatial
target on a sheet of paper. The average distance is determined by subtracting the
average no-delay distance from the average delayed recall distance.
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10.Sternberg Memory Comparison Task. The subject is asked to cancel out digits or
letters between letters, while the memory load is expanded. Two variables are of
relevance: the memory comparison stage (expressed in the slope) and the stage of
motor organization and response execution (the intercept).
11.Line Orientation Test. This test measures spatial perception ability by requiring
subjects to match angled lines to an array of lines with varying slopes. The task is
administered as a control task to ensure that any correlations that were found on
neuropsychological testing could not be attributed to global neuropsychological
dysfunction.
One to two weeks preoperatively tests 2, 3, 7, and 11 are administered to control for
practice effects. Duration of administration is 45 minutes. The whole test battery is
administered 1 day before the operation, and 4 days and 3 and 12 months
postoperatively. The whole battery takes 100 minutes.
According to the guidelines of the 1994 meeting on this subject, cognitive dysfunction is
defined as > 20% decrease in a patient’s individual performance from baseline (1 day
before operation) to a postoperative assessment in three or more tests.22
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Appendix 2: Definition of myocardial infarction
Definition 1: Within 7 days after intervention
A. Q-wave infarction
See ECG-criteria new Q-wave infarction
and
Enzyme elevation as follows:
- After PTCA: CKMB elevation 3 _ upper limit of normal
- After CABG or MI-CABG: CKMB elevation 5 _ upper limit of normal
- If CKMB is not available: use CK 
or in absence of Q-wave infarction (see definition 1A)
B. Enzymatic/non-Q-wave infarction
Enzyme elevation as follows:
- After PTCA: CKMB elevation 3 _ upper limit of normal
- After CABG or MI-CABG: CKMB elevation 5 _ upper limit of normal
- If CKMB is not available: use CK
Definition 2: At least 7 days after any intervention (PTCA, CABG, or MI-CABG)
A. Q-wave infarction
See ECG criteria new Q-wave infarction, or in absence of Q-wave infarction (see
definition 1A)
B. Enzymatic/non-Q-wave infarction
Enzyme elevation as follows:
* Peak CKMB/CK ratio > 10% 
* If no ratio available: CKMB elevation 2 _ upper limit of normal after any intervention
ECG criteria new Q-wave infarction
1. New QS in two associated leads in absence of left bundle branche block
(LBBB)/Wolff-Parkinson-White Syndrome (WPW)
or
2. New Q-wave in two associated leads, defined as 0.04 seconds broad and/or Q/R
ratio 1/4
or
3. Posterior wall infarction: new broad R-wave ( 0,04 seconds) and tall R-wave (R/S
ratio > 1 or R-wave 0.5 mv) in lead V1 and V2, in absence of right bundle branche
block (RBBB)/right ventricular hypertrophy (RVH)
or
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4. New permanent LBBB and enzyme elevation (see definition 1B and 2B)
or
5. Reversed R-wave progression precordial: decrement R-wave 0.2 mv in two
consecutive precordial leads and enzyme elevation (see definition 1B and 2B)
or
6. Any new Q-wave in lead V2 and V3 and enzyme elevation (see definitions 1B and
2B)
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Abstract
Context Coronary artery bypass graft (CABG) surgery is associated with a
decline in cognitive function, which has largely been attributed to
the use of cardiopulmonary bypass (on-pump procedures). Cardiac
stabilizers facilitate CABG surgery without use of cardiopulmonary
bypass (off-pump procedures) and should reduce the cognitive
decline associated with on-pump procedures.
Objective To compare the effect of CABG surgery with (on-pump) and with-
out (off-pump) cardiopulmonary bypass on cognitive outcome.
Design and setting Randomized controlled trial conducted in the Netherlands of
CABG surgery patients enrolled from March 1998 through August
2000, with 3- and 12-month follow-up.
Participants and intervention Patients scheduled for their first CABG surgery (mean age, 61
years; n = 281) were randomly assigned to off-pump surgery (n =
142) or on-pump surgery (n = 139).
Main outcome measures Cognitive outcome at 3 and 12 months, which was determined by
psychologists (blinded for randomization) who administered 10
neuropsychological tests before and after surgery. Quality of life,
stroke rate, and all-cause mortality at 3 and 12 months were sec-
ondary outcome measures.
Results Cognitive outcome could be determined at 3 months in 248
patients. Cognitive decline occurred in 21% in the off-pump group
and 29% in the on-pump group (relative risk [RR], 0.65; 95% confi-
dence interval [CI], 0.36-1.16; p=0.15). The overall standardized
change score (ie, improvement of cognitive performance) was 0.19
in the off-pump vs 0.13 in the on-pump group (p=0.03). At 12
months, cognitive decline occurred in 31% in the off-pump group
and 34% in the on-pump group (RR, 0.88; 95% CI, 0.52-1.49; p=
0.69). The overall standardized change score was 0.19 in the off-
pump vs 0.12 in the on-pump group (p=0.09). No statistically sig-
nificant differences were observed between the on-pump and
off-pump groups in quality of life, stroke rate, or all-cause mortali-
ty at 3 and 12 months.
Conclusion Patients who received their first CABG surgery without cardiopul-
monary bypass had improved cognitive outcomes 3 months after
the procedure, but the effects were limited and became negligible
at 12 months.
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Introduction
Coronary artery bypass graft (CABG) surgery with the use of car-
diopulmonary bypass (CPB) is associated with significant cerebral
morbidity, usually manifested as cognitive decline or stroke.1 The
incidence of cognitive decline ranges from 3% to 50%, depending
on patient characteristics, definition of decline, and timing of
neuropsychologic assessment.1,2 A recent pooled analysis of 6
comparable studies yielded a proportion of 23% of patients with
cognitive decline 2 months after surgery.3 Although this degree of
cognitive decline does not affect most patients in functional
terms, a small proportion of patients with cognitive decline
becomes sufficiently disabled to prevent return to employment.1
Perioperative stroke occurs in approximately 3% of the patients
undergoing CABG surgery.1,4
Cerebral morbidity after CABG surgery has largely been attrib-
uted to the use of CPB.1 Cardiopulmonary bypass increases the
permeability of the blood-brain barrier and generates microem-
boli, which may affect cognitive function,5-7 and also requires
cannulation and cross-clamping of the ascending aorta, which
may induce atheromatous macroemboli causing stroke.8 Factors
increasing the risk of cerebral morbidity include advanced age
and prolonged time undergoing CPB.1,4 However, the assump-
tion that CPB is the main cause of cerebral morbidity after CABG
surgery has not been quantified in randomized trials of sufficient
size. Two small trials showed conflicting results. One study (n =
40) demonstrated a marked improvement of cognitive outcome
by using off-pump CABG surgery,5 while the other study (n =
60) showed no improvement.6
Recently, cardiac stabilization devices were developed to facili-
tate CABG surgery on the beating heart (off-pump CABG),
which allow immobilization and presentation of all sides of the
beating heart,9,10 and for many patients complete revasculariza-
tion can now be achieved without the use of CPB.10-12 In a pre-
vious article,12 we reported the clinical outcomes at 1 month after
on-pump vs off-pump CABG surgery for patients in this clinical
trial. In this study, we compared the effect of CABG surgery with
and without CPB on cognitive outcome.
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Methods
Design and patients
The design and methods of
the Octopus trial have been
described in detail.13 In
brief, patients were eligible
if referred for first-time iso-
lated coronary bypass sur-
gery and an off-pump
procedure was deemed tech-
nically feasible. Patients
were excluded in case of
emergency or concomitant
major surgery, Q-wave
myocardial infarction in the
last 6 weeks, or poor left
ventricular function. Patients
who were unlikely to com-
plete 1-year follow-up,
unable to give informed
consent, or undergo neu-
ropsychologic testing were
excluded. There were no
restrictions to age. Eligible
patients were informed with
a letter and invited to the outpatient clinic to receive additional
information. After written informed consent was obtained,
patients were randomly assigned by computerized block-random-
ization, over the telephone, to off-pump or on-pump CABG sur-
gery. The block size varied from 8 to 20 patients and was
unknown by the physicians who randomized the patients. The
study was approved by the ethics committees of the 3 participat-
ing centers.
Between March 1998 and August 2000, 281 patients were
enrolled, of whom 265 were treated according to randomization
(Figure and Table 1). Ten patients randomized to off-pump sur-
gery underwent CABG with CPB because progression of symp-
toms required emergency surgery or because technical problems
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Figure: Flow of patients throughout the trial
were encountered during the procedure. One other off-pump
patient underwent coronary angioplasty. In 5 patients assigned to
on-pump CABG surgery, an off-pump procedure was performed.
Outcome
The primary end point of the study was cognitive outcome at 3
months after surgery. Patients underwent a battery of 10 neu-
ropsychologic tests 1 day before and 3 and 12 months after opera-
tion. The tests were administered in the participating hospitals by
trained psychologists who were blinded to treatment allocation.
Administration of the tests lasted approximately 100 minutes.
In accordance with the Statement of Consensus on Assessment of
Neurobehavioral Outcomes after Cardiac Surgery,14 the battery
included tests for motor skills, verbal memory capacity, and
attention. In addition, tests were included to assess speed and
capacity of working memory, visuospatial capacity, selective and
sustained attention, and information processing. Each test yielded
1 or more variables, with different ranges per variable. Eleven
main variables were chosen a priori to be used in the analyses.
The cognitive domains that were covered, the tests, and the main
variables13 are listed in Table 2. Cognitive decline was defined as
a decrease in an individual’s performance of at least 20% from
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Table 1: Patients characteristics at baseline
Off-pump On-pump
Characteristics, % (n=142) (n=139)
Age, mean (SD), y 61.7 (9.2) 60.8 (8.8)
Education, mean (SD), y 9.3 (2.4) 9.7 (2.8)
Sex, male 66 71
Coronary artery disease
1-vessel disease 30 22
2-vessel disease 50 50
3-vessel disease 20 27
Peripheral vascular disease 7 13
Diabetes 9 17
History of stroke 4 3
Hypertension 40 44
Pulmonary disease 9 10
baseline, in at least 20% (3) of the main variables.15 Patients who
sustained a stroke were considered to have cognitive decline. To
limit practice effects, 6 of the 10 tests were also administered 2
weeks before baseline assessment (pretest, Table 2) and, wherever
possible, parallel forms of the tests were used in the consecutive
assessments.
In addition to the primary analysis based on a dichotomous cogni-
tive outcome, 2 additional analyses were performed, both includ-
ing continuous cognitive outcome measures. The first consisted
of a direct comparison of the continuous test scores. To estimate
the change in performance from baseline to 3 months after opera-
tion, a standardized change score (SCS) was calculated for each
main variable in each patient by subtracting the preoperative
score from the postoperative score and dividing the difference by
the preoperative SD of that variable. If improved performance
Chapter 4
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Table 2: Cognitive domains and neuropsychologic tests at pretesting and baseline*
Domain Test Main variable
Verbal memory, learning Rey Auditory Verbal Learning total score trial 1-5
Verbal memory, retrieval Rey Auditory Verbal Learning delayed recall score
Motor capacity Grooved Pegboard time dominant hand, s
Divided attention Trail Making Test Part A and B time trail B, s
Working memory speed Sternberg Memory Comparison time 4 character chart, s
Visuospatial capacity Line Orientation Test total score
Selective attention Stroop Color Word Test time C – time B, s
Sustained attention Continuous Performance Task mean reaction time, ms
Working memory Self Ordering Tasks sum score
Visual working memory Visuospatial Working Memory average distance, cm
Information processing Symbol Digit Modalities Test total score
* Ellipses indicate not applicable. All values are raw data and presented as medians, with 10th and 90th percentiles in
parentheses. Pretest denotes cognitive performance two weeks before baseline assessment.
was reflected by a lower score (eg, in timed tasks), the directional
data were reversed so that all improvements gave positive change
scores. Per subject, the mean of the 11 SCSs was taken as a quan-
titative measure of the overall postoperative change in perform-
ance.16,17
The second additional analysis of cognitive outcome included a
factor analysis with orthogonal rotation, which was performed to
minimize the overlap between the 11 main test variables and to
facilitate interpretation.2,18 This reduced the data set to 4 inde-
pendent factor scores, each representing a separate domain of
cognitive function: (1) attention and visuospatial capacity; (2)
verbal memory; (3) selective attention and motor capacity; and
(4) working memory. The factor coefficients needed to calculate
the factor scores at the various time points were derived using the
factor loadings and weights from the baseline cognitive data.
Cognitive outcome at three and twelve months
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Table 2: (continued)
Off-pump On-pump
pretest baseline pretest baseline
37 36 35 36
(25-49) (25-48) (24-48) (26-48)
7 6 7 6
(4-11) (3-9) (3-10) (3-10)
107 106 107 104
(91-147) (88-137) (91-157) (91-141)
97 83 91 84
(56-176) (49-153) (61-165) (52-154)
62 59 60 57
(42-89) (43-88) (45-86) (43-87)
25 24 24 24
(17-29) (17-29) (17-29) (18-28)
48 43 46 40
(29-98) (23-76) (29-85) (23-77)
... 544 ... 544
(460-711) (476-738)
... 9 ... 10
(5-16) (6-17)
... 0.4 ... 0.5
(-0.3-1.5) (-0.1-1.1)
... 41 ... 39
(25-55) (26-53)
Factor change scores were obtained by subtracting the baseline
factor scores from the postoperative factor scores.
Secondary end points included identical measures of cognitive
outcome at 12 months, differences in quality of life at 3 and 12
months, and stroke rate and all-cause mortality at 3 and 12
months. Health-related quality of life was assessed using 2 generic
questionnaires. The EuroQol questionnaire generates a single
index, ranging from -1 to +1, with -1 reflecting the worst imagi-
nable quality of life and +1 reflecting the best imaginable quality
of life.19 The Short Form-36 questionnaire comprises 8 different
domains all ranging from 0 to 100. Higher scores indicate higher
levels of functioning or well-being.20 Stroke was defined as focal
brain injury, detected by standard neurologic examination, per-
sisting for more than 24 hours, and combined with an increase in
functional deficit of at least 1 grade on the Rankin Scale.21
Treatment and procedures
The goal of surgery was to obtain complete arterial revasculariza-
tion. With the exception of 2 emergency procedures, all opera-
tions were performed by cardiac surgeons experienced in both
off-pump and on-pump bypass surgery. During off-pump proce-
dures, the Octopus method9 (Octopus Device, Medtronic,
Minneapolis, Minn) was used for stabilization of the target coro-
nary artery.
The use of CPB requires full heparinization, which influenced the
selection of anaesthetic technique. In the on-pump group, 99% of
the patients received total intravenous anesthesia including high
dose opioids, whereas in the off-pump group, 54% of the patients
received thoracic epidural anesthesia combined with low-dose
opioids. Cardiopulmonary bypass was managed according to the
alpha-stat principle,22 with a minimal nasopharyngeal temperature
of 32°C and a nonpulsatile perfusion of 2.0 to 2.4 L/m2 per
minute. The pump was primed with a crystalloid-colloid mixture.
During rewarming, the maximal gradient between blood and
water in the heat exchanger was 5°C with a maximal water tem-
perature of 39°C. To reduce blood loss in the CPB group, blood
was recollected using a suction cardiotomy reservoir, without fil-
ter or processing. In the off-pump group, a cell-saver was used.
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Data analysis
The sample size calculation was based on the assumptions that
the incidence of cognitive decline at 3 months is 21% after on-
pump CABG surgery3 and that a two-thirds reduction could be
achieved using an off-pump technique. With the alpha-error set
at 0.05 and beta-error set at 0.10 (power of 90%), a total of 125
patients in each group were required, which was increased to 140
patients per group because a 10% loss to follow-up was anticipat-
ed.
Data were analyzed according to randomization. Incidences of
cognitive decline and mortality were compared using Fisher exact
test and the relative risk (RR) estimate with 95% confidence
interval (CI). Odds ratios were used as a measure of RR.
Continuous outcome measures were compared using the
Wilcoxon nonparametric test. Differences in quality of life are
presented as means with 95% CIs. For the cognitive outcome
measures, multivariable regression models were used to adjust for
possible baseline differences.
Missing data
At 3 months, cognitive outcome and quality of life could be
determined in 128 patients in the off-pump group and 120
patients in the on-pump group (Figure). Within these groups, 4
patients completed fewer neuropsychologic tests during postoper-
ative assessment than at baseline. In the primary analysis
(dichotomous cognitive outcome), these patients were considered
to have a decreased performance of at least 20% on the missing
tests (worst-case score).23 To assess the effect of loss to follow-
up, several additional analyses were performed. The baseline
characteristics of the patients who completed cognitive follow-up
were compared. A sensitivity analysis was performed in which the
outcome, cognitive decline, was first assigned to the 19 on-pump
CABG surgery patients without 3-month neuropsychologic test-
ing, and then to the 14 off-pump patients without 3-month neu-
ropsychologic testing. Finally, missing cognitive data were
imputed by means of linear regression modeling using SPSS ver-
sion 10.0 (SPSS Inc, Chicago, Ill). Such modeling predicts the
value of a missing variable by using all available cognitive and
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clinical data of that patient. Analyses were repeated with the
completed data set.
Results
Patient population and operation
Baseline characteristics of the patients, including preoperative
cognitive test performance, were well balanced between the 2
groups (Table 1 and Table 2). Patients in the off-pump group
were on average 1 year older than the on-pump group and com-
prised slightly fewer men and patients with diabetes, peripheral
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Table 3: Neuropsychologic tests and standardized change scores (SCSs) at 3 and 12 months
after surgery *
Off-pump
3 months 12 months
Test raw change raw change
Rey, total score 38 0.00 41 0.33
(24-49) (27-53)
Rey, delayed recall 7 0.40 8 0.79
(3-11) (5-12)
Grooved Pegboard 100 0.07 99 0.03
(86-134) (85-130)
Trail Making Test part B 75 0.13 77 0.16 
(50-137) (45-137)
Sternberg Memory Comparison 56 0.18 57 0.12
(39-86) (38-82)
Line Orientation Test 26 0.23 25 0.23
(19-29) (19-30)
Stroop Color Word Test 39 0.41 43 0.08
(26-73) (22-71)
Continuous Performance Task 536 0.11 544 0.04
(452-735) (444-726)
Self Ordering Tasks 11 0.12 11 0.25
(6-17) (6-17)
Visuospatial Working Memory 0.3 0.08 0.5 0.11
(-0.3-10.3) (-0.3-10.5)
Symbol Digit Modalities Test 45 0.27 42 0.09
(28-60) (26-59)
Overall postoperative change ... 0.19 ... 0.19
(mean of the change scores)
* Values are medians, with 10th and 90th percentiles in parentheses. Change denotes standardized change score and
reflects improved performance from baseline to 3 or 12 months after surgery. Ellipses indicate not applicable.
vascular disease, and 3-vessel disease. The latter is reflected by
the mean number of distal anastomoses, which was 2.4 in the off-
pump and 2.6 in the on-pump group. For proximal anastomoses,
aortic side clamps were used in 36% of the off-pump patients and
50% of the on-pump patients. In the on-pump group, time under-
going CPB averaged 66 minutes with 44 minutes cross-clamp
time.
To assess the theoretical possibility of selection bias, the likeli-
hood of the participants randomized to the off-pump group,
which was influenced by the assignments of the previous patients,
was entered in a logistic regression model. This variable appeared
to be no determinant of cognitive outcome (p=0.99). We also
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Table 3: (continued)
On-pump p-value of off-pump
3 months 12 months vs on-pump
raw change raw change 3 months 12 months
37 0.11 37 0.22 0.59 0.26
(23-51) (28-53)
7 0.00 7 0.40 0.13 0.01
(2-11) (3-11)
102 0.14 102 0.07    0.78 0.85
(88-124) (90-135)
79 0.11 76 0.09    0.33 0.51
(50-137) (50-134)
59 0.06 58 0.03 0.28 0.19
(44-88) (45-81)
25 0.12 25 0.23 0.31 0.57
(19-29) (19-29)
37 0.12 40 0.00 0.69 0.50
(21-69) (24-69)
521 0.09     526 0.08    0.59 0.25
(467-737) (451-717)
S11 0.12 11 0.12 0.61 0.18
(6-17) (5-16)
0.4 0.23 0.4 -0.04 0.71 0.56
(-0.4-10.2) (-0.4-10.2
42 0.18 41 0.18 0.23 0.64
(29-55) (26-56)
... 0.13 ... 0.12 0.03 0.09
compared 21 baseline characteristics from off-pump patients who
had a high likelihood of being randomized to off-pump with the
baseline characteristics from on-pump patients with a low likeli-
hood. No significant differences were observed in all the compar-
isons on the 21 baseline characteristics. Both analyses indicate that
there was no selection bias (ie, the randomization sequence was
well concealed).24
Cognitive outcome
The mean interval between operation and 3-month follow-up
was 92 (SD, 17) days in the off-pump group and 96 (SD, 12) days
in the on-pump group (p=0.06). At 3 months after surgery, cog-
nitive decline occurred in 21.1% of patients after off-pump CABG
surgery and 29.2% after on-pump CABG surgery (RR, 0.65; 95%
CI, 0.36-1.16; p=0.15). The RR did not change after adjusting
for baseline differences in age, sex, diabetes, peripheral vascular
disease, and number of diseased vessels (RR, 0.65; 95% CI, 0.36-
1.17; p=0.15) or with adjustment for anesthetic technique (data
not shown). Within the off-pump group, cognitive decline
occurred in 22.7% of patients who received epidural anesthesia
with low-dose opioids and 18.9% of patients who received high-
dose opioids without epidural anesthesia (p=0.67).
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Table 4. Factor change score analysis of cognitive function at 3 and 12 months*
off-pump on-pump
Cognitive score 3 months 12 months 3 months 12 months
Change in factor 1 0.21 -0.02 0.18 0.14
(-0.46-0.80) (-0.67-0.75) (-0.61-0.86) (-0.58-0.71)
Change in factor 2 0.19 0.53 0.09 0.18
(-0.92-10.55) (-0.64-10.70) (-10.31-10.05) (-0.79-10.40)
Change in factor 3 0.08 -0.03 0.08 0.01
(-0.47-0.80) (-0.59-0.81) (-0.49-0.71) (-0.52-0.67)
Change in factor 4 0.08 -0.04 0.09 -0.04
(-0.67-0.73) (-0.67-0.84) (-0.71-0.89) (-0.68-0.75)
* Values are medians, with 10th and 90th percentiles in parentheses. Positive values reflect improved performance from
baseline to 3 or 12 months after surgery. Factor 1 denotes attention and visuospatial capacity; factor 2, verbal memory;
factor 3, selective attention and motor capacity; and factor 4, working memory.
The results per neuropsychologic
test variable are presented in Table
3. At 3 months, the patients in both
groups improved on all 11 main
variables. The overall postoperative
change in performance (ie, overall
improvement; mean of the 11 SCSs)
was 0.19 SCS in the off-pump and
0.13 SCS in the on-pump group
(p=0.03). Adjustment for baseline
differences did not change the dif-
ference between the groups.
The change in performance per cog-
nitive domain, as calculated with
factor analysis, is presented in Table
4. Patients improved on all domains from baseline to 3 months
after surgery, but no statistically significant differences between
the groups were present.
At 12 months, cognitive decline occurred in 30.8% of patients
after off-pump CABG surgery and 33.6% after on-pump CABG
surgery (RR, 0.88; 95% CI, 0.52-1.49; p=0.69). The other analy-
ses (Table 3 and Table 4) also showed nonsignificant differences
between the groups. An exception was the domain verbal memo-
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Table 4. (continued)
p-value
3 months 12 months
0.76 0.19
0.19 0.01
0.94 0.97
0.85 0.67
.
Table 5. Reasons for missing neuropsychologic assessment
3-month analysis 12-month analysis
Reason Off-pump On-pump Off-pump On-pump
Patient appeared to be unsuitable for neuropsychologic 
testing 1 1 1 1
Withdrawal immediately after randomization 0 3 0 3
Withdrawal after baseline assessment, but before surgery 2 4 2 4
Failure to administer baseline tests (logistic) 2 1 2 1
(Noncerebral) mortality at time of cognitive follow-up 1 1 2 1
Readmission to hospital or too ill for postoperative 
assessment 3 2 1 1
Failure to administer tests at time of cognitive follow-up 
(logistic) 1 0 1 0
Unable to come for follow-up (holiday or care for ill 
partners) 1 4 0 0
Not motivated for follow-up/withdrawal 3 3 3 6
Total No. of patients with failed neuropsychologic 
assessment 14 19 12 17
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ry (factor 2), which had improved twice as much in the off-pump
group (p=0.01). At 12 months, the overall change in cognitive
performance was 0.19 SCS in the off-pump group and 0.12 SCS
in the on-pump group (p=0.09).
Missing data
At 3 months, the cognitive outcome of 33 (12%) patients could
not be determined and at 12 months the cognitive data of 29
(10%) patients were not obtained. Reasons for not obtaining neu-
ropsychological test data testing are summarized in Table 5. The
3-month sensitivity analysis yielded an RR of 0.37 (95% CI, 0.22-
0.63) and 1.21 (95% CI, 0.71-2.05), which are the extremes that
could be obtained if all patients had been available for 3-month
follow-up. The baseline characteristics of the patients who were
available for analysis of cognitive outcome were comparable to
the baseline characteristics of the entire patient sample.
Imputation of all missing data by means of linear regression
increased the differences in cognitive decline between the 2
groups at 3 months. After imputation, the rate of cognitive
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Table 6: Comparison of quality of life, within and between the treatment groups*
Off-pump† On-pump†
Domain baseline 3 months 12 months baseline 3 months 12 months
Overall 0.64 (0.27) 0.86 (0.17) 0.82 (0.23) 0.65 (0.27) 0.83 (0.20) 0.86 (0.19)
PF 52 (25) 82 (17) 80 (20) 52 (25) 81 (18) 81 (21)
RP 23 (36) 62 (43) 69 (41) 23 (38) 56 (44) 74 (39)
BP 62 (26) 80 (20) 82 (23) 61 (26) 77 (21) 84 (21)
GH 56 (17) 71 (18) 67 (20) 54 (20) 68 (18) 66 (20)
VT 49 (23) 69 (19) 68 (20) 49 (24) 65 (20) 67 (18)
SF 61 (30) 83 (22) 83 (22) 61 (30) 77 (24) 82 (21)
RE 51 (46) 79 (37) 79 (36) 53 (47) 76 (37) 84 (32)
MH 66 (20) 80 (16) 78 (18) 67 (22) 78 (18) 78 (16)
* Values are means with standard deviation in parentheses. Overall denotes overall quality of life; PF, physical functioning;
RP, role limitations due to physical health problems; BP, bodily pain; GH, general health perceptions; VT, vitality; SF, social
functioning; RE, role limitations due to emotional problems; and MH, general mental health.
† All differences within the groups between baseline and 3 months, and baseline and 12 months: p < 0.01 by the Wilcoxon
signed ranks test.
decline at 3 months was
19.0% in the off-pump
group and 28.8% in the
on-pump group (RR,
0.58; 95% CI, 0.33-1.02;
p=0.07), and the overall
postoperative change in
performance became
0.18 SCS and 0.13 SCS
in the off-pump and on-
pump groups, respec-
tively (p=0.25). After
imputation, the RR for
cognitive decline at 12
months was 0.90 (95%
CI, 0.53-1.54; p=0.79)
and the overall postop-
erative change in per-
formance became 0.20
SCS and 0.12 SCS in
the off-pump and on-pump groups, respectively (p=0.05).
Quality of life
Both groups reported a marked improvement in overall quality of
life at 3 months as well as each of the 8 subdomains (Table 6).
Within these domains, only bodily pain and general health per-
ceptions improved further from 3 to 12 months. Direct compari-
son between the groups of the overall scores and scores per
domain at 3 and 12 months revealed only nonsignificant differ-
ences.
Mortality and stroke
At 3 months, 1 nonfatal stroke (perioperative) occurred in the
off-pump group and 2 nonfatal strokes (1 perioperative) in the
on-pump group. One off-pump patient died from gastrointestinal
bleeding 49 days after CABG surgery and 1 on-pump patient died
58 days after perioperative myocardial infarction.
At 12 months, the mortality was 2 per group. In the off-pump
group, 1 patient died from hepatic cancer 153 days after CABG
surgery and in the on-pump group, 1 patient (who had had a pre-
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Table 6: (continued)
Difference between off-pump
and on-pump (95% CI)
3 months 12 months
0.03 (-0.02 – 0.07) -0.04 (-0.09 – 0.02)
1 (-4 – 6) -1 (-6 – 4)
6 (-5 – 17) -5 (-15 – 5)
3 (-2 – 8) -2 (-7 – 3)
3 (-2 – 8) 2 (-3 – 7)
4 (-1 – 9) 1 (-4 – 6)
5 (-1 – 11) 0 (-5 – 6)
3 (-7 – 13) -5 (-13 – 4)
2 (-2 – 6) 0 (-4 – 4)
vious stroke just prior to CABG surgery) died after a second 232
days after CABG surgery. The number of patients who had expe-
rienced stroke at 12 months remained 1 in the off-pump group
and 2 in the on-pump group.
Comment
The use of CPB is generally regarded as the main cause of cogni-
tive decline following heart surgery.1 The present study demon-
strates limited improvement of cognitive outcome at 3 months in
patients undergoing off-pump CABG surgery. The 29% incidence
of cognitive decline after on-pump CABG surgery is consistent
with previous, uncontrolled studies2,3 but the benefit of avoiding
CPB was smaller than was anticipated. Moreover, at 12 months,
the small differences between the groups had become negligible.
The present study is to our knowledge the largest randomized
trial on cognitive outcome after off-pump and on-pump CABG
surgery. Two other randomized studies on cognitive outcome
after CABG surgery were published recently. Age and extent of
coronary disease of the participants of both studies were compa-
rable with the present study. Diegeler et al5 administered the
Syndrom Kurz Test to 40 patients and demonstrated a marked
improvement of cognitive outcome after 7 days by using off-
pump CABG surgery. Lloyd et al,6 in contrast, administered 7
tests from the Wechsler Memory Scale and Wechsler Adult
Intelligence Scale to 60 patients and found no difference in cog-
nitive function after 3 months.
Several reasons may be considered to explain the limited differ-
ence in cognitive outcome between the treatment groups
observed in the present study. First, factors other than CPB may
cause cognitive decline after CABG surgery. It is conceivable that
undergoing anesthesia affects cognitive function, though in the
present study no association was found between cognitive decline
and type of anesthetic technique. Moller et al25 demonstrated a
10% incidence of cognitive decline after noncardiac surgery, inde-
pendent of regional or general anesthesia. These observations
suggest that surgical trauma could be a source of cognitive
decline.
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Second, to minimize crossovers from off-pump to on-pump
groups, stringent patient selection criteria were used. This has
resulted in a relatively young group of patients (mean, 61 years)
with less advanced coronary artery disease and limited comorbidi-
ty. The effects of an off-pump technique may be more marked in
older patients, patients with more extensive coronary artery and
aortic disease, and patients with substantial comorbidity.1,4,26
Third, the off-pump technique may be a new source of cognitive
decline. Exposure of the posterior cardiac wall frequently leads to
transient episodes of elevated central venous pressure and concur-
rent decreased systemic blood pressure, resulting in a decreased
cerebral perfusion pressure.27
Fourth, improved cognitive outcome by using an off-pump tech-
nique may only become more clear in the long term. In a recent
long-term follow-up study by Newman et al,2 cognitive decline
was found in 24% of the patients 6 months after on-pump CABG
surgery, which increased to 42% after 5 years. The present study
demonstrated an increasing incidence of cognitive decline from 3
to 12 months, but the difference in cognitive decline observed
earlier between patients in the on-pump group and the off-pump
group decreased.
A final explanation involves the definition of cognitive decline
(20% decrease in performance in 20% of the variables), which
appears to have limited precision. Although this definition has
been reported to be sensitive and reliable,15,28,29 the cut-off value
may be within the range of an individual’s natural fluctuations in
performance. Recently, the International Study of Post-Operative
Cognitive Dysfunction group applied an almost similar definition
to 176 volunteers undergoing 5 neuropsychologic tests.30 After 3
months, 25% of the volunteers were identified as having cogni-
tive decline. Therefore, it is likely that the true incidence of cog-
nitive decline after CABG surgery is lower than generally
assumed.30 Moreover, measurement errors may have diluted the
difference in cognitive decline found in the present study.
Because of the methodological difficulties associated with defin-
ing cognitive outcome at the individual patient level, we regard
the analysis based on comparison of the continuous neuropsycho-
logic test scores more reliable than the analysis based on the
dichotomous outcome measure.
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The present study has several limitations, including single blind-
ing and a 12% loss to follow-up. It is unlikely, however, that the
differences in cognitive outcome found between the groups were
caused by loss to follow-up. Both the drop-out rate and the base-
line characteristics of the remaining patients were largely similar
across the groups. Adjustments for small inequalities in baseline
characteristics did not affect the results. Imputation of cognitive
data for the patients that were lost to follow-up increased the dif-
ference in cognitive decline between the groups. Only a small
number of the patients in whom cognitive outcome could not be
determined lost motivation for cognitive follow-up after their
surgery. A relation between loss to follow-up and cognitive out-
come may therefore be present in only a very small proportion of
the patients. In addition, the sample size calculation was based on
achieving a two-thirds reduction in cognitive decline at 3 months.
Thus, a more modest benefit in reducing cognitive decline cannot
be excluded and would need to be evaluated in larger random-
ized trials.
We conclude that patients who received their first CABG surgery
without CPB had improved cognitive outcomes 3 months after
the procedure, but the effects were limited and became negligible
at 12 months.
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Abstract
Objective Coronary artery bypass surgery is associated with postoperative
cognitive decline, which has generally been attributed to the use of
cardiopulmonary bypass. In a recently conducted trial that com-
pared off-pump and conventional bypass surgery, avoiding car-
diopulmonary bypass only slightly improved cognitive outcome.
The aim of the present study was to identify other determinants of
cognitive outcome after bypass surgery.
Methods Ten neuropsychologic tests were repeatedly administered to 248
first time coronary bypass surgery patients (mean age 61 y). A
dichotomous and a continuous measure of cognitive outcome were
established by comparing test performance before and 3 months
after surgery. Thirteen possible clinical predictors of cognitive out-
come and 2 measures of early cognitive performance (4th day
after surgery), were entered into logistic and linear regression
models.
Results Variables identified in previous studies as determinants of cognitive
outcome were no predictor of cognitive outcome in the present
patient sample. As was demonstrated before, the use of cardiopul-
monary bypass was not a major determinant of cognitive decline
either. The only variables that were significantly associated with
cognitive outcome after 3 months, were measures of cognitive out-
come 4 days after surgery. This association was stronger in
patients operated with cardiopulmonary bypass (odds ratio 4.72;
p<0.01) than in patients operated without cardiopulmonary
bypass (odds ratio 2.00; p=0.16).
Conclusions Cognitive outcome four days after coronary bypass surgery pre-
dicted cognitive outcome after three months. Previously reported
associations between patient variables or perioperative variables
and cognitive outcome could not be confirmed in the present
study.
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Introduction
Coronary artery bypass surgery (CABG) effectively relieves angi-
na but may affect cognitive function.1 This may occur in up to 50
percent of the patients, depending on the type of patient, and
timing and methodology of neuropsychologic assessment.1-3
Cognitive decline after CABG has largely been attributed to the
use of CPB.4 We conducted the Octopus trial to directly compare
the effect of CABG with and without CPB on cognitive out-
come.5,6 At three months, the incidence of cognitive decline was
29 percent after on-pump CABG and 21 percent after off-pump
CABG.6 The improvement of cognitive outcome when avoiding
CPB was smaller than anticipated, suggesting that other factors
determine cognitive outcome after coronary bypass surgery as
well. It would be helpful for both the patient and the physician to
know the determinants of postoperative cognitive decline,
because this may guide decisions such as the choice between sur-
gical and non-surgical treatment, or between off-pump and on-
pump surgery.
In previous studies, advanced age,1,7-9 female sex,10 diabetes,10
history of stroke,11 manipulation of the ascending aorta,7,10 CPB-
rewarming rate,12 prolonged perfusion time,8 postoperative
hyperthermia,13 and postoperative time to awakening,11 were
identified as predictors of cognitive decline. In other studies, cog-
nitive decline in the first week after surgery predicted late cogni-
tive decline (six months and five years after surgery).1,14
The aim of the present study was to determine which demo-
graphic and peri-operative variables predict cognitive outcome
three months after surgery, using the data obtained from the
Octopus study. We also evaluated whether the predictors and
their predictive value differed between patients operated with and
without CPB.
Methods
Patients
The present prognostic analyses are based on data of the Octopus
multicenter trial, in which 281 patients were randomized to off-
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pump or on-pump CABG. The methods of this trial have been
described elsewhere.5,6 In brief, patients were included if referred
for first time isolated CABG and eligible for both off-pump and
on-pump surgery. Patients were excluded from the trial in case of
emergency or concomitant major surgery, Q-wave myocardial
infarction in the last six weeks or poor left ventricular function.
Also patients that were unlikely to complete one year follow-up
or undergo neuropsychologic testing, were excluded. There were
no restrictions to age. The study was approved by the local Ethics
Committee of each participating hospital and written informed
consent was obtained from all patients.
Operative procedure
Goal of surgery was to obtain complete, arterial revascularization.
During off-pump procedures, the Octopus method15 was used for
stabilization of the target coronary artery. During on-pump pro-
cedures, CPB was managed according to the alpha-stat principle,
with a minimal nasopharyngeal temperature of 32 °C and a non-
pulsatile perfusion of 2.0 to 2.4 l/m2/min. During rewarming,
the maximal gradient between blood and water in the heat
exchanger was 5 °C, with a maximal water temperature of 39 °C.
Outcome
To establish cognitive outcome at three months, patients under-
went a battery of ten neuropsychologic tests, comprising eleven
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Table 1: Cognitive test battery and raw data
Test Cognitive domain Main variable
Rey Auditory Verbal Learning verbal memory, learning total score trial 1-5
Rey Auditory Verbal Learning verbal memory, retrieval delayed recall score
Grooved Pegboard motor capacity time dominant hand, s
Trail Making Test Part A and B divided attention time trail B, s
Sternberg Memory Comparison working memory speed time 4 character chart, s
Line Orientation Test visuospatial capacity total score
Stroop Color Word Test selective attention time C – time B, s
Continuous Performance Task sustained attention mean reaction time, ms
Self Ordering Tasks working memory sum score
Visuospatial Working Memory visual working memory average distance, cm
Symbol Digit Modalities Test information processing total score
All values are means, with standard deviations in parentheses.
main variables, one day before
and three months after opera-
tion. The battery included tests
for motor skills, verbal memo-
ry capacity, speed of working
memory, visuospatial capacity,
selective and sustained atten-
tion and information process-
ing (Table 1). Two outcome
measures of cognitive outcome
were used. Both were based
on a comparison of the test
results after three months with
those at baseline (preoperative-
ly). As a dichotomous measure, we defined ‘cognitive decline’,
conform commonly used criteria, as a decrease in an individual’s
performance of at least 20 percent from baseline, in at least 20
percent (i.e. three) of the main variables.16 Patients who had suf-
fered a stroke were considered to have cognitive decline. To
establish a continuous cognitive outcome measure, the relative
cognitive performance (RCP) was calculated for each main vari-
able in each patient by subtracting the preoperative score from
the postoperative score and dividing the difference by the preop-
erative standard deviation (SD) of that variable. If improved per-
formance was reflected by a lower score (e.g. in timed tasks), the
directional data were reversed so that all improvements gave rise
to a positive RCP. ‘Overall RCP’ at three months was defined as
the mean of the RCPs that were calculated per test.17,18
Three months after surgery, the cognitive outcome could be
determined in 248 patients (88%). Reasons for loss to follow-up
were withdrawal before surgery (9 patients), failure to administer
the pre-operative or postoperative tests (6 patients), mortality at
the time of follow-up (2 patients), patients being too ill at the
time of follow-up (5 patients), patients unable to appear for fol-
low-up (5 patients), and a lack of motivation for follow-up (6
patients).
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Table 1: (continued)
Baseline Day 4 3 months
37 (9) 35 (8) 37 (10)
6 (3) 6 (3) 7 (3)
112 (29) 114 (27) 105 (21)
95 (46) 97 (46) 85 (37)
61 (16) 60 (22) 60 (16)
24 (4) 24 (4) 25 (4)
47 (25) 45 (25) 44 (26)
544 (117) - 559 (114)
10 (4) - 11 (4)
0.53 (0.79) - 0.42 (0.63)
40 (11) - 43 (11)
Potential predictors
Fifteen potential predictors of cognitive outcome at three months
were evaluated. Preoperative patient characteristics included age,
sex, diabetes, peripheral vascular disease, history of stroke or
transient ischaemic attack, and the number of diseased coronary
arteries. Intra-operative characteristics included sternotomy (ver-
sus anterolateral thoracotomy), milligrams of opioids (sufentanil)
used during anesthesia (which influences the postoperative awake
time), off-pump or on-pump treatment, perfusion time (in
patients operated with CPB), use of aortic side clamps, and trans-
fusion of blood products. Postoperative characteristics included
number of days in hospital, and two overall measures of cognitive
performance on the fourth day after surgery. Analogous to the
measures of cognitive outcome at three months, we obtained a
dichotomous measure of cognitive outcome at the fourth day
(‘cognitive decline at day four’), as well as a continuous outcome
measure (‘overall RCP at day four’). Cognitive performance at
day four was determined with a battery of six tests, including
seven main variables. Thirty-eight patients refused or were
unable to undergo neuropsychologic assessment on the fourth
day. Of the remaining 210 patients 28 actually underwent the
assessment on the fifth postoperative day, but their test results
were not excluded from the analyses.
Data analysis
All analyses were performed using SPSS version 10.0 software.
We used logistic regression analysis to determine which charac-
teristics predicted ‘cognitive decline’ at three months (dichoto-
mous outcome) and to what extent, and linear regression analysis
to determine which characteristics predicted ‘overall RCP’ at
three months (continuous outcome). Both models were obtained
following the same procedure. First, for explorative reasons, the
association between cognitive outcome at three months and each
of the possible predictors was quantified using univariable analy-
sis. Continuous variables were initially included as continuous
terms as a linear relation was plausible, but logical transforma-
tions (e.g. squared and log) were evaluated as well.19 As the aim
of this study was to obtain optimal prediction of cognitive out-
come after three months, all predictors contributing prognostic
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information should preferably be included in a multivariable
model.20 Therefore, as is common in prediction research, we
included all predictors with p-value 0.25 in the univariable analy-
sis in a multivariable model.20
This overall multivariable model was then reduced by excluding
predictors one by one and comparing each reduced model to the
overall model using the LR-test in case of logistic regression and
the partial F-test in case of linear regression. If the p-value of
these tests became < 0.15 the variable was retained in the final
(reduced) model. Then all previously excluded predictors were
one by one re-entered in the final model to evaluate whether
they indeed did not contain any additional prognostic informa-
tion. Finally, if previously excluded, the final model was extend-
ed with the variables, age, sex and surgery with or without CPB,
regardless their p-value. We assumed that these three variables
are important predictors of cognitive function anyhow and should
be left in the model to enhance comparison with the literature.
In the prediction of ‘cognitive decline’ at three months (logistic
model), the odds ratio (OR) and 95% confidence interval (95%
CI) were used as measures of association. Of the overall and the
reduced multivariable model, the ability to discriminate between
patients with and without cognitive decline at three months was
estimated using the area under the Receiver Operating
Characteristic curve (ROC area).20,21 The ROC area is a suit-
able parameter to summarize the predictive or discriminative abil-
ity of a model and can range from 0.5 (useless model, like a coin
flip) to 1.0 (perfect discrimination). A value over 0.7 is often
interpreted as reasonable and over 0.8 as good.20,21
In the prediction of ‘overall RCP’ at three months (linear model),
the linear regression coefficient with 95% CI was used as the
measure of association. This coefficient reflects the amount of
improvement (positive value) or decrease (negative value) in cog-
nitive performance. The ability of the linear model to explain the
variation in the outcome was estimated by using R2, which repre-
sents the proportion of ‘overall relative cognitive performance’ at
three months that can be explained by the model.
Of all 248 cases, 38 had no neuropsychologic assessment on the
fourth (or fifth) postoperative day. Perfusion time was known
only in patients operated with CPB. The other predictors were
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known in at least 98 percent of the patients. To decrease bias and
increase statistical efficiency we filled in (imputed) the missing
values using the linear regression method.22 Such imputation is
based on the correlation between each variable with missing val-
ues and all other variables. The results of the analyses based on
the complete subjects and on all subjects after imputation were
compared. Since this yielded no different results (i.e. the same
independent predictors were selected with similar regression coef-
ficients) only the analyses based on observed (i.e. unimputed)
data are presented.
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Table 2: Characteristics of patients and results of univariable analyses for both measures of
three-month cognitive outcome
Logistic regression
All Decline Decline 
patients absent present Odds 
Predictor (n=248) (n=185) (n=63) ratio* p-value
Age, y‡ 61 61 61 1.02‡ 0.90
Female sex, % 29 29 29 1.00 1.00
Diabetes, % 12 12 13 1.10 0.82
Peripheral vascular disease,% 8 8 8 1.00 1.00
Previous stroke or TIA, % 4 4 3 0.74 0.71
No. of diseased coronary arteries 2.0 2.0 2.0 1.06 0.79
Sternotomy, % 96 96 94 0.57 0.37
Sufentanil dose, mg 0.23 0.23 0.24 1.00 0.75
Off-pump treatment, % 49 52 42 0.68 0.19
Perfusion time, min § 66 65 68 1.04§ 0.61
Use of sideclamp(s), % 42 40 48 1.42 0.24
Blood transfusion, % 30 31 29 0.91 0.78
Days in hospital 8.5 7.6 9.3 1.02 0.21
Cognitive decline at day 4, % 52 46 72 3.07 <0.01
Overall RCP at day 4 -0.13 -0.10 -0.22 0.47 0.07
Individual cognitive tests day 4:
-RCP Rey test-totalscore day 4 -0.25 -0.18 -0.45 0.72 0.08
-RCP Rey test-recallscore day 4 -0.20 -0.16 -0.23 0.94 0.68
-RCP Grooved Pegboard day 4 -0.22 -0.21 -0.27 0.87 0.59
-RCP Trailmaking test day 4 -0.17 -0.15 -0.25 0.76 0.32
-RCP Sternberg test day 4 0.11 0.16 -0.08 0.81 0.18
-RCP Line Orientation test day 4 -0.12 -0.17 -0.03 1.28 0.30
-RCP Stroop test day 4 -0.01 0.00 -0.06 0.86 0.58
TIA denotes transient ischaemic attack, RCP denotes relative cognitive performance
* odds ratio > 1.0 predicts cognitive decline at three months (< 1.0 absence)
† positive coefficient predicts better cognitive outcome at three months (negative coefficient predicts worse outcome)
‡ odds ratio and coefficient per 10 years
§ applies only to the on-pump patients; odds ratio and coefficient per 10 minutes
To examine whether the determinants
of cognitive outcome after off-pump
CABG differed from those after on-
pump CABG, all analyses were repeat-
ed in exclusively the patients who
underwent off-pump CABG (n=122),
and then in those who underwent on-
pump CABG (n=126).
Results
The raw data of the neuropsychologic
tests are presented in Table 1. Table 2
shows the distribution of the predic-
tors in all patients (first column).
Dichotomous outcome
Table 2 shows the results of the uni-
variable logistic regression analysis
(2nd to 5th column). At three months,
63 of the 248 patients had ‘cognitive
decline’. Three clinical variables were
weakly associated with cognitive
decline: on-pump versus off-pump
treatment (p=0.19), use of sideclamps
(p=0.24), and days in hospital
(p=0.21). Cognitive decline at day
four (p<0.01) and overall RCP at day
four (p=0.07) were stronger associat-
ed. To distinguish which of the component tests were responsible
for this, we analyzed the association of the individual tests at day
4 with the outcome. It appeared that the Rey Auditory Verbal
Learning Test (total score) was mainly associated with the out-
come (p=0.08).
We fitted a multivariable model including the use of side clamps,
cognitive decline at day four plus off-pump surgery, age and sex.
In this model, decline at day four was the only important predic-
tor of cognitive decline at 3 months (OR 3.11; p<0.01). The OR
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Table 2: (continued) 
Linear regression
Coefficient‡ p-value
0.011‡ 0.54
0.039 0.30
0.046 0.38
0.038 0.55
-0.066 0.45
0.025 0.31
-0.068 0.41
-0.21 0.05
0.061 0.08
0.0098§ 0.36
-0.013 0.70
0.024 0.53
-0.0020 0.33
-0.038 0.31
0.16 <0.01
0.050 0.01
0.053 <0.01
0.0035 0.90
0.11 <0.01
-0.0038 0.83
0.035 0.17
0.019 0.51
of off-pump treatment was 0.96 (p=0.91). The ROC area of this
model was 0.68 (95% CI 0.59 - 0.76).
Continuous outcome
‘Overall relative cognitive performance’ had a normal distribu-
tion, with mean 0.139; standard deviation 0.268; and median
0.164. The last two columns of Table 2 show that the dose of
sufentanil (p=0.05), off-pump surgery (p=0.08), and overall rela-
tive cognitive performance at day four (p<0.01) were associated
with ‘overall relative cognitive performance’ at three months.
Further analysis of the individual neuropsychologic tests at day
four showed that performance on the Trail Making Test and Rey
Auditory Verbal Memory Test were mainly associated with the
outcome (p-values < 0.01).
We fitted a multivariable model including overall RCP at day
four, off-pump treatment, age and sex. Overall RCP at day four
(coefficient 0.16; p<0.01) and off-pump treatment (coefficient
0.071; p=0.05) predicted ‘overall relative cognitive performance’
at three months. The R-square was 0.08, i.e. the model explained
only 8% of the variance in cognitive performance at three
months.
Off-pump versus on-pump treatment
The incidence of cognitive decline at day four was 46% in
patients operated off-pump, and 59% in patients operated on-
pump (p=0.07). Within the group of 122 patients that was oper-
ated without CPB, cognitive decline (dichotomous) on day four
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Table 3: Univariable logistic regression analysis: off-pump versus on-pump
Off-pump treatment (n=122) On-pump treatment (n=126)
Predictor Odds ratio* p-value Odds ratio* p-value
Cognitive decline at day 4 2.00 0.16 4.72 <0.01
Age, y 1.12† 0.64 0.94† 0.79
Female sex 0.93 0.88 1.12 0.80
* odds ratio > 1.0 predicts cognitive decline at three months (< 1.0 absence)
† odds ratio per 10 years
was the only predictor of cognitive decline after three months
(OR 2.00; 95% CI 0.77 - 5.20). Within the group of 126 on-
pump patients, the association between early and late cognitive
decline was considerably stronger (OR 4.72; 95% CI 1.63 - 13.66)
(Table 3). Comparable results were found when cognitive out-
come was analyzed as a continuous variable (Table 4).
Discussion
This study aimed to identify predictors of cognitive outcome after
CABG. The study was conducted in a sample of 248 patients, of
whom 63 suffered cognitive decline at three months, but in
whom the use of CPB appeared not to be the major determinant
of this outcome. The principal result of the present study, which
was based on multivariable analyses, is that previously reported
predictors of cognitive decline, including age and sex, were not
associated with this outcome in the present patient sample. The
only peri-operative variable that was significantly associated with
cognitive outcome at three months was early cognitive outcome,
measured on the fourth day after surgery. The effect of CPB on
cognitive outcome in the present study differs slightly from what
was described in the trial report,6 because the trial analyses were
based on assigned treatment (‘intention to treat’), while the pres-
ent analyses were based on actually undergone treatment (i.e.
cross-overs were taken into account).
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Table 4: Univariable linear regression analysis: off-pump versus on-pump
Off-pump treatment (n=122) On-pump treatment (n=126)
Predictor Coefficient* p-value Coefficient* p-value
Overall RCP at day 4 0.12 0.02 0.21 0.02
Age, y -0.011† 0.64 0.037† 0.20
Female sex -0.007 0.88 0.081 0.16
RCP denotes relative cognitive performance
* positive coefficient predicts better cognitive outcome at three months (negative coefficient predicts worse outcome)
† coefficient per 10 years
Several aspects need to be discussed. First, in prediction research,
the number of subjects with the outcome of interest (i.e. cogni-
tive decline) determine the ability to identify relevant predictors
of that outcome (statistical power).23-25 The sample may have
been too small to find relatively weak predictors such as diabetes
and perfusion time, which have been found in other studies.8,10
A rule of thumb for prediction studies with a dichotomous out-
come, is that the number of candidate predictor variables (in our
case 15) does not exceed the number of patients in the smallest
group divided by 10 (in our case this would be 6.3).23-25 We did
exceed this ratio. However, this rule of thumb was introduced to
prevent overfitting, i.e. to prevent the selection of predictors
which in fact are spurious (or ‘noise’) predictors. In this study we
did hardly detect any predictors of cognitive outcome. The prob-
lem of overfitting may therefore be less applicable.
We may have selected the wrong candidate predictors. A vast
body of literature indicates that CABG with CPB affects cogni-
tive outcome.1-4,6-13,17 However, in the first randomized study of
substantial sample size, we only found slight improvement of
cognitive outcome when avoiding CPB.6 This suggests other
variables may play a role in the development and therefore in the
prediction of cognitive decline. Advanced age represents the least
controversial demographic risk factor for cognitive decline,1,7-9
but even this association could not be confirmed in the present
patient sample. Many other previously reported predictors were
considered in our study as well, with exception of rewarming rate
and postoperative hyperthermia. The present study was conduct-
ed in relatively young patients with limited co-morbidity, but
they were comparable to the patients included in previous stud-
ies.1,7-13 The fact that previously reported associations could not
be confirmed suggests that new determinants of cognitive injury
are yet to be identified and unknown mechanisms are to be eluci-
dated.
An alternative explanation for our inability to predict cognitive
decline is that modern CPB management, with use of membrane
oxygenators, mild rather than moderate hypothermia, relatively
slow rewarming rates, and prevention of postoperative hyperther-
mia, has reduced the incidence of cognitive decline. This would
imply that the > 20% incidence of decline found in our patient
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sample is an overestimation of the true size of the problem. The
instrument used to measure cognitive decline (i.e. the repeated
administration of a battery of neuropsychologic tests) is not very
accurate. It was recently suggested that the current definitions of
cognitive decline after CABG have limited precision and may
overestimate its true incidence.26 The definitions are based on a
particular degree of decline in test performance, for example
postoperatively 20 percent or one SD worse than preoperatively.
These cut-off values may be within the range of an individual’s
natural fluctuations in performance. Recently, the ISPOCD group
determined cognitive status using five neuropsychologic tests in
176 volunteers, not undergoing surgery.26 After three months, 25
percent of the volunteers was identified as having cognitive
decline, which suggests a considerable degree of measurement
error. Incorrect identification of patients with and without cogni-
tive decline, and/or a severe overestimation of the number of
patients with cognitive decline, may both explain our inability to
find predictors of cognitive decline in a sample of 248 patients.
The data from volunteer studies emphasize our inability to reli-
ably dichotomize patients into ‘normal’ and ‘declined’ by means
of repeated administration of neuropsychologic tests. This raised
the question whether our neuropsychologic test battery measures
cognitive performance sufficiently accurately, which is a prerequi-
site for capturing subtle decreases in performance from before to
after surgery. These observations prompted us to quantify the
association between the patient’s baseline characteristics and cog-
nitive performance at baseline. Cognitive performance at baseline
was defined as the mean of the standardized neuropsychologic
test scores before surgery. A multivariable linear regression model
identified advanced age (p<0.001) and female sex (p=0.01) as
independent predictors of a low cognitive performance at base-
line. The presence of these associations suggests that the neu-
ropsychologic tests are able to determine cognitive performance.
We did find an association between cognitive decline in the first
week and after three months. Several authors have described
comparable associations.1,3,14 However, since all definitions of
cognitive decline are based on a comparison between postopera-
tive and preoperative test performance, this association may be
explained by regression to the mean.27 Patients who perform well
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-according to their own standards- on their preoperative assess-
ment, have a greater risk to perform worse on all future (postop-
erative) assessments, and therefore might repeatedly meet the
criteria of cognitive decline. Nevertheless, it is a remarkable find-
ing that in the present study, the association between early and
late cognitive decline was stronger in patients operated with CPB
than in those operated without CPB.
In conclusion, cognitive outcome four days after coronary bypass
surgery predicted cognitive outcome after three months.
Previously reported associations between patient variables or peri-
operative variables and cognitive outcome could not be con-
firmed in the present study.
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Abstract
Background The use of cardiopulmonary bypass during coronary artery bypass
surgery (CABG) has been associated with substantial morbidity.
The recent introduction of cardiac stabilizers facilitates CABG
without cardiopulmonary bypass (off-pump CABG), but it is
unknown whether cardiac outcome after off-pump surgery is simi-
lar to that for the on-pump procedure.
Methods and Results In a multicenter trial, 281 patients (mean age 61 years, SD 9
years) were randomly assigned to off-pump or on-pump CABG. In-
hospital results and cardiac outcome and quality of life after 1
month are presented. Cardiac outcome was defined as survival
free of stroke, myocardial infarction, and coronary reintervention.
The mean numbers of distal anastomoses per patient were 2.4 (SD
1.0) and 2.6 (SD 1.1) in the off-pump and on-pump groups,
respectively. Completeness of revascularization was similar in both
groups. Blood products were needed during 3% of the off-pump
procedures and 13% of the on-pump procedures (p<0.01).
Release of creatine kinase muscle-brain isoenzyme was 41% less in
the off-pump group (p<0.01). Otherwise, no differences in compli-
cations were found postoperatively. Off-pump patients were dis-
charged 1 day earlier. At 1 month, operative mortality was zero in
both groups, and quality of life had improved similarly. In both
groups, 4% of the patients had recurrent angina. The proportions
of patients surviving free of cardiovascular events were 93.0% in
the off-pump group and 94.2% in the on-pump group (p=0.66).
Conclusions In selected patients, off-pump CABG is safe and yields a short-
term cardiac outcome comparable to that of on-pump CABG.
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Introduction
Coronary artery bypass surgery (CABG) using cardiopulmonary
bypass (CPB) relieves angina but is associated with substantial
morbidity.1,2 CPB requires full heparinization, induces a whole-
body inflammatory response, and generates microemboli.3-5 It
also requires cannulation and cross-clamping of the ascending
aorta, which may lead to atheromatous macroemboli.6 Procedures
that do not use CPB are likely to prevent these unwanted effects.
Moreover, in selected patients, the operation may be performed
via a left anterior thoracotomy or a substernal incision, which
makes sternotomy unnecessary.7 Avoiding full heparinization
allows safe use of a thoracic epidural catheter. Apart from tho-
racic sympatholysis, this may lead to improved postoperative pain
relief and reduced mechanical ventilation time.8 Consequently, if
CPB can be avoided (off-pump CABG), a reduction in periopera-
tive morbidity and mortality is anticipated, with faster recovery,
shorter hospitalization, and less need of medical facilities and
materials.9,10
Recently, cardiac stabilization techniques were developed to
facilitate bypass surgery on the beating heart (off-pump CABG).
The Octopus11 is one of the devices that can immobilize and
present all sides of the beating heart. This allows off-pump
CABG in patients with 3-vessel disease.9,12 The feasibility of off-
pump CABG depends primarily on the coronary anatomy and the
hemodynamic consequences of exposure of the posterior ventric-
ular wall.9,13,14 The procedure is technically more demanding,
and it is unknown whether cardiac outcome is comparable to on-
pump procedures.9
This randomized trial compared off-pump and on-pump CABG.
We present in-hospital results and cardiac outcome and quality of
life after 1 month.
Methods
Study design and patients
Design and methods of the Octopus multicenter trial have been
described in detail.15 In brief, after they had given written
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informed consent, patients were randomly assigned to off-pump
or on-pump CABG. Patients were eligible if referred for first-
time isolated coronary bypass surgery and an off-pump procedure
was deemed technically feasible. Patients were excluded in case
of emergency or concomitant major surgery, Q-wave myocardial
infarction in the previous 6 weeks, or poor left ventricular func-
tion or if they were unlikely to complete 1 year of follow-up or
unable to give informed consent. There were no restrictions as to
age. The study was approved by the ethics committees of the par-
ticipating centers.
Between March 1998 and August 2000, 281 patients were
enrolled in 3 hospitals in the Netherlands, of whom 265 under-
went treatment according to randomization. In 10 patients ran-
domized to off-pump surgery, CPB was used during the
procedure. One other patient randomized to off-pump surgery
underwent coronary angioplasty because of infection. In 5
patients assigned to on-pump CABG, an off-pump procedure was
performed.
Treatment and procedures
Before randomization, the treatment plan was recorded on dedi-
cated forms. The goal of surgery was to obtain complete arterial
revascularization. With the exception of 2 emergency procedures,
all operations were performed by cardiac surgeons experienced in
both off-pump and on-pump bypass surgery. During off-pump
procedures, the Octopus method11 was used for stabilization of
the target coronary artery.
Anesthetic technique varied according to the treatment alloca-
tion. In the on-pump group, 99% of the patients received total
intravenous anesthesia, including high-dose opioids, whereas in
the off-pump group, 54% of the patients received thoracic epidur-
al anesthesia combined with low-dose opioids. The CPB was
primed with a crystalloid-colloid mixture, and the minimal
nasopharyngeal temperature was 32°C. During aortic cross-
clamping, cold crystalloid cardioplegia (St Thomas solution) was
used for myocardial protection. To reduce blood loss, blood was
recollected with a suction cardiotomy reservoir in the CPB
group, whereas a cell saver was used in the off-pump group. In
an attempt to reduce the incidence of postoperative atrial fibrilla-
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tion, all patients were given sotalol 40 mg twice daily from the
first day to 1 month after surgery.
Data collection and outcome measures
During surgery, the following parameters were recorded: access
to the heart, number of distal anastomoses, type of graft (arterial
versus venous), completeness of revascularization (the agreement
between treatment plan and actual number of distal anastomoses),
switch to CPB for the off-pump group, time on CPB and cross-
clamp time for the on-pump group, use of blood products, and
time between arrival in the operating room and transfer to the
intensive care unit (ICU).
After surgery, the following were measured: serum creatine
kinase muscle-brain isoenzymes (CK-MB) (mean area under the
curve, based on 5 measurements within the first 20 hours), inci-
dence of atrial fibrillation, use of inotropes, blood loss during the
first 12 hours, use of blood products, overall postoperative com-
plication rate (cardiac arrest, cardiac failure, repeat thoracotomy,
infection requiring antibiotics or surgical treatment, pneumotho-
rax, time to extubation >24 hours, or renal failure requiring dial-
ysis), weight changes, time to extubation, time spent in the ICU,
number of days until discharge, pain during the first 3 days (visu-
al analog score, with 0 reflecting no pain and 10 reflecting the
worst imaginable pain), hemoglobin at discharge, and creatinine
at discharge.
As part of a formal long-term cost-effectiveness analysis, all mate-
rial and resources used during the hospital stay were recorded.
Also, in parallel, a cost study on the unit costs was performed.
Actual costs were estimated by multiplying resource use by unit
costs.
Cardiac outcome 1 month after surgery was defined as survival
free of cardiovascular events, which included stroke, myocardial
infarction, and coronary reintervention (CABG or coronary
angioplasty). These events were evaluated by an independent
committee blinded to treatment allocation. Stroke was defined as
focal brain injury persisting for >24 hours, combined with an
increase in handicap of 1 grade on the Rankin scale.16 During the
first 7 days after surgery, myocardial infarction was defined by
elevation of serum CK-MB to >5 times the upper limit of nor-
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mal.17 After 7 days, it was considered present when 2 of the fol-
lowing criteria were met: chest discomfort lasting 30 minutes,
CK-MB/CK ratio >0.1, and the development of abnormal new
Q waves on the ECG. The latter distinguished Q-wave and non-
Q-wave myocardial infarction at any time.15 Recurrence of stable
or unstable angina after 1 month was defined according to the
Canadian Cardiovascular Society18 and Braunwald classifica-
tions,19 respectively.
Health-related quality of life was assessed 1 week before and 1
month after surgery by use of 2 generic questionnaires. The
EuroQol questionnaire generates a single index, ranging from -1
to +1, with -1 reflecting the worst imaginable quality of life and
+1 reflecting the best imaginable quality of life.20 The
ShortForm-36 questionnaire comprises 8 different domains, all
ranging from 0 to 100. Higher scores indicate higher levels of
functioning or well-being.21
Data analysis
All data were analyzed on an intention-to-treat basis, ie, based on
randomization. Differences are presented with 95% CIs.
Dichotomous data were compared by the Chi2 statistic. Means
are presented with SD and were compared by a 2-sample t test.
Nonnormally distributed continuous variables are presented as
medians and were compared by a Mann-Whitney test.
Results
Patient population and in-hospital results
Baseline characteristics were well balanced across the randomized
groups (Table 1). The small difference between the 2 groups in
patients with 3-vessel disease is reflected by the mean number of
grafts per patient (Table 2), which was 2.4 in the off-pump group
and 2.6 in the on-pump group. There was no difference in com-
pleteness of revascularization. Use of vein grafts was avoided in
84.4% of the off-pump patients and 75.7% of the on-pump
patients. In 8% of the off-pump patients, access to the heart was
obtained via left anterior thoracotomy instead of sternotomy.
Two patients randomized to off-pump CABG were operated on
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Table 1: Baseline Characteristics
Off-pump On-pump
Variable (n=142) (n=139)
Age, y 61.7 (9.2) 60.8 (8.8)
Male sex, % 66 71
One-vessel disease, % 30 22
Two-vessel disease, % 50 50
Three-vessel disease, % 20 27
Normal left ventricular function, % 77 79
Moderate left ventricular function, % 23 21
Angina CCS class I or II, % 32 26
Angina CCS class III or IV, % 45 49
Unstable angina, Braunwald I to IIB, % 22 21
Previous myocardial infarction, % 34 26
History of coronary angioplasty, % 17 20
Currently smoking, % 14 14
Hypertension, % 40 44
Hypercholesterolaemia, % 68 68
Family history of coronary disease, % 59 58
Obesity (quetelet index >30 kg/m2), % 18 22
Peripheral vascular disease, % 7 13
Diabetes, % 9 17
History of stroke, % 4 3
Pulmonary disease, % 9 10
Hemoglobin, g/dl 14.25 (1.24) 14.20 (1.11)
Serum creatinine, mg/dl 1.01 (0.17) 1.04 (0.22)
CCS indicates Canadian Cardiovascular society. Values are percentage or mean (SD). 
Table 2: Intraoperative data
Variable Off-pump On-pump Difference 95% CI p-value
Access to the heart via sternotomy, % 92 100 8 4 – 13 <0.01
Number of distal anastomoses 2.4 (1.0) 2.6 (1.1) 0.3 0.0 – 0.5 0.05
Graft left anterior descending artery, % 98 96 -2 -6 – 2 0.44
Graft right coronary artery, % 53 64 11 -1 – 22 0.07
Graft ramus circumflexus, % 40 45 5 -7 – 17 0.39
Exclusive use of arterial grafts, % 84 76 -9 -18 – 1 0.07
Grafting according to treatment plan, % 83 83 0 -9 – 9 0.98
Switch to cardiopulmonary bypass, % 7.7
Time on cardiopulmonary bypass, min 66 (23)
Cross-clamp time, min 44 (18)
Use of blood products, % 3 13 10 4 – 17 <0.01
Time in operating room, hours 4.2 (1.1) 3.8 (0.7) -0.4 -0.6 – -0.1 <0.01
Values are percentage or mean (SD).
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with CPB because progression of symptoms necessitated emer-
gency surgery. In 4 off-pump patients, CPB was used because of
persistent arrhythmias, myocardial ischemia, and hypotension dur-
ing the procedure. In 4 others, CPB was used because the coro-
nary anatomy turned out to be unsuitable for a beating-heart
approach. The proportion of patients in whom blood products
were used during surgery was 4 times lower in the off-pump
group.
Detailed data of the postoperative period are presented in
Table 3. The release of CK-MB, expressed as area under the
curve, was 41% less in the off-pump group (p<0.01). There was
no difference in frequency of postoperative atrial fibrillation,
overall complication rate, or pain. After surgery, the proportion
of patients receiving blood products was similar. After 4 days, on-
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Table 3: Postoperative data
Variable Off-pump On-pump Difference 95% CI p-value
Release of CK-MB, AUC (median) 164 277 113 <0.01
CK-MB, 2 h after surgery, U/l (median) 7.0 16.0 9.0 <0.01
CK-MB, 4 h after surgery, U/l (median) 7.0 15.0 8.0 <0.01
CK-MB, 8 h after surgery, U/l (median) 8.0 14.5 6.5 <0.01
CK-MB, 12 h after surgery, U/l (median) 8.5 13.0 4.5 <0.01
CK-MB, 20 h after surgery, U/l (median) 10.0 13.5 3.5 <0.01
Atrial fibrillation, % 20 21 1 -8 – 11 0.79
Use of inotropes, % 27 28 1 -10 – 11 0.88
Blood loss first 12 h, L 0.5 (0.4) 0.4 (0.2) -0.1 -0.2 – 0.0 0.02
Use of blood products, % 28 29 1 -10 – 12 0.85
Overall postoperative complication rate, % 14 11 -3 -10 – 5 0.52
cardiac arrest, % 1 0 -1 -2 – 1 0.32
cardiac failure, % 2 2 -1 -4 – 2 0.68
repeat thoracotomy, % 4 2 -2 -6 – 2 0.33
infection, % 5 5 0 -5 – 5 0.96
pneumothorax, % 2 2 0 -3 – 4 0.97
time to extubation > 24 h, % 1 2 0 -3 – 3 0.98
renal failure, % 0 1 1 -1 – 2 0.31
Weight day 4 – preoperative weight, kg 0.1 (2.1) -0.8 (2.2) -0.9 -1.5 – -0.4 <0.01
Time to extubation, h (median) 3 9 6 <0.01
Time in intensive care, h (median) 22 22 0 0.88
Time before discharge, days (median) 6 7 1 <0.01
Pain, mean visual analog score day 1 - 3 2.6 (1.7) 2.6 (1.8) 0.1 -0.4 – 0.5 0.84
Hemoglobin at discharge, g/dl 11.5 (1.5) 11.5 (1.5) 0.0 -0.2 – 0.2 0.88
Serum creatinine at discharge, mg/dl 0.94 (0.18) 0.98 (0.26) 0.04 -0.02 – 0.09 0.16
AUC indicates area under the curve (h x U/L).Values are percentage, median, or mean (SD). 
pump patients had lost weight, whereas off-pump patients had
gained weight. Off-pump patients were discharged 1 day earlier
than on-pump patients.
The costs of the surgical procedure were slightly lower for the
off-pump group, ie, US $3112 versus $3535 (p<0.01). The overall
costs associated with hospitalization and the procedure, however,
were not significantly different for the off-pump and on-pump
groups, ie, US $8796 and $9118, respectively (p=0.75).
Cardiac outcome at 1 month
The mean follow-up period was 37 days (SD 8 days) in both
groups. None of the patients died. In the off-pump group, 93.0%
of the patients had survived free of cardiovascular events, com-
pared with 94.2% in the on-pump group (difference 1.2%; 95%
CI -4.4 to 7.0%; P=0.66) (Table 4). In the off-pump group, 4
patients suffered a Q-wave and 3 patients a non-Q-wave myocar-
dial infarction. In the on-pump group, 4 Q-wave and 2 non-Q-
wave myocardial infarctions occurred. One patient had
supplementary angioplasty after off-pump surgery because the
deep intramural course of the left anterior descending coronary
artery prevented grafting of this vessel without cardioplegia. In
both groups, 5 patients had recurrent, stable angina. One on-
pump patient had unstable angina.
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Table 4: Cardiac outcome after 1 month
Off-pump On-pump
Event (n=142) (n=139)
All-cause mortality 0 (0%) 0 (0%)
Stroke 1 (0.7%) 2 (1.4%)*
Myocardial infarction 7 (4.9%)† 6 (4.3%)*
PTCA 2 (1.4%) 0 (0%)
Repeat CABG 0 (0%) 0 (0%)
Survival free of cardiovascular events 132 (93.0%) 131 (94.2%)
* One occurred before surgery.
† Two occurred before surgery.
Quality of life
In both groups, there was a marked improvement in self-reported
quality of life at 1 month (Table 5). This improvement was statis-
tically significant for overall quality of life, as well as for the
domains “physical functioning,” “general health,” “vitality,”
“role limitations due to emotional problems,” and “general men-
tal health.” No differences in quality of life were observed
between the off-pump and on-pump CABG group.
Discussion
The results of this randomized trial indicate that there is no dif-
ference between off-pump and on-pump CABG in completeness
of revascularization and cardiac outcome after 1 month. Off-
pump CABG, however, resulted in reduced CK-MB release,
reduced use of blood products, and shorter hospital stay.
To appreciate these results, certain features of the study need to
be addressed. Although the difference in survival free of cardio-
vascular events at 1 month was negligible, the 95% CI was wide,
ranging from -4% to +7%, owing to the low number of clinical
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Table 5: Comparison of quality of life within and between the treatment groups
Off-pump* On-pump*
Domain Baseline 1 month p-value Baseline 1 month p-value
Overall 0.64 (0.27) 0.69 (0.26) 0.03 0.65 (0.27) 0.71 (0.22) 0.05
PF 52 (25) 66 (20) <0.01 52 (25) 69 (20) <0.01
RP 23 (36) 21 (34) 0.86 23 (38) 19 (31) 0.45
BP 62 (26) 57 (21) 0.24 61 (26) 59 (21) 0.61
GH 56 (17) 67 (18) <0.01 54 (20) 69 (19) <0.01
VT 49 (23) 58 (20) <0.01 49 (24) 57 (22) <0.01
SF 61 (30) 60 (26) 0.95 61 (30) 59 (26) 0.40
RE 51 (46) 60 (46) 0.04 53 (47) 69 (43) <0.01
MH 66 (20) 76 (18) <0.01 67 (22) 76 (18) <0.01
Overall denotes overall quality of life; PF, physical functioning; RP, role limitations due to physical health problems; BP, bodily
pain; GH, general health perceptions; VT, vitality; SF, social functioning; RE, role limitations due to emotional problems; and
MH, general mental health. Values are mean (SD).
* Differences within the groups between baseline and 1 month were compared by the paired t-test.
events in this trial. Another limi-
tation is that, although the car-
diovascular events were judged
by an independent blinded com-
mittee, the patients and their
attending physicians were not
blinded for randomization. This
may have influenced the timing
of hospital discharge, self-report-
ed quality of life, and anginal
assessment.
In several respects, the present
study could not show benefits
that were anticipated from off-
pump CABG.1,3,12,22 The peri-
operative complication rate,
however, was already quite low
in the patients undergoing on-
pump CABG. The incidence of postoperative atrial fibrillation
was similar in both groups. This deviates from the results of
Ascione et al,22 who did not administer a prophylactic ß-blocker
after surgery and found an absolute difference of 39% in favor of
off-pump CABG. The shorter mechanical ventilation in off-pump
patients has been caused at least partially by differences in anes-
thetic technique. This did not shorten ICU stay, because all
patients stayed 1 night. Off-pump patients were discharged from
hospital 1 day earlier, but the presumed faster recovery after off-
pump CABG9,12 was not reflected in better scores in health-relat-
ed quality of life after 1 month. Overall hospital costs were not
significantly different, although costs of the surgical procedure
were slightly lower for the off-pump group. This was caused pri-
marily by the materials used, i.e. stabilizer versus CPB. The cur-
rent cost difference, however, should be interpreted cautiously,
because long-term clinical outcomes will determine actual cost-
effectiveness.
Two findings favor off-pump CABG. First, the intraoperative use
of blood products was reduced in the off-pump group. This may
be because dilution of the patient’s blood with 2 L of CPB prim-
ing solution was avoided. Second, the 41% reduction in postoper-
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Table 5: (continued)
Off-pump versus on-pump
after one month
Difference 95% CI p-value
-0.01 -0.08 – 0.05 0.57
-3 -9 – 3 0.28
3 -6 – 11 0.58
-2 -8 – 4 0.49
-2 -7 – 3 0.41
1 -5 – 6 0.82
2 -5 – 9 0.66
-9 -21 – 4 0.17
0 -5 – 5 0.99
ative CK-MB release suggests that avoiding CPB reduced the
degree of myocardial necrosis. This is supported by the strong
(up to 22-fold) reduction in maximum cardiac troponin I release
in off-pump patients that was reported previously.23,24
Apparently, local ischemia during clamping of the coronary arter-
ies is less harmful than global cardiac ischemia. The clinical sig-
nificance of this finding is uncertain. In patients undergoing
PTCA, elevation of CK-MB was associated with higher risk of
subsequent cardiac events and mortality.17
Completeness of revascularization was similar in both groups, but
the study was conducted in relatively young patients with pre-
dominantly 1- or 2-vessel disease and normal left ventricular
function. Old patients with generalized vascular disease and poor
left ventricular function may benefit more from an off-pump
technique,25 because the risk of adverse outcomes after on-pump
CABG in these patients is much higher.2,26,27 Conversely, off-
pump procedures in these patients carry a greater risk of hemody-
namic instability or inadequate revascularization.
In conclusion, the results of this randomized trial in 281 patients
suggest that in selected patients, off-pump CABG is safe and
yields a short-term cardiac outcome comparable to that with on-
pump CABG. In addition, omitting CPB leads to reduced cardiac
enzyme release, reduced use of blood products, and a slightly
shorter hospital stay.
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Abstract
Background Avoiding cardiopulmonary bypass during coronary artery bypass
surgery may reduce perioperative morbidity and costs. It is, howev-
er, unknown whether cardiac outcome is similar to bypass surgery
using cardiopulmonary bypass. The purpose of this study was to
compare cardiac outcome and cost-effectiveness at one year
between bypass surgery on the beating heart (off-pump surgery)
and conventional bypass surgery with the use of cardiopulmonary
bypass (on-pump surgery).
Methods In a multicenter randomized clinical trial, 142 patients were ran-
domly assigned to off-pump surgery and 139 patients to on-pump
surgery. Cardiac outcome, cost-effectiveness and graft patency
were determined at one year after surgery.
Results At one year, survival free from stroke, myocardial infarction and
coronary re-intervention was 88.0% after off-pump and 90.6%
after on-pump surgery (p=0.48). Survival free from angina was
89.3% vs 89.0% (p=0.93), respectively. Graft patency determined
in a randomized subset of patients, was 91% in the off-pump and
93% in the on-pump group (p=0.65). Off-pump surgery reduced
costs by $ 2,329 (13.1%) per patient ($ 15,479 vs $ 17,808
p<0.01). Quality adjusted life expectancy after off-pump and on-
pump surgery was 0.82 vs 0.83 year (p=0.70). The cost-effective-
ness ratio for off-pump compared with on-pump surgery as
estimated by bootstrapping, remained in 98% of estimates below
the conservative ‘willingness to pay’ threshold of $20,000 per
quality adjusted life year.
Conclusions At one year, off-pump surgery was more cost-effective than on-
pump surgery, while maintaining comparable cardiac outcome. In
selected patients, off-pump surgery as an alternative for on-pump
surgery is justified from an economic perspective.
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Introduction
Coronary artery bypass graft surgery (CABG) plays an important
role in the management of patients with ischemic heart disease.1-3
Although excellent clinical results have been reported in a wide
range of patients, the safety of CABG is being questioned.4,5
Data from the National Cardiac Surgery Database of the Society
of Thoracic Surgeons (January 1998) encompassing 170,895
patients, show that the proportion of patients without complica-
tions is only 65.4%.6 In addition, health insurance data from
101,812 patients show that 10.2% of the patients do not leave the
hospital within 14 days after the operation and 3.6% are dis-
charged to a non-acute-care facility.7
Cardiopulmonary bypass (CPB) with cardiac arrest offers a still
and bloodless surgical field allowing safe construction of the anas-
tomoses. Yet, the use of CPB is believed to be a major determi-
nant of perioperative morbidity,4,5 hospital stay and costs.8 As a
result, bypass surgery on the beating heart without the use of
CPB (off-pump surgery) has been reintroduced in clinical prac-
tice9 and was stimulated by the introduction of cardiac stabilizers
in the mid-nineties.10 By immobilizing local areas of the beating
heart, cardiac stabilizers facilitate the construction of the anasto-
moses.11,12
Off-pump surgery is expected to lower costs by reducing periop-
erative morbidity and recovery time. Nevertheless, the procedure
is technically more demanding and it is unknown whether off-
pump surgery can match the long-term benefits of on-pump sur-
gery. The purpose of this randomized multicenter trial was to
compare cardiac outcome and cost-effectiveness between off-
pump and on-pump surgery at one year after the operation.
Methods
Study design and patients
The design and methods of the trial have been described in detail
elsewhere.13 In brief, patients with stable or unstable angina
(Braunwald class I-II, B) with normal or moderately impaired
ventricular function were randomly assigned to off-pump or on-
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pump surgery. Patients were eligible if referred for first time iso-
lated coronary bypass surgery and an off-pump procedure was
deemed technically feasible. Patients were excluded in case of
emergency or concomitant major surgery, Q-wave myocardial
infarction in the last six weeks or poor left ventricular function.
The study was carried out according to the principles of the dec-
laration of Helsinki. Written informed consent was obtained in
all patients. The ethics committees of the three participating cen-
ters approved the study protocol.
Treatment and procedures
The goal of surgery was to obtain complete, arterial revascular-
ization. Surgeons experienced in both off-pump and on-pump
surgery performed all operations. In the off-pump group, the
‘Octopus’ suction stabilizer was used for stabilization of the target
coronary arteries.11 In the CPB-group, cold crystalloid cardiople-
gia was used for myocardial protection.
Cardiac outcome
Cardiac outcome was defined as the composite of the following
events: all-cause mortality, stroke, myocardial infarction and
coronary re-intervention (CABG or angioplasty). Stroke was
defined as focal brain injury persisting for more than 24 hours,
combined with an increase in handicap of at least one grade on
the Rankin Scale.14 Within seven days of surgery, a myocardial
infarction was diagnosed if serum creatine kinase (CK-MB)
exceeded 5 times the upper limit of the normal value (non-Q-
wave) and if concomitantly new pathological Q-waves appeared
(Q-wave).15 Seven days after surgery, a Q-wave infarction was
documented in the presence of new pathological Q-waves and a
non-Q-wave infarction in case of isolated CK-MB elevation with
a CK-MB/CK ratio > 0.1. An independent committee blinded to
the treatment allocation evaluated all events.
Additional endpoints were survival free of angina, anti-anginal
medication (Beta-blockers, calcium entry-blockers or nitrates)
and of exercise induced ischaemia. Stable and unstable angina
were defined according to the Canadian Cardiovascular Society16
and Braunwald classification, respectively.17
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At the time of inclusion a subset of 110 patients was randomly
assigned to control angiography at one year after surgery. A car-
diologist and a cardiac surgeon independently examined the qual-
ity of the grafts using the Fitzgibbon criteria.18 Also the flow was
graded using the Thrombolysis In Myocardial Infarction (TIMI)
classification.19
Costs and Cost-effectiveness
Costs were assessed in 1999 Dutch florins (DFL) and were con-
verted in US dollars using an exchange rate of 1$=2.5DFL.
Direct medical costs were assessed separately during initial hospi-
talization and subsequent follow-up until one year. Costs per
patient were calculated by multiplying resource use by the cost
per unit. Costs of myocardial infarction20 and stroke21-23 after the
initial hospitalization were calculated using unit costs, as assessed
by other investigators in the Netherlands. The direct in-hospital
costs of on-pump surgery from the present study, were used as an
estimate of costs of repeat CABG during follow-up. The unit
costs of coronary angioplasty were previously determined at the
University Medical Center Utrecht. Indirect costs concern losses
of productivity and were calculated over a period of 4 weeks at
baseline and prior to every 1, 3, 6 and 12 months follow-up by
the ‘friction cost’ method.24
Health related quality of life was assessed using the Euroqol and
its summary score (EQ-5D)25 at baseline and 1, 3, 6 and 12
months after surgery. Using linear extrapolation for the periods in
between measurements, quality adjusted survival time was esti-
mated by calculating the individual area under the curve of the
EQ-5D. Event-free survival was defined as the average time-
interval in years between the randomization and first event, or
one year follow-up if no event occurred. Effectiveness was
expressed in terms of quality adjusted life year (QALY) and event
free survival year (EFSY). Efficiency was addressed by calculating
cost-effectiveness ratios by dividing the difference in costs by the
difference in effects (QALY and EFSY). The uncertainty sur-
rounding the obtained costs and effects was evaluated by standard
bootstrap techniques.26
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Data analysis
The sample size calculation was based on neurocognitive out-
come after bypass surgery and has been described elsewhere.27
All data were analyzed on an intention to treat basis. The risk of
an event after off-pump surgery was compared with on-pump
surgery and is presented as relative risk (RR) with 95% confi-
dence intervals (CI). Dichotomous data were compared using the
chi-square statistic. Means are presented with standard deviation
(SD) and were compared using a two-sample t-test. Non-normal-
ly distributed continuous variables were compared by a Mann
Whitney test. Event-free survival was graphically compared using
Kaplan-Meier curves. Overall change from baseline of the EQ-
5D was analyzed by repeated measures anova.28
Results
Patient characteristics and treatment allocation
Between March 1998 and August 2000, 281 patients were ran-
domly assigned to off-pump (142 patients) and on-pump surgery
(139 patients) in three hospitals in the Netherlands. Their baseline
characteristics are summarized in Table 1. Ten patients random-
ized to off-pump surgery were intra-operatively converted to an
on-pump procedure. One other patient randomized to off-pump
surgery underwent coronary angioplasty. Five patients random-
ized to on-pump surgery underwent off-pump surgery.
Therefore, a total of 265 patients (94%) were treated according to
the randomization protocol.
The mean number of grafts per patient was 2.4 in the off-pump
and 2.6 in the on-pump group. Complete arterial revasculariza-
tion was achieved in 84% and 76% of the patients in the off-pump
and on-pump group, respectively. In both treatment groups, 83%
of patients were revascularized according to the surgical treat-
ment plan which was defined before the randomization. The
mean interval between operation and one year follow-up was 375
(SD 29) days in the off-pump and 378 (SD 33) days in the on-
pump group (p=0.42).
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Cardiac outcome at one
year
The frequency of events
is shown in Table 2 and
illustrated by the Kaplan-
Meier curve (Figure 1). In
the off-pump group, two
patients died from a non-
cardiac cause and in the
on-pump group two
patients from a cardiac
cause. One patient in the
off-pump group and two
patients in the on-pump
group suffered a stroke
(one patient who experi-
enced a stroke just before
Cardiac outcome and cost-effectiveness at one year
Table 1: Baseline characteristics*
Off-pump On-pump 
Variable (n=142) (n=139)
Age, years 61.7 (9.2) 60.8 (8.8)
Male sex, % 66 71
One-vessel disease, % 30 22
Two-vessel disease, % 50 50
Three-vessel disease, % 20 27
Normal left ventricular function, % 77 79
Moderate left ventricular function, % 23 21
Angina CCS class I or II, % 32 26
Angina CCS class III or IV, % 45 49
Unstable angina, Braunwald I-II, B, % 22 21
Previous myocardial infarction, % 34 26
History of coronary angioplasty, % 17 20
Currently smoking, % 14 14
Hypertension, % 40 44
Hypercholesterolaemia, % 68 68
Family history of coronary disease, % 59 58
Obesity (quetelet index >30 kg/m2), % 18 22
Peripheral vascular disease, % 7 13
Diabetes, % 9 17
History of stroke, % 4 3
Pulmonary disease, % 9 10
* Values are percentages or means with standard deviation in parentheses. 
CCS denotes Canadian Cardiovascular Society.
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Figure 1: Kaplan-Meier estimates of survival free from
stroke, myocardial infarction and coronary
reintervention, (p=0.48 by the log rank test).
CABG, died 8 months after surgery from a second stroke). Seven
patients in the off-pump group (Q-wave 4, non Q-wave 3) and 9
patients in the on-pump group (Q-wave 6 and non Q-wave 3)
had sustained a myocardial infarction (p=0.60). Six patients in the
off-pump group and 3 patients in the on-pump group (one
patient twice), underwent percutaneous coronary angioplasty
(p=0.33). Repeat CABG was performed in one patient in each
group. At least one event occurred in 17 patients (12.0%) in the
off-pump group and in 13 patients (9.4%) in the on-pump group,
resulting in event-free survival of 88.0% and 90.6%, respectively
(p=0.48). Survival free of stroke and myocardial infarction was
93.0% after off-pump and 92.1% after on-pump surgery (p=0.78).
Freedom of angina at one year was 89.3% in the off-pump and
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Table 2: Clinical events at one year, in descending order of severity*
Worst event† All events‡
Off-pump On-pump Off-pump On-pump
Variable (n=142) (n=139) (n=142) (n=139) 
In-hospital events ¶
All cause mortality 0 (0.0) 1 (0.7) 0 (0.0) 1 (0.7)
Stroke 1 (0.7) 2 (1.4) 1 (0.7) 2 (1.4)
Myocardial infarction 7 (4.9) 6 (4.3) 7 (4.9) 7 (5.0)
Repeated CABG 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
PTCA 2 (1.4) 0 (0.0) 2 (1.4) 0 (0.0)
Any event occurred 10 (7.0) 9 (6.5) 10 (7.0) 10 (7.2)
Events at 1 year||
All cause mortality 2 (1.4) 2 (1.4) 2 (1.4) 2 (1.4)
Stroke 1 (0.7) 1 (0.7) 1 (0.7) 3 (2.2)
Myocardial infarction 7 (4.9) 8 (5.8) 7 (4.9) 9 (6.5)
Repeated CABG 1 (0.7) 1 (0.7) 1 (0.7) 1 (0.7)
PTCA 6 (4.2) 1 (0.7) 6 (4.2) 4 (2.9)
Any event occurred 17 (12.0) 13 (9.4) 17 (12.0) 19 (13.7)
Event-free survival 125 (88.0) 126 (90.6) --     -- --     --
* Values are numbers of patients, with percentages in parentheses.
† If a patient died after myocardial infarction or stroke, only the worst event (mortality) was counted.
‡ If a patient died after myocardial infarction or stroke, both events were counted.
§ Relative risk ratios and p-values concern the worst event.
¶ Between randomization and discharge.
In the off-pump group, one patient underwent PTCA while waiting for surgery. In the on-pump group, one patient suffered
a myocardial infarction and another patient a minor stroke while waiting for surgery. 
|| Between randomization and 1 year follow-up.
CABG denotes coronary artery bypass grafting and PTCA percutaneous transluminal coronary angioplasty.
89.0% in the on-pump group
(p=0.93).
Exercise testing was performed
in 246 patients (88%) at one year
after surgery. The test was
inconclusive in 7.1 % of the off-
pump group and in 8.4% of the
on-pump group. Myocardial
ischaemia was documented in
16.9 % and 20.2 % of the
remaining 227 patients, respec-
tively (p=0.53). The exercise
capacity expressed by metabolic
equivalents (METS) was 9.0
METS in the off-pump and 9.5
METS in the on-pump group
(p=0.28).
Forty of the 110 selected
patients refused to undergo con-
trol angiography. Angiography
was performed in 28 patients
randomized to off-pump surgery
and in 42 patients randomized to
on-pump surgery. The angio-
graphic results are shown in
Table 3. The overall patency
rate (Fitzgibbon grade A+B) was 91% in the off-pump and 93%
in the on-pump group (p=0.65).
Costs and Cost-effectiveness
Average costs per patient per treatment are presented in Table 4.
Off-pump surgery reduced the direct in-hospital costs by $1,375
(13.6%) per patient ($8,720 vs $10,095; p<0.01). The overall costs
at one year were $2,329 (13.1%) per patient lower after off-pump
surgery ($15,479 vs $17,808; p<0.01). The direct follow-up costs
and the indirect costs at one year were comparable between
treatment groups. Medication accounted for more than 50% of
the one year direct follow-up costs.
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Table 2: (continued)
Worst event†
Relative Risk§
(95% CI)   p-value§
-- 0.31
0.49 (0.05 – 5.38) 0.55
1.14 (0.39 – 3.31) 0.80
-- --
-- 0.16
1.09 (0.46 – 2.60) 0.85
0.98 (0.14 – 6.85) 0.98
0.98 (0.06 – 15.50) 0.99
0.86 (0.32 – 2.30) 0.76
0.98 (0.06 – 15.50) 0.99
5.87 (0.72 – 48.16) 0.06
1.28 (0.65 – 2.54) 0.48
0.97 (0.90 – 1.05) 0.48
Quality of life as assessed by the EQ-5D increased significantly
after surgery (Figure 2: overall change p<0.01)28 and, moreover,
fell within normal limits at 3 months.29 There was, however, no
difference between treatment groups. The QALYs after off-pump
and on-pump surgery were 0.82 vs 0.83 (p=0.70) and the EFSYs
1.02 vs 1.03 (p=0.72), respectively. The cost-effectiveness ratio
for off-pump surgery compared with on-pump surgery was
$232,900 for one QALY gained (i.e. difference in overall costs
divided by the difference in QALYs: -$2,329/-0.01). The ratio for
EFSY was also $232,900. Note that cost savings were realized at
the expense of a marginal difference in effects.
The bootstrap estimates in terms of incremental costs per QALY
are illustrated by Figure 3. The solid lines in this figure indicate a
conservative threshold of $20,000 society is ‘willing to pay’ per
QALY gained, and a more stringent threshold of $40,000 society
is ‘willing to accept’ per QALY lost.30 The cost-effectiveness
ratios were below the defined thresholds in 95% of estimates,
indicating better cost-effectiveness of off-pump surgery. In case
the stringent ‘willingness to accept’ threshold per QALY lost is
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Table 3: Angiographic results at one year*
Off-pump On-pump
(69 grafts) (89 grafts) Difference (95% CI) p-value
Patency†
grade A (excellent) 53 (77%) 71 (80%) 3% (-10% – 16%) 0.65
grade B 10 (14%) 12 (13%) -1% (-12% – 10%) 0.86
grade A + B 63 (91%) 83 (93%) 2% (-7% – 10%) 0.65
grade O (occlusion) 6 (9%) 6 (7%) -2% (-10% – 7%) 0.65
Disease†
I (smooth) 54 (78%) 75 (84%) 6% (-6% – 18%) 0.33
II (<50%) 5 (7%) 3 (3%) -4% (-11% – 3%) 0.27
III (>50%) 1 (1%) 0 (0%) -1% (-4% – 1%) 0.25
Inconclusive 9 (13%) 11 (12%) -1% (-11% – 10%) 0.90
Flow‡
TIMI III (normal) 58 (84%) 70 (79%) -5% (-18% – 7%) 0.39
TIMI I or II 3 (4%) 7 (8%) 4% (-4% – 11%) 0.37
TIMI 0 (no flow) 3 (4%) 4 (4%) 0% (-6% – 7%) 0.97
Inconclusive 5 (7%) 8 (9%) 2% (-7% – 10%) 0.69
* Values are numbers of grafts, with percentages in parentheses. 
Every distal anastomosis was counted as a separate graft. 
† Graft patency and graft disease were determined by the Fitzgibbon criteria.18
‡ Flow was determined by the TIMI (Thrombolysis In Myocardial Infarction) criteria.19
replaced by a conservative
one of $20,000, even 98%
of estimates would indi-
cate better cost-effective-
ness.
Discussion
The results of this ran-
domized trial at one year
indicate that cardiac out-
come, symptomatic status
and quality of life were
comparable between off-
pump and on-pump sur-
gery. However, off-pump
surgery was less expensive
and more cost-effective
than on-pump surgery.
Therefore, from an eco-
nomic perspective, off-
pump surgery can be
justified as an alternative
treatment for ‘conven-
tional’ CABG. To appre-
ciate these results certain
features of the study need
to be addressed.
By nature of the study
design and the fact that it
concerns the first multi-
center randomized clinical
trial comparing a novel
surgical strategy with
‘conventional’ on-pump
surgery, a low to moder-
ate risk population was
treated. The mean age of
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Figure 2: Quality of life after off-pump and on-pump
coronary bypass surgery, as expressed by the summary
score of the Euroqol (EQ-5D).25 The EQ-5D increased
significantly from baseline (overall p<0.01), without
differences between treatment groups. Controls: EQ-5D
scores of age matched controls.29
Figure 3: Bootstrap estimates of expected costs and
quality adjusted life years (QALYs) after off-pump and
on-pump coronary bypass surgery. The solid lines
indicate threshold values society is ‘willing to pay’ for
one QALY gained ($ 20,000) or ‘willing to accept’ for
one QALY lost ($ 40,000).30 This figure demonstrates
that off-pump surgery is more cost-effective from a
societal perspective, as 95% of all 500 estimates were
under acceptability threshold values (♦ under solid lines).
CER denotes cost-effectiveness ratio. 
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Table 4: Average resource use and costs per patient at one year*
Average resource use
Off-pump On-pump Costs ($)
Resource (n=142) (n=139) per unit
Direct in-hospital costs 
Staff: operating time (hours)† 4.17 3.82 338
Intra-operative material use: 
Off-pump CABG 0.99 0.04 1235
Cardiac stabilizer 0.99 0.04 438
On-pump CABG 0.08 0.96 2092
Cardio-pulmonary bypass 0.08 0.96 902
Intensive care unit (days) 1.43 1.62 1057
Ward (days) 8.11 8.65 247
Transfusion blood products ‡ 0.85 1.07 --
Additional investigations § -- -- --
Total  direct in-hospital costs -- -- --
Direct follow-up costs (discharge – 1 year)
Stroke -- 0.01 6818
Myocardial infarction -- 0.01 10908
CABG, on-pump 0.01 0.01 10095
Percutaneous coronary angioplasty 0.03 0.02 3740
Angiography (not study-protocol) 0.06 0.05 809
Hospitalization, other cardiac (days) ¶ 2.46 2.17 --
Rehabilitation, intramural (days)|| 0.68 2.20 --
Outpatient health care # -- -- --
Medication use -- -- --
Total direct follow-up costs -- -- --
Total direct costs at 1 year -- -- --
Total indirect  costs at 1 year -- -- --
Total direct and indirect costs at 1 year -- -- --
* The costs per unit have been rounded in the calculation of the average.
† Costs of  all staff: Surgeon, Anesthesiologist, Perfusionist and Nurse.
‡ Costs of  all transfusions: erythrocyte, platelets and fresh frozen plasma.
§ Costs of blood tests, radiology, electrocardiography, intra-aortic balloon pump, pulmonary artery catheter, angiography,
coronary angioplasty,  myocardial infarction, consulting pysicians and  in-hospital rehabilitation. 
¶ Costs of  hospitalizations: intensive care unit , coronary care unit and ward.
|| Costs of  intramural rehabilitation: rehabilitation center and nursing home.
# Costs of outpatient care: rehabilitation, consulting Physician and Nurse.
CABG denotes coronary artery bypass graft surgery.
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Table 4: (continued)
Average costs ($)
Off-pump) On-pump
(n=142) (n=139) p-value
1411 1290 <0.01
1226 44 <0.01
435 16 <0.01
162 2017 <0.01
70 870 <0.01
1512 1712 0.98
2002 2134 0.06
35 44 0.38
1867 1968 0.02
8720 10095 < 0.01
-- 49 0.31
-- 157 0.15
71 71 0.98
96 91 0.73
46 41 0.62
736 827 0.47
81 322 0.05
564 555 0.63
2755 2700 0.16
4349 4813 0.32
13069 14908 <0.01
2410 2900 0.23
15479 17808 <0.01
the patients was 61 years and the majority had single or double
vessel disease with preserved ventricular function and limited co-
morbidity. The low risk profile may explain the lower in-hospital
mortality (off-pump 0% and on-pump 0.7%) than the mortality
after first time elective CABG reported by the Society of
Thoracic Surgeons (1.8%).6 It may also explain the lower one
year mortality of the present population (off-pump and on-pump
surgery both 1.4%) in comparison to the mortality in patients
who underwent conventional CABG in the recently conducted
ARTS study (2.8%).31
The characteristics of the present population may also explain the
low incidence of perioperative stroke after off-pump and on-
pump surgery (both 0.7%). It was lower than the one reported by
Roach et al (3.1%)5 and by the Society of Thoracic Surgeons
(1.7%)6 but is comparable to the incidence reported in a review
of observational studies on off-pump surgery, encompassing 1,582
patients (0.6%).12 The use of CPB is considered a major determi-
nant of perioperative stroke during on-pump surgery.4,5 In con-
trast to a decade ago, patients undergoing CABG nowadays are
older and have more comorbid conditions.3 These patients are at
higher risk of perioperative mortality and stroke, and may partic-
ularly benefit from off-pump surgery.32 This in turn may have a
pronounced effect on costs and cost-effectiveness. A retrospective
analysis of high risk patients from the database of the Society of
Thoracic Surgeons showed, indeed, a lower incidence of stroke
after off-pump surgery.33 The possible benefits and role of off-
pump surgery in patients known to be at increased risk of stroke
needs to be addressed in appropriately designed trials.
The incidence of perioperative myocardial infarction in the pres-
ent study was comparable between treatment groups. The inci-
dence of perioperative Q-wave infarction after off-pump surgery
however, was higher (2.8%) than the one reported from a recent
randomized trial (0.5%).34 Differences in the definition of infarc-
tion may explain this discrepancy. In a series of observational
studies, myocardial infarction after off-pump surgery was report-
ed in 0.0%32 to 4.0% of the patients.10
We have previously reported that off-pump as compared with
on-pump surgery, reduced the release of CKMB postoperatively
by 41% (p<0.01).35 Troponin-I release after off-pump surgery was
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also significantly lower in one other randomized trial.36 This may
have important clinical implications since a lower CKMB release
after CABG37 and coronary angioplasty is associated with a better
prognosis.38
Both surgical approaches resulted in a comparable improvement
of angina, quality of life and exercise capacity. It is unlikely that
the small difference in repeat revascularization after off-pump
(4.9%) and on-pump surgery (3.6%) contributed to this observa-
tion. The angiographic data showed no difference in graft paten-
cy and quality of the anastomoses. Unfortunately, a substantial
number of patients refused to undergo control angiography
because of absence of symptoms. Although not proven, it sug-
gests the existence of patent grafts in these patients. Graft patency
may, therefore, have been underestimated. It precludes, anyway,
the precise interpretation and comparison of the angiographic
data of the present study with those of other series. Nevertheless,
graft patency after off-pump surgery at one year in the present
study (91%) was comparable to the early graft patency reported in
a review of non-randomized studies (91%-99%).39
In the present population, cardiac outcome was comparable
between treatment groups. Yet, off-pump surgery was associated
with cost savings and, therefore, was more cost-effective than on-
pump surgery. One might consider 13% cost savings irrelevant.
Yet, considering the 571,000 bypass operations performed in 1999
in the United States (American Heart Association, 2002), and
much more worldwide, the saving of money may be substantial.
Our findings are in concordance with a recently conducted sin-
gle-center randomized trial.40 In this trial, off-pump surgery low-
ered hospital costs by 30%, mainly because perioperative
morbidity was reduced.40
The main limitations of the present study are the sample size and
the risk profile of the population. As a result, the point estimates
of the (cost-)effectiveness lack precision. The difference in effects
in a high risk population may be more pronounced. Also, the
open design of the trial may have affected the assessment of the
outcome measures such as the need of repeat revascularization,
angina and quality of life. Finally one could question the limited
time horizon of the (cost-)effectiveness analysis of one year. Yet,
it is reasonable to assume that beyond one year, cardiac events
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because of graft failure and progression of atherosclerosis will
occur to a similar degree in both groups.
We conclude that at one year, off-pump surgery was more cost-
effective than on-pump surgery, while maintaining comparable
cardiac outcome. In selected patients, off-pump surgery as an
alternative for on-pump surgery is justified from an economic
perspective.
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The Octopus Trial: hypotheses and findings
The aim of the Octopus Trial was to directly compare off-pump
and on-pump coronary artery bypass surgery (CABG).1 We
assumed that both strategies would have similar cardiac outcome,
but that cognitive outcome would be better in patients operated
without cardiopulmonary bypass (CPB). 
Two hundred eighty-one patients were included in the study, and
randomly assigned to off-pump and on-pump coronary bypass
surgery.2 Cognitive performance of the participants was assessed
at four days and three and twelve months after surgery. At three
months, a slightly better cognitive outcome in the off-pump
group was demonstrated, but the effect was smaller than antici-
pated and became negligible at twelve months.3 Twelve months
after surgery, the incidence of cardiovascular events, and other
measures of cardiac outcome including anginal status, exercise
testing and coronary angiography, were similar between the two
groups.4 The confidence intervals of the point estimates, howev-
er, were wide. Off-pump surgery was more cost-effective because
quality of life across the groups was similar, while the costs of
off-pump procedures were lower.4
The Octopus Study was largely unable to substantiate the antici-
pated benefits of off-pump CABG. Several explanations are possi-
ble. We may have overestimated the potential advantages of
off-pump surgery. Perhaps we also overestimated the complica-
tions of conventional bypass surgery. Finally, we may have under-
estimated some methodological limitations of the trial. In the
following paragraphs, these possible explanations will be dis-
cussed in detail.
Overestimation of the potential advantages
of off-pump surgery
It was expected that avoiding CPB would improve cognitive out-
come.5,6 Cognitive decline after CABG is well documented.5
However, data from our study suggest that CPB is not the only
cause of cognitive decline.3,7 Undergoing major surgery and anes-
thesia may also be responsible for cognitive decline.8
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Alternatively, the off-pump technique may be a new source of
cognitive decline. Manipulation of the beating heart, especially
exposure of the posterior cardiac wall, might dislocate aortic
atheromas. Moreover, such manipulations cause a drop in cere-
bral perfusion pressure due to an elevated central venous pressure
and a concurrent decreased systemic blood pressure.9 Together,
this may be equally harmful to the brain as CPB.10,11
One of the most reported advantages of off-pump CABG is
shorter hospitalization.2,12-15 This outcome, however, is sensitive
to bias. In studies where the doctors responsible for discharge of
the patients are not blinded (including our own), we cannot
exclude that enthusiasm for the new technique caused earlier dis-
charge. A possible faster recovery of the patients should translate
to improved short-term quality of life. In the Octopus Study,
quality of life had significantly improved from before to one
month after surgery, but no difference was observed between the
off-pump and on-pump group.2 Altogether, there is little proof of
faster recovery after off-pump surgery.
While sternotomy is virtually always required when CPB is used,
off-pump CABG may in selected cases be performed via left lat-
eral thoracotomy, mini-incisions or ‘port-access’.16,17 It is difficult
to argue against attempts to decrease the invasiveness of a surgi-
cal procedure. However, a lateral thoracotomy seems to be
equally invasive as sternotomy. Patients report more pain in the
first postoperative days and a substantial proportion of the
patients may develop chronic intercostal neuralgia (unpublished
results). The term ‘minimally invasive CABG’ is therefore mis-
leading and should be reserved for true keyhole surgery, which is
currently at an experimental stage.18 Off-pump CABG as current-
ly practiced is still major surgery, with all the possible complica-
tions that are associated with conventional CABG.19
Overestimation of the disadvantages of
conventional bypass surgery
CABG may lead to perioperative mortality, stroke, myocardial
infarction, and prolonged hospital stay.20,21 Age and co-morbidity
largely determine the risk of these complications.20-22 In the ini-
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tial case series of relatively young and healthy patients, off-pump
surgery was associated with a low complication rate.12,13
However, it appears that patients of comparable age and with a
similar degree of co-morbidity undergoing conventional on-pump
CABG do also well.23 As several authors have suggested, it may
not be the off-pump procedure, but the selection of young and
relatively healthy patients that generates favorable outcomes.24,25
It is beyond doubt that CABG may cause serious cognitive
impairment, even to such an extent that it prevents patients from
return to work and normal social activities.20,26 Previous studies
have demonstrated that advanced age increases the risk of postop-
erative cognitive decline,6,27-29 but this association could not be
confirmed in the Octopus Study.7 Moreover, high incidences of
subtle brain injury have also been reported in younger
patients.27,30-33 Therefore, the inclusion of relatively young
patients in the Octopus Study does not entirely explain its inabili-
ty to demonstrate a marked difference in cognitive outcome
between the groups.
An alternative explanation is that, due to methodological limita-
tions, the true incidence of cognitive decline after CABG is lower
than has been reported.30,34 There is evidence that the instrument
used to measure cognitive status (a series of neuropsychological
tests) is not very accurate. Both patients and healthy controls
have natural fluctuations in their performance on neuropsycho-
logical tests.34 To identify patients with cognitive decline these
natural fluctuations must be taken into account, which requires a
control group.8 However, most studies reporting high incidences
of cognitive decline after CABG are without non-surgical con-
trols. At least three commonly used definitions of cognitive
decline (an arbitrary decrease of 20% or 1 SD in cognitive per-
formance in an arbitrary proportion of the tests or cognitive
domains)6,35,36 are therefore without empirical basis. The cut-off
values for abnormal performance may be well within the range of
an individual’s natural fluctuations in performance. Current defi-
nitions of cognitive decline may therefore generate false positive
outcomes, as was recently demonstrated in two studies. We
administered a battery of cognitive tests to 110 volunteers (mean
age 60.5 y) with a time interval of three months. More than 20%
of the volunteers had ‘cognitive decline’ after three months,
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according to the definition that was also used in the Octopus
Study.37 The ISPOCD group found similar results.34 A virtually
identical definition was applied to 176 volunteers undergoing five
neuropsychologic tests. After three months, 25% of the volunteers
was identified as having cognitive decline.
Misclassification of patients with and without cognitive decline,
and an overestimation overestimation of the number of patients
with cognitive decline, may both explain our inability to show
improvement after off-pump procedures and to identify other
determinants of cognitive decline. It would also imply that the
proportion of 22.5% found in the pooled analysis in Chapter 2 of
this thesis5 overestimates the true incidence of cognitive decline
after CABG.
Methodological limitations
A lower incidence of cognitive decline after conventional CABG
and a smaller potential benefit of off-pump CABG both have
consequences for the statistical power of the trial.38 In retrospect,
we must conclude that the power calculation may have been too
optimistic. More subtle benefits of off-pump surgery might have
become clear with a larger sample size. Moreover, the claim of
equivalence in cardiac outcome would have been more precise.
Comparable problems were encountered in the recently published
BHACAS studies. Pooled analysis of two randomized trials, in
total including 2 x 200 patients, demonstrated lower mortality
and less cardiac related events 25 months after off-pump surgery,
but the confidence intervals were wide.39
A major restriction of the study is the unreliability of the neu-
ropsychologic tests. When conducting a trial on cognitive out-
come, we have to rely on these tests because we are lacking
better instruments. The test battery applied in the Octopus Study
evaluated a broad spectrum of cognitive functions,1 but was not
targeted to assess tasks of daily life, i.e. to measure outcomes that
matter to the patients. More important, a high level of noise (pre-
vious paragraph) may have diluted the difference in cognitive
outcome between the groups.
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The Octopus Study was designed as a pragmatic trial, i.e. as a
trial comparing two strategies.1 This seemed logical, as the parallel
OctoStent Trial evaluated two completely different treatments of
coronary artery disease (intracoronary stenting versus off-pump
bypass surgery). Such a study obviously can not be conducted as
an explanatory trial, which aims to quantify the effect of one spe-
cific treatment feature, keeping all other medical procedures simi-
lar.40 When designing the present study (the OctoPump Trial),
off-pump and on-pump CABG were also perceived as two differ-
ent strategies. After all, off-pump CABG could be performed via
small incisions,16,17 allowed the use of epidural anesthesia,41 and
was performed without high dose steroids, which attenuate the
inflammatory reaction on CPB.42 However, the strategies of con-
ventional CABG and off-pump CABG appeared not to be as dif-
ferent as perhaps anticipated. In the trial, only 8% of the
off-pump patients were operated via another incision than ster-
notomy.2 In several hospitals, epidural anesthesia is now also
applied in on-pump procedures, because a short period of com-
plete heparinization is not considered an absolute contra-indica-
tion for epidural anesthesia anymore.43,44 In addition only some,
but not all centers administer high dose steroids before commenc-
ing CPB.42
A more explanatory design of the study, in which the use of CPB
is the only difference between the two treatment groups, would
have avoided a number of problems.40 Only around 50% of the
off-pump patients in the trial received epidural anesthesia,
because this depended on the preference of the attending anes-
thesiologist. This complicated the interpretation of the early out-
comes. The selective use of steroids in the on-pump group may
have prevented postoperative hyperthermia. A recent study by
Grocott et al. found an association between postoperative hyper-
thermia and cognitive decline,45 which is again a possible expla-
nation for the Octopus Study failing to demonstrate a difference
in cognitive outcome. The most important disadvantage of the
pragmatic study design, however, is that it lacks blinding. It was
assumed that a substantial proportion of the off-pump patients
would be operated on via left lateral thoracotomy. Therefore, the
patients were not blinded. This, however, decreased their motiva-
tion for neuropsychologic testing and caused withdrawals from
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the study if they were assigned to conventional treatment. The
physicians discharging the patients were also not blinded and may
have been tempted to discharge the off-pump patients sooner
than the on-pump patients. The doctors who determined postop-
erative anginal status were not blinded either because they also
inspected the surgical wound. It turned out, however, that only a
very small proportion of the patients could be operated via alter-
native incisions. If sternotomy had been applied to all participants
of the study, a completely blinded design would have been possi-
ble.
Future studies
It is currently still unknown whether off-pump CABG, compared
to on-pump CABG, leads to long-standing better cerebral out-
come. The participants of the Octopus Study will be reassessed
five years after surgery, but the limited statistical power of the
study may again preclude a precise estimate of the effect of CPB
on cardiac and cognitive outcome.38 Retrospective cohort studies
suggest a lower risk-adjusted perioperative complication rate after
off-pump CABG, but the question whether long-term graft
patency and freedom from reintervention is comparable to on-
pump CABG remains unanswered.14,15
A new randomized study evaluating cognitive outcome needs an
even larger sample size and a more reliable definition of cognitive
decline. Such a definition is currently being developed at Utrecht
University. It is based on indices, derived from non-surgical con-
trols, which reflect the normal range in which an individual’s per-
formance on cognitive tests may fluctuate.37 Alternatively, we
may have to accept that we are presently unable to reliably iden-
tify patients with subtle cognitive decline. Direct comparison of
the mean cognitive performances of two randomized groups, at
some time after surgery, is sufficient to identify the better treat-
ment. No pre-surgery assessments are necessary and less sources
of noise may dilute the difference between the groups. The only
prerequisite is that randomization is performed adequately so that
the groups are really comparable at baseline. And then of course
cognitive decline after CABG really needs to exist. 
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The advantages of off-pump surgery may be more apparent in
older patients. Cohort studies have described an association
between age and the risk of cognitive decline.6,27-29 Within the
patients of the Octopus Study, however, age was not a predictor
of cognitive outcome. The association between age and the risk
of peri-operative stroke, on the other hand, is well established. A
Stroke Risk Index, derived from over 2000 patients, identified
age as a major determinant of peri-operative stroke22 and Tuman
found that in CABG patients older than 80 years, the risk of
stroke is 9%.21 The most probable mechanism is that aortic ather-
osclerosis is more pronounced in older people and that atheromas
may be dislocated by cannulation and clamping of the aorta.46
The Octopus Study could be repeated in older patients. The
applicability of cognitive tests, however, is even lower in older
patients. As the results of the studies in volunteers suggest that
cognitive decline is less common than was assumed, the premise
that cognitive decline is a ‘surrogate endpoint’ for more severe
cerebral injury is no longer valid. Because the diagnosis of stroke,
in contrast to the diagnosis of cognitive decline, is relatively
uncomplicated, the occurrence of stroke could be chosen as an
alternative endpoint. Stroke, however, only occurs in a minority
of the patients and this has consequences for the power of a
future study. For instance, to demonstrate a reduction in stroke
rate in elderly patients from 5% to 2.5% by avoiding CPB, with
the alpha error set at 0.05 and a power of 80%, a sample size of
1000 patients per group is needed. The large number of study
subjects that is required to obtain sufficient power is offset by
several advantages. Neuropsychologic testing can be avoided,
which circumvents the need for intensive patient cooperation and
the availability of neuropsychologists and testing rooms. Loss to
follow-up will be uncommon. Because determining the primary
outcome measure is straightforward, the logistics of a multicenter
trial are less complicated. The large sample size also allows reli-
able inference with respect to cardiac outcome after off- and on-
pump surgery. If the one-month survival free from cardiovascular
events again would be 93% in the off-pump group and 94% in the
on-pump group (like it was in the Octopus Study), the risk dif-
ference is again 1%, but if studied in 2 x 1000 patients, this esti-
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mate has a high level of precision, e.g. a narrow 95% confidence
interval ranging from -1% to 3%. 
Because establishing cognitive outcome is difficult and not per-
formed in routine patient care, it cannot be studied in a retro-
spective study. In contrast, the occurrence of stroke is routinely
recorded in patient files, and made available in databases, such as
those maintained by the Society of Thoracic Surgeons (STS:
National Adult Cardiac Surgery Database), or the Department of
Veterans Affairs (Continuous Improvement in Cardiac Surgery
Program Records). Because ten thousands of off-pump proce-
dures are now performed annually, retrospective multivariate
studies can be carried out to quantify the effect of off-pump sur-
gery on stroke rate. A first study of this design has been per-
formed recently. Cleveland et al. retrospectively studied 118,140
CABG procedures from the STS database, of which 10% was per-
formed off-pump. The use of an off-pump procedure decreased
the risk-adjusted operative mortality from 2.9% to 2.3% (p<0.001)
and in patients with known cerebrovascular disease, the risk-
adjusted peri-operative stroke rate decreased from 4.6% to 2.5% if
CPB was avoided (p<0.001).14 These results are encouraging, but
because retrospective observational studies are prone to con-
founding, randomized data are still needed to confirm better
cerebral outcome after off-pump CABG.
Conclusions
In selected patients, off-pump CABG is safe and yields a cardiac
outcome that is comparable to that of on-pump CABG. Avoiding
CPB is more cost-effective. It slightly decreases the need for
blood transfusion, but other clinically relevant benefits of off-
pump CABG are not established yet. Patients undergoing off-
pump CABG have better cognitive outcome at 3 months after
surgery, but the effect is of limited size. This may be caused by
an overestimation of the incidence of cognitive decline after
bypass surgery. Off-pump CABG still has significant potential
advantages compared to on-pump surgery. Future randomized
studies are essential and should focus on clinically relevant out-
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comes such as stroke, which is a common complication of CABG
in elderly patients.
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The complications associated with coronary artery bypass surgery
(CABG) using cardiopulmonary bypass (CPB) have led to a
renewed interest in coronary bypass surgery on the beating heart.
The Octopus Stabilizer is one of the recently developed devices
that facilitate CABG without CPB (off-pump CABG) by immobi-
lizing the target coronary arteries. CABG may lead to a decline in
cognitive function, which has largely been attributed to the use of
CPB. Therefore, CABG without CPB should improve cognitive
outcome. It is assumed that cardiac outcome after off-pump
CABG is similar to conventional procedures using CPB (on-pump
CABG). Nevertheless, bypass surgery on the beating heart is
technically more demanding and no proof is yet available that
off-pump CABG can match the long-term cardiac benefits of the
on-pump operation.
The primary objective of the Octopus Study was to compare cog-
nitive outcome between patients randomized to off-pump or on-
pump CABG. As it was assumed, but not established that
off-pump and on-pump CABG are equally effective in terms of
myocardial revascularization, an important secondary objective of
the trial was to compare cardiac outcome.
In chapter 2, the literature suggesting that CABG may impair cog-
nitive function is systematically reviewed. As methods and defini-
tions differ greatly across studies, the reported incidence of
cognitive decline after coronary bypass surgery varies widely as
well. Only those studies on cognitive decline that were relatively
comparable and met with certain quality criteria were included in
the review. Four electronic databases and the references of sever-
al abstract books and earlier reviews were used to identify rele-
vant literature. Stringent criteria, based in part on the 1994
consensus meeting on assessment of neurobehavioral outcomes
after cardiac surgery, were used to assess the studies that were
found. In total, 256 different titles were found, of which twelve
cohort studies and eleven intervention studies met with the for-
mulated selection criteria. A pooled analysis of six highly compa-
rable studies yielded a proportion of 22.5% (95% confidence
interval [CI] 18.7%-26.4%) of patients with a cognitive deficit (a
decrease of at least 1 standard deviation in at least two of nine or
ten tests) 2 months after the operation. This suggested that cogni-
tive dysfunction is a frequently occurring complication of coro-
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nary artery bypass grafting. A randomized trial directly comparing
off-pump and on-pump bypass surgery could reveal the etiologic
contribution of cardiopulmonary bypass to this complication.
Chapter 3 describes in detail the rationale and design of the
Octopus Study. The Octopus Study comprised two randomized
trials: one directly comparing off-pump CABG and intracoronary
stent implantation (OctoStent Trial) and one directly comparing
off-pump CABG and on-pump CABG (OctoPump Trial). In both
trials, the Utrecht Octopus Method was used for the off-pump
CABG procedures.
In this thesis, the results of the OctoPump Trial are presented.
The term Octopus Study therefore refers here to the OctoPump
Trial, i.e. the randomized comparison of off-pump and on-pump
CABG. Patients were eligible for this trial if they were referred
for first-time isolated coronary bypass surgery and an off-pump
procedure was deemed technically feasible. Patients were exclud-
ed in case of emergency surgery, Q-wave myocardial infarction in
the last 6 weeks, or poor left ventricular function. Patients who
were unlikely to complete 1-year follow-up, unable to give
informed consent, or undergo neuropsychologic testing were also
excluded. There were no restrictions to age. The primary end-
point of the trial was the presence or absence of cognitive decline
and/or stroke, at 3 months after surgery. Secondary endpoints
included cognitive outcome at 12 months, occurrence of cardio-
vascular events, recurrence angina, presence of cardiac ischaemia
during exercise testing, quality of life, and cost-effectiveness.
Stable and unstable angina were classified according to the
Canadian Cardiovascular Society and Braunwald classification,
respectively. Quality of life was assessed using the EuroQol and
ShortForm-36 questionnaires. Per treatment group, 140 patients
were to be enrolled. A subsample of the patients was randomized
to undergo repeat coronary angiography at 1 year to assess graft
patency.
In chapter 4, the cerebral outcome and quality of life after off-
pump and on-pump CABG is presented. From March 1998
through August 2000, 281 patients were enrolled. At 3 and 12
months after surgery, there was no difference in quality of life
between the two groups. Psychologists, blinded for randomiza-
tion, repeatedly administered 10 neuropsychological tests to
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determine cognitive outcome at 3 and 12 months. At 3 months,
cognitive outcome could be determined in 248 patients.
Cognitive decline (or stroke) occurred in 21% in the off-pump
group and 29% in the on-pump group (relative risk 0.65; 95% CI
0.36-1.16; p=0.15). The overall standardized change score (i.e.
improvement of cognitive performance from before to 3 months
after surgery) was 0.19 in the off-pump vs 0.13 in the on-pump
group (p=0.03). At 12 months, cognitive decline occurred in 31%
in the off-pump group and 34% in the on-pump group (relative
risk 0.88; 95% CI 0.52-1.49; p=0.69). The overall standardized
change score was 0.19 in the off-pump vs 0.12 in the on-pump
group (p=0.09). These results indicate that patients undergoing
first-time CABG without cardiopulmonary bypass have improved
cognitive outcomes 3 months after the procedure, but the effects
are limited and become negligible at 12 months.
Chapter 5 is a prediction study on cognitive outcome. Because
avoiding cardiopulmonary bypass only slightly improved cogni-
tive outcome, an effort was made to identify other determinants
of cognitive outcome after bypass surgery. In previous studies,
advanced age, female sex, diabetes, history of stroke, manipula-
tion of the ascending aorta, prolonged perfusion time, and post-
operative time to awakening were identified as predictors of
cognitive decline. The dichotomous and the continuous measure
of 3-month cognitive outcome, used before in the analyses of the
randomized trial (chapter 4), were applied again as dependent
variables. Thirteen possible clinical predictors of 3-month cogni-
tive outcome and two measures of early cognitive performance
(4th day after surgery), were entered into logistic and linear
regression models. The previously identified determinants of cog-
nitive outcome were no predictor of cognitive outcome in the
present patient sample. The only variables that were significantly
associated with cognitive outcome after 3 months, were measures
of cognitive outcome 4 days after surgery. This association was
stronger in patients operated with cardiopulmonary bypass (odds
ratio 4.72; 95% CI 1.63 - 13.66; p<0.01) than in patients operated
without cardiopulmonary bypass (odds ratio 2.00; 95% CI 0.77 -
5.20; p=0.16).
In chapter 6 measures of early clinical outcome after off-pump and
on-pump CABG are compared. In-hospital results and cardiac
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outcome and quality of life after 1 month are presented. Cardiac
outcome was defined as survival free of cardiovascular events
(stroke, myocardial infarction, and coronary reintervention). The
mean numbers of distal anastomoses per patient were 2.4 and 2.6
in the off-pump and on-pump group, respectively. Completeness
of revascularization was similar in both groups. Blood products
were needed during 3% of the off-pump procedures and 13% of
the on-pump procedures (p<0.01). Release of creatine kinase
muscle-brain isoenzyme was 41% less in the off-pump group
(p<0.01). Off-pump patients were discharged 1 day earlier.
Otherwise, no differences in complications were found postoper-
atively. At 1 month, operative mortality was zero in both groups,
and quality of life had improved similarly. In both groups, 4% of
the patients had recurrent angina. The proportions of patients
surviving free of cardiovascular events were 93.0% in the off-
pump group and 94.2% in the on-pump group (difference 1.2%;
95% CI -4.4 to 7.0%; p=0.66). These results suggest that in
selected patients, off-pump CABG is safe and yields a short-term
cardiac outcome comparable to that of on-pump CABG.
In chapter 7, a comparison of cardiac outcome and cost-effective-
ness one year after off-pump and on-pump CABG is reported.
One year survival free from stroke, myocardial infarction and
coronary re-intervention was 88.0% after off-pump surgery and
90.6% after on-pump surgery (p=0.48). Survival free from angina
was 89.3% vs 89.0% (p=0.93). Graft patency, determined in a ran-
domized subset of patients, was 91% after off-pump and 93%
after on-pump surgery (p=0.65). Off-pump surgery reduced costs
by $2,329 (13.1%) per patient ($ 15,479 vs $ 17,808; p<0.01).
Quality adjusted life years (0.82 vs 0.83; p=0.74) and event free
survival years (1.02 vs 1.03; p=0.23) did not differ. Consequently,
off-pump bypass surgery was more cost-effective than on-pump
surgery, with comparable cardiac outcome and graft patency. In
selected patients, the application of off-pump bypass surgery as an
alternative for on-pump surgery is therefore justified from an
economic perspective.
Finally, Chapter 8 comprises a general discussion of the Octopus
Study. The discussion focuses on the inability of the study to
demonstrate several of the anticipated benefits of off-pump
CABG. Several explanations are possible.
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First, the potential advantages of off-pump surgery may have
been overestimated. The Octopus Study suggests that CPB is not
the only cause of cognitive decline. Undergoing major surgery
and anesthesia may also be responsible for cognitive decline or,
alternatively, the off-pump technique may be a new source of
cognitive decline. The reports that off-pump CABG shortens hos-
pitalization may be biased due to a lack of blinding. Even when
access to the heart is achieved via left lateral thoracotomy, the
procedure may lead to most of the complications that are associ-
ated with conventional CABG.
Second, the complications of conventional bypass surgery may
have been overestimated. Off-pump surgery is generally associat-
ed with a low complication rate, but it appears that patients with
a similar (usually low) risk profile undergoing conventional on-
pump CABG do also well. The incidence of cognitive decline
after CABG may have been overestimated, because the currently
used definitions of cognitive decline may generate false positive
outcomes. Misclassification of patients with and without cognitive
decline, and an overestimation of the number of patients with
cognitive decline, may both explain our inability to show sub-
stantial improvement when avoiding CPB.
Third, methodological limitations of the trial may have been
underestimated. More subtle benefits of off-pump surgery might
have become clear with a larger sample size. The high level of
noise associated with neuropsychologic testing and defining cog-
nitive decline, may have diluted the difference in cognitive out-
come that was found. Too little attention was paid to blinding.
Future studies evaluating the cerebral effects of CPB should be
carried out in elderly patients, because in these patients improved
cerebral outcome after off-pump surgery may be more apparent.
A new study needs a more reliable definition of cognitive decline.
With a larger sample size, stroke could be chosen as an alterna-
tive endpoint. The diagnosis of stroke, in contrast to the diagno-
sis of cognitive decline, is relatively straightforward. In older
patients, the risk of stroke after CABG is up to 9%, and there is
no doubt that this is an outcome that matters to the patient.
It is concluded that in selected patients, off-pump CABG is safe
and yields a cardiac outcome that is comparable to that of on-
pump CABG. Avoiding CPB is cost-effective and slightly
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Summary
decreases the need for blood transfusion, but other clinically rele-
vant benefits of off-pump CABG are not established yet. Patients
undergoing off-pump CABG have better cognitive outcome at 3
months after surgery, but the effect is of limited size.
148
Samenvatting
149

De complicaties die kunnen optreden bij coronaire bypass chirur-
gie (CABG) met gebruik van de hart-longmachine, hebben tot
een hernieuwde aandacht geleid voor bypass chirurgie op het
kloppende hart. De Octopus Methode is één van de recentelijk
ontwikkelde technieken die CABG zònder hart-longmachine
(off-pump CABG) vereenvoudigen door het kloppende hart
gedeeltelijk te immobiliseren. Coronaire bypass chirurgie kan tot
een achteruitgang van cognitieve functies leiden, die wordt toe-
geschreven aan het gebruik van de hart-longmachine. Daarom
zou CABG zònder hart-longmachine gepaard moeten gaan met
minder cognitieve schade. Verondersteld wordt dat off-pump
CABG en conventionele CABG met gebruik van de hart-longma-
chine (on-pump CABG) tot een vergelijkbare cardiale uitkomst
leiden. Chirurgie op het kloppende hart is echter technisch lasti-
ger en er bestaat nog geen bewijs dat off-pump CABG op lange
termijn even succesvol de cardiale klachten wegneemt als on-
pump CABG.
Het primaire doel van de Octopus Studie was om een vergelij-
king te maken tussen patiënten die door loting (randomisatie)
ofwel off-pump CABG, ofwel on-pump CABG kregen toegewe-
zen. Omdat het nog niet aangetoond is dat beide operatietechnie-
ken tot een even goed cardiaal resultaat leiden, was een
belangrijk secundair doel om de cardiale uitkomsten van beide
operatie methodes te vergelijken.
In hoofdstuk 2 van dit proefschrift wordt de literatuur samengevat
die suggereert dat CABG samengaat met cognitieve schade (sys-
tematisch review). Omdat er grote verschillen bestaan tussen de
diverse studies met betrekking tot methodologie en definiëring
van cognitieve schade, bestaat er eveneens een groot verschil in
de gerapporteerde incidenties. Uitsluitend studies die in enige
mate onderling vergelijkbaar waren en die aan bepaalde kwaliteits
criteria voldeden werden betrokken in het literatuuroverzicht.
Vier elektronische bibliografieën en de referenties van een aantal
boeken werden gebruikt om relevante literatuur op te sporen. Bij
de beoordeling van de gevonden literatuur werd gebruik gemaakt
van criteria, die gedeeltelijk ontleend waren aan een consensus
bijeenkomst over onderzoek naar cognitieve schade na hart-
chirurgie. In totaal werden 256 verschillende artikelen gevonden,
waarvan 12 cohort studies en 11 interventie studies voldeden aan
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de opgestelde criteria. In een gepoolde analyse van 6 sterk verge-
lijkbare studies werd een incidentie van cognitieve beschadiging
berekend van 22,5%, 2 maanden na CABG (95% betrouwbaar-
heids interval [BTI] 18,7%-26,4%). Cognitieve beschadiging was
hier gedefinieerd als een achteruitgang in cognitieve prestaties
van minimaal 1 standaarddeviatie, in minimaal 2 uit 9 of 10
neuropsychologische tests. Dit resultaat suggereert dat cognitieve
beschadiging een frequent voorkomende complicatie van coronai-
re bypass chirurgie is. In hoeverre dit veroorzaakt wordt door de
hart-longmachine, kan worden onderzocht in een gerandomiseer-
de studie, waarin off-pump CABG en on-pump CABG direct met
elkaar vergeleken worden.
Hoofdstuk 3 beschrijft in detail de opzet van de Octopus Studie.
De studie bestaat feitelijk uit twee gerandomiseerde onderzoeken.
In het ene onderzoek wordt een vergelijking gemaakt tussen off-
pump CABG en dotterbehandeling (PTCA) met stentimplantatie
(OctoStent Trial). In het andere onderzoek wordt een vergelij-
king gemaakt tussen off-pump CABG en on-pump CABG
(OctoPump Trial). In beide studies werd voor de off-pump ope-
raties de Octopus Methode toegepast. 
In dit proefschrift worden de resultaten van de OctoPump Trial
gepresenteerd. Met Octopus Studie wordt daarom hier steeds de
OctoPump Trial bedoeld, de gerandomiseerde vergelijking tussen
off-pump en on-pump CABG. In deze studie werden patiënten
opgenomen die verwezen werden voor een eerste CABG, zonder
bijkomende interventies als klepchirurgie en bij wie een off-pump
operatie technisch mogelijk werd geacht. Patiënten werden van
de studie uitgesloten indien een spoedoperatie noodzakelijk was,
indien zij de afgelopen 6 weken een Q-wave myocardinfarct had-
den doorgemaakt, of indien zij een slechte linker hartkamer func-
tie hadden. Ook patiënten bij wie het voltooien van 1 jaar
follow-up onwaarschijnlijk geacht werd, patiënten die niet
geschikt waren voor neuropsychologisch onderzoek en patiënten
die geen schriftelijke toestemming gaven werden uitgesloten van
het onderzoek. Er bestonden geen restricties met betrekking tot
de leeftijd van de patiënten. De primaire uitkomstmaat van de
studie was de aanwezigheid of afwezigheid van cognitieve
beschadiging en/of beroerte, 3 maanden na de operatie.
Secundaire eindpunten waren onder meer de cerebrale uitkomst
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na 12 maanden, het optreden van cardiovasculaire complicaties,
het opnieuw ontstaan van angina pectoris, het optreden van car-
diale ischemie tijdens ergometrie, kwaliteit van leven en kosten-
effectiviteit. Stabiele angina pectoris werd geclassificeerd volgens
de indeling van de Canadian Cardiovascular Society en instabiele
angina pectoris volgens de indeling van Braunwald. Kwaliteit van
leven werd gemeten met behulp van de EuroQol en de
ShortForm-36 vragenlijsten. De benodigde omvang van de studie
(power calculatie) was 140 patiënten per groep. Een deel van de
patiënten werd bovendien gerandomiseerd om een jaar na de
operatie coronair-angiografie te ondergaan, teneinde de doorgan-
kelijkheid van de aangelegde omleidingen te beoordelen. 
In hoofdstuk 4 worden de cerebrale uitkomsten en de kwaliteit van
leven na off-pump en on-pump CABG gepresenteerd. Tussen
maart 1998 en Augustus 2000 werden 281 patiënten geïncludeerd
in de studie. Zowel 3 als 12 maanden na chirurgie bestond er
geen verschil in kwaliteit van leven tussen de beide groepen.
Psychologen, die geblindeerd waren voor de soort operatie die
aan de patiënten was toegewezen, namen herhaaldelijk een serie
van 10 neuropsychologische tests af om de cognitieve uitkomst na
3 en 12 maanden te kunnen bepalen. Na 3 maanden kon de cog-
nitieve uitkomst in 248 patiënten worden vastgesteld. Cognitieve
beschadiging (of een beroerte) was aanwezig bij 21% van de off-
pump patiënten en 29% van de on-pump patiënten (relatief risico
0,65; 95% BTI 0,36-1,16; p=0,15). De gemiddelde, gestan-
daardiseerde cognitieve verbetering (van pre-operatief naar 3
maanden post-operatief) was 0,19 in de off-pump groep versus
0,13 in de on-pump groep (p=0,03). Twaalf maanden na de ope-
ratie was cognitieve beschadiging aanwezig bij 31% van de off-
pump patiënten en 34% van de on-pump patiënten (relatief risico
0,88; 95% BTI 0,52-1,49; p=0,69). De gemiddelde gestan-
daardiseerde cognitieve verbetering bedroeg 0,19 in de off-pump
groep en 0,12 in de on-pump groep (p=0,09). Deze resultaten
suggereren dat patiënten die voor het eerst een CABG ondergaan
na 3 maanden een betere cognitieve uitkomst hebben als deze
zonder hart-longmachine wordt uitgevoerd. Het effect is echter
klein en wordt na 12 maanden verwaarloosbaar.
Hoofdstuk 5 bestaat uit een predictie-studie. Omdat het vermijden
van de hart-longmachine slechts tot een kleine verbetering van
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de cognitieve uitkomsten leidde, werd getracht om andere deter-
minanten te identificeren. In eerder uitgevoerde studies werden
gevorderde leeftijd, vrouwelijk geslacht, diabetes, een beroerte in
de voorgeschiedenis, manipulatie van de aorta ascendens, een
lange tijd aan de hart-longmachine en een lange tijd voor ontwa-
ken na de operatie, gevonden als voorspellers (predictoren) van
cognitieve beschadiging. De dichotome en continue maat voor
cognitieve uitkomst na 3 maanden die in de analyse van de geran-
domiseerde studie gehanteerd werden (hoofdstuk 4), werden
opnieuw toegepast als afhankelijke variabelen. Dertien klinische
potentiële predictoren van de cognitieve uitkomst na 3 maanden
en 2 maten van vroege cognitieve uitkomst (4 dagen na de opera-
tie) werden opgenomen in logistische en lineaire regressiemodel-
len. De eerder gevonden determinanten van cognitieve uitkomst
hadden in de huidige patiënten groep geen predictieve waarde.
De enige variabelen die geassocieerd waren met de cognitieve
uitkomst na 3 maanden waren maten voor cognitieve uitkomst na
4 dagen. Dit verband was sterker aanwezig in patiënten die
geopereerd waren met hart-longmachine (odds ratio 4,72; 95%
BTI 1,63 - 13,66; p<0,01) dan in patiënten die geopereerd waren
zònder hart-longmachine (odds ratio 2,00; 95% BTI 0,77 - 5,20;
p=0,16).
In hoofdstuk 6 worden de vroege klinische uitkomsten van off-
pump en on-pump CABG met elkaar vergeleken. Zowel het
beloop tijdens de ziekenhuisopname als de cardiale uitkomst en
kwaliteit van leven na 1 maand worden gerapporteerd. De cardi-
ale uitkomst werd gedefinieerd als overleving zonder cardiovas-
culaire complicaties (beroerte, hartinfarct, of coronaire
re-interventie). Het gemiddelde aantal distale anastomoses was
2,4 in de off-pump groep en 2, 6 in de on-pump groep, maar het
percentage patiënten waarin sprake was van volledige revasculari-
satie was in beide groepen gelijk. Tijdens 3% van de off-pump
operaties en 13% van de on-pump operaties moesten bloedpro-
ducten getransfundeerd worden (p<0,01). De post-operatieve stij-
ging van een enzym dat duidt op hartspierschade (CK-MB) was
in de off-pump groep 41% minder dan in de on-pump groep. De
off-pump patiënten werden gemiddeld 1 dag eerder uit het zie-
kenhuis ontslagen. Voor het overige werden tijdens de zieken-
huisopname geen verschillen waargenomen. Na 1 maand was er
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geen mortaliteit opgetreden en de kwaliteit van leven was in de 2
groepen in gelijke mate verbeterd. In beide groepen had 4% van
de patiënten opnieuw angina pectoris. Het aandeel patiënten dat
overleefde zonder cardiovasculaire complicaties was 93,0% in de
off-pump groep en 94.2% in de on-pump groep (verschil 1,2%;
95% BTI -4,4 tot 7,0%; p=0,66). Dit suggereert dat in geselec-
teerde patiënten off-pump chirurgie veilig is en gepaard gaat met
een cardiale uitkomst die vergelijkbaar is met on-pump CABG.
In hoofdstuk 7 wordt een vergelijking gerapporteerd van cardiale
uitkomsten en kosten-effectiviteit, 1 jaar na de operatie. De over-
leving zonder cardiovasculaire complicaties was 88.0% na off-
pump chirurgie en 90.6% na on-pump chirurgie (p=0,48).
Overleving zonder dat opnieuw angina pectoris optrad was even-
eens vergelijkbaar (respectievelijk 89,3% en 89,0%; p=0,93). In de
off-pump groep was 91% van de aangelegde omleidingen nog
doorgankelijk; in de on-pump groep was dat 93% (p=0,65). De
totale kosten na 1 jaar waren na een off-pump operatie $ 2.329
lager dan na een on-pump operatie ($ 15.479 versus $ 17.808;
p<0,01). ‘Quality adjusted life years’ (respectievelijk 0.82 en 0.83;
p=0,74) and ‘event free survival years’ (respectievelijk 1,02 en
1,03; p=0,23), waren echter gelijk. Daardoor was off-pump chi-
rurgie kosten-effectiever dan on-pump chirurgie, terwijl de cardi-
ale uitkomsten na beide behandelingen gelijk waren. De
toepassing van off-pump CABG lijkt daarom vanuit economisch
perspectief gerechtvaardigd.
Hoofdstuk 8 tenslotte omvat een algemene bespreking van het uit-
gevoerde onderzoek. Deze is met name gericht op het feit dat
een aantal van de verwachte voordelen van off-pump CABG niet
kon worden aangetoond. Hiervoor worden mogelijke verklarin-
gen aangedragen.
Allereerst is het mogelijk dat de potentiële voordelen van off-
pump CABG zijn overschat. De resultaten van de Octopus Studie
suggereren dat de hart-longmachine niet de enige oorzaak van
cognitieve schade na hartchirurgie is. Het ondergaan van chirur-
gie en narcose zouden eveneens oorzaken kunnen zijn. Ook is
het voorstelbaar dat de off-pump techniek zelf een nieuwe bron
van cognitieve schade is. De waarneming dat off-pump chirurgie
tot een korter ziekenhuis verblijf leidt kan voortkomen uit een
gebrekkige blindering van de artsen die de patiënten uit het zie-
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kenhuis ontsloegen. Ook indien in plaats van een sternotomie een
laterale thoracotomie wordt toegepast, blijft de kans op serieuze
chirurgische complicaties bestaan. 
Ten tweede is het mogelijk dat de schadelijke gevolgen van con-
ventionele bypass chirurgie zijn overschat. Off-pump CABG gaat
gepaard met weinig complicaties, maar het blijkt dat patiënten
met een vergelijkbaar (doorgaans laag) risicoprofiel, die een con-
ventionele operatie ondergaan, het eveneens goed doen. De inci-
dentie van cognitieve beschadiging na bypass chirurgie is
mogelijk overschat omdat de thans gebruikelijke definities van
cognitieve beschadiging tot vals-positieve uitkomsten kunnen lei-
den. Misclassificatie van patiënten met en zonder cognitieve
beschadiging en een overschatting van het aantal patiënten met
dergelijke schade vormen beide een verklaring voor de slechts
beperkte verbetering die in de Ocopus Studie kon worden aange-
toond na off-pump chirurgie.
Een derde verklaring wordt gevormd door de methodologische
beperkingen van de studie. Een kleine verbetering in cognitieve
uitkomsten was mogelijk overtuigender aangetoond met een gro-
ter aantal patienten. Het hoge ruis-niveau van de neuropsycholo-
gische tests en de definitie van cognitieve schade kan het
waargenomen verschil in cognitieve uitkomsten tussen de groe-
pen hebben verkleind. Ook werd in de studie te weinig aandacht
aan blindering geschonken.
Een toekomstige studie zou moeten worden uitgevoerd in oudere
patiënten. Hier zou het effect van off-pump chirurgie op cogni-
tieve uitkomst groter kunnen zijn. In een nieuwe studie dient een
betrouwbaarder definitie van cognitieve beschadiging te worden
gehanteerd. Indien besloten wordt een beduidend groter aantal
patiënten in een nieuwe studie op te nemen, kan ook het optre-
den van een beroerte worden gekozen als primaire uitkomstmaat.
De diagnose van een beroerte is, in tegenstelling tot die van cog-
nitieve beschadiging, relatief eenvoudig. In oudere patiënten is de
kans op een beroerte na CABG bijna 9% en het lijdt geen twijfel
dat een dergelijke complicatie voor de patiënt verstrekkende
gevolgen heeft.
Geconcludeerd wordt dat binnen een geselecteerde patiënten-
populatie de off-pump operatie veilig is en tot een cardiale uit-
komst leidt die vergelijkbaar is met on-pump CABG. Het
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vermijden van de hart-longmachine is kosten-effectief en vermin-
dert in geringe mate de bloedtransfusie-behoefte, maar andere
klinisch relevante voordelen van off-pump CABG zijn nog niet
aangetoond. Patiënten die zonder hart-longmachine geopereerd
worden hebben na 3 maanden een betere cognitieve uitkomst,
maar de verbetering is slechts beperkt.
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Dankwoord
Wetenschappelijk onderzoek kent vele verschijningsvormen.
Eénzame opsluiting in het lab behoort tot de mogelijkheden.
Maar het kan ook uitpakken als een wervelend circus vol mede-
onderzoekers, patiënten, hoogleraren en andere artiesten. De
Octopus Studie behoort ongetwijfeld tot de laatste soort. De dis-
ciplines thoraxchirurgie, cardiologie, anesthesiologie, epidemiolo-
gie en psychiatrie hebben ieder belangrijke bijdragen geleverd aan
het ontwerp en de uitvoering van dit onderzoek. Bij het schrijven
van dit proefschrift heb ik dan ook kunnen profiteren van een
overvloed aan begeleiding en hulp. Enkelen wil ik hierbij bijzon-
der danken voor hun inbreng.
Allereerst mijn directe begeleider en promotor, Prof. dr. Cor
Kalkman. Beste Cor, de Octopus Studie was al op volle stoom
toen jij als kersverse hoogleraar anesthesiologie in Utrecht arri-
veerde. Na een maand leek het niettemin alsof peri-operatief
neuropsychologisch onderzoek van kinds af aan je lust en je leven
is. Door je grote inhoudelijke belangstelling en kennis van zaken
(die zich ook uitstrekt tot onder meer duikboten, rockbands en
Monthy Python) was je voor mij de ultieme coach. Je hebt als
geen ander richting gegeven aan mijn schrijfpogingen en onder-
zoeksplannen voor de toekomst.
Mijn andere promotor, Prof. dr. Diederick Grobbee. Vanaf de
eerste kennismaking was ik geïmponeerd, en niet alleen door de
snor. Hoewel ik, zoals iedere beginnende arts-assistent, liet weten
wetenschappelijk onderzoek een warm hart toe te dragen, achtte
ik epidemiologie ongetwijfeld het saaist denkbare vak. Jij hebt
daar verandering in gebracht door me op cursus te sturen en me
te leren dat het onderscheid tussen Goed en Kwaad (p<0.05?)
ook in onderzoeksland niet altijd even duidelijk is.
Mijn co-promotor, Dr. Peter de Jaegere. Jij bent het bewijs dat
zuidelijk temperament zelfs binnen de Benelux volop bestaat. Als
studie-directeur sta je open voor het werkvloer-leed van de jong-
ste bediendes en we hebben vanaf de eerste kennismaking meer
dan uitstekend kunnen samenwerken. Eigenlijk zouden we ook in
de bergsport meer moeten kunnen realiseren dan plannen maken.  
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Jan Diephuis. Bestaat er een menselijker staflid? Met je ongebrei-
delde enthousiasme en jonge geest ben jij voor mij de ware aan-
jager van dit onderzoek geweest. Nadat ik, na een half jaar
AGNIO-schap, per abuis Professor Knape geschoffeerd had, heb
jij mij zonder twijfel gered van een voortijdige en roemloze
aftocht door me voor te dragen als coördinator van de Octopus
Studie. 
Prof. dr. Hans Knape. Gelukkig is het ruimschoots goed gekomen
tussen ons. Voor aankomst van Professor Kalkman hebben we
regelmatig gesprekken over de Octopus Studie gehad. Op één of
andere wijze voelde ik me nadien altijd een topwetenschapper in
de dop. Het is goed dat de Utrechtse anesthesie divisie geleid
wordt door iemand met ruim voldoende humor op zijn reper-
toire.
Prof. dr. Kees Borst. Behalve onderzoeker en uitvinder van een
listig en uiterst succesvol chirurgisch instrument bent u een
schoolmeester in hart en nieren (vooral hart, allicht). Van nie-
mand kreeg ik zo snel en zo gedegen commentaar op mijn manu-
scripten. Nooit is het mij gelukt een taal- of rekenfout ongemerkt
langs bureau Borst te loodsen.
Erik Jansen. Een andere Octopus-man van het eerste uur. Dankzij
jouw gedrevenheid werd de Octopus succesvol in de kliniek
geïntroduceerd, en werd de gedroomde studie werkelijkheid. Ik
schat dat ongeveer de helft van alle deelnemende patiënten door
jou persoonlijk geopereerd is. 
Arno Nierich. Toen wij even niet opletten, toverde jij op eigen
kracht een proefschrift over anesthesie bij off-pump hartchirurgie
uit je mouw. Met dit ongehoorde staaltje voortvarendheid gaf je
en passant mij de ruimte om een proefschrift over de Octopus
Randomized Trial te brouwen.
Hendrik Nathoe. Mijn meest directe collega. Ik ken weinig men-
sen die zo energiek -of zeg maar gerust fanatiek- organisatorische
problemen weten aan te pakken. Het was een enorm genoegen
samen met de jou de Octopus Studie te runnen. Wil je tezijner-
tijd mijn cardioloog worden?
Annemieke Keizer. Een psycholoog waarmee ik praten kan, en
niet alleen over het werk. Voorzien van ferme doses humor en
relativeringsvermogen. Katten-aanbidster ook, wat wil een mens
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nog meer. Ik hoop dat we onze aangename analyse-aanvaringen
nog lang voort kunnen zetten.
Karl Moons. Je verspreidt effectief het epidemiologie-evangelie
door de afdeling anesthesiologie. Ambitieus, maar vooral ook
enthousiast en hartelijk. Jij bent iemand die het saaiste van het
saaiste kan brengen als een spannend jongensboek.
Erik Buskens. Behalve één van de breinen achter het onderzoeks-
ontwerp was jij vijf jaar lang een betrouwbare vraagbaak voor
methodologische kwesties. Je bent méér dan kosten-effectief.
Jaap Lahpor, Frank Eefting en bovenal Pieter Stella. Absoluut
onmisbaar bij het identificeren van patiënten die geschikt waren
voor deelname aan de studie. 
Guido van Aarnhem. In de eerste jaren van het onderzoek een
betrouwbare collega in het ‘vangen’ van studie-deelnemers.
Marcel Bruens. Onverstoorbaar dataverzamelaar op de OK; ook
bij de tweehonderdste patiënt nog even nauwgezet.
Ron Hijman. Leverancier van neuropsychologische tests, gedegen
kritiek op manuscripten en natuurlijk de test-psychologen:
Catelijne, Rinske, Liesbeth, Milo en Christianne. Het herhaalde-
lijk afnemen van de neuropsychologische tests bij alle deelnemers
aan de studie was bepaald monnikenwerk. Dank voor jullie
geduld en nauwkeurigheid.
Eveneens was een indrukwekkend bataljon secretaresses direct of
indirect bij de studie betrokken. Allereerst waren dat Annemieke
en Millie: twee academische breinen die een steeds groter deel
van de organisatie voor hun rekening namen. Maar ook bedank
ik Chantal, Ellie en Willie voor het oppikken van de vele losse
eindjes.
Op het Juliuscentrum werden ruim 280.000 getallen op betrouw-
bare wijze ingevoerd in de databases. Met bijna duizelige dank
aan Ronald, Frank en Hanneke. 
De verpleegkundigen van de afdeling thoraxchirurgie dank ik
voor hun flexibiliteit bij het inpassen van de extra onderzoeken
die de studie-patiënten moesten ondergaan en hun hulp bij het
verzamelen van peri-operatieve gegevens.
In het bijzonder dank ik ook de 281 patiënten die bereid waren
zich door loting de ‘gewone’ of de octopus-operatie te laten toe-
wijzen en die in grote meerderheid trouw de vele follow-up
bezoeken aflegden. 
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I am very proud that Professor Stanton Newman (UK) participa-
ted in the assessment of the scientific quality of this thesis. You
are certainly one of the most significant researchers in the field of
cardiac surgery and the brain and I especially appreciate your
sound views on the analysis of neuropsychologic tests. I would
also like to thank Professor Jan Tijssen, Professor Jaap Kappelle,
Professor Johan Bredée en Professor Hans Knape sincerely for the
evaluation of this thesis.
Alle stafleden Anesthesiologie. U heeft veel geduld met mij
gehad. Het valt ook niet mee, een arts-assistent die in vertraagd
tempo zijn klinische vaardigheden opdoet. Assistenten die onder-
zoek doen blijken extra flexibiliteit van de fulltime clinici te vra-
gen. Maar wat krijgen jullie er wel niet voor terug?! (een
dankwoordje dus).
Alle collega’s arts-assistenten. Ook jullie houden je in grote
meerderheid voltijds bezig met het echte werk: anesthesie, trau-
ma opvang, intensive care, pijnbestrijding. Ondanks mijn fre-
quente uitstapjes naar onderzoeksland, alwaar geen Nachtdiensten
en ander Banaal Ongemak bestaan en iedereen een comfortabel
leven leidt, hebben jullie mij het gevoel gegeven gewoon deel uit
te maken van de assistentenploeg. Dank daarvoor, het is een eer
onderdeel te zijn van de leukste assistentengroep van het AZU.
Ook een ieder die op enigerlei wijze aan dit proefschrift heeft bij-
gedragen maar ik niet hierboven heb kunnen vermelden, wil ik
hartelijk danken.
Lieve ouders, dat het geneeskunde is geworden was niet speciaal
voorzien. Ook in allerlei andere wilde en minder wilde carrière-
plannen hebben jullie me onvoorwaardelijk gesteund en gestimu-
leerd. Dat jullie nu zelfs voor hart-longmachines, narcose-
middelen en neuropsychologische tests een welgemeende belang-
stelling aan den dag leggen vind ik ongelooflijk.
Tot slot de man om wie het allemaal werkelijk draait: Toon, ik
had al horen fluisteren dat er meer bestaat dan arbeidsvreugde
alleen. Je hebt mijn werk gerelativeerd en je hebt het pas echt de
moeite waard gemaakt. Je liefde is onmisbaar geworden.
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